Meganuclease Variants Cleaving A Dna Target Sequence From The Mouse Rosa26 Locus And Uses Thereof

Abstract

An I-CreI variant, wherein one of the two I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the mouse ROSA26 locus. Use of said variant and derived products for the engineering of transgenic mice and recombinant mouse cell lines expressing an heterologous protein of interest.

Description

[0001] The present application is a continuation of U.S. Ser. No. 12/663,164, filed Apr. 16, 2010, which is a National Stage of PCT/IB08/002,500, filed Jun. 6, 2008, and claims the benefit of PCT/IB07/002,830, filed Jun. 6, 2007, the entire contents of these applications are incorporated herein by reference.

[0002] The invention relates to a meganuclease variant cleaving a DNA target sequence from the mouse ROSA26 locus, to a vector encoding said variant, to a cell, an animal or a plant modified by said vector and to the use of said meganuclease variant and derived products for mouse genome engineering (recombinant protein production, construction of transgenic mice and recombinant mouse cell lines).

[0003] The mouse ROSA26 locus has been discovered by Friedrich and Soriano in 1991 by gene trap experiment using embryonic stem (ES) cells infected with a retrovirus (Friedrich, G. and P. Soriano, Genes & Development, 1991, 5, 1513-1523). The ROSA26 mouse gene trap line, where insertion occurs in intron 1 of the ROSA26 locus, a non-essential site, displays ubiquitous expression of the reporter gene during embryonic development, in newborn (Friedrich and Soriano, 1991, precited) and in hematopoietic cells (Zambrowicz et al., Proc. Natl. Acad. Sci. USA, 1997, 94, 3789-3794). The ROSA26 locus, located in mouse chromosome 6, produces three transcripts (FIG. 1). Two transcripts originate from a common promoter share identical 5' ends (exon 1 and start exon 2), but neither contains a significant ORF. And a third one originated from the reverse strand (Zambrowicz et al., 1997, precited). Transgenes under the control of the mouse ROSA26 promoter show ubiquitous expression in embryo and adult mouse (Soriano, P., Nature Genetics, 1999, 21, 70-71). Targeting the ROSA26 locus in mouse ES cells has been largely used to construct transgenic mouse models (Kisseberth et al., Developmental Biology, 1999, 214, 128-138; Mao X. et al., Proc. Natl. Acad. Sci. USA, 1999, 96, 5037-5042; Soriano, 1999, precited; Awatramani et al., Nature Genetics, 2001, 29, 257-259; Mao X. et al., Blood, 2001, 97, 324-326; Possemato et al., Genesis, 2002, 32, 184-186; Mao, J. et al., Nucleic Acids Res., 2005, 33, e155; Yu et al., Proc. Natl. Acad. Sci. USA, 2005, 102, 8615-8620; International PCT Applications WO 99/53017, WO 02/098217, WO 03/020743, WO 2004/063381 and WO 2005/116070)).

[0004] However, the efficacy of homologous recombination in mouse cells is very low (frequency: 10.sup.-6 to 10.sup.-9).

[0005] This efficiency can be enhanced by a DNA double-strand break (DSB) in the targeted locus. Such DSBs can be created by Meganucleases, which are by definition sequence-specific endonucleases recognizing large sequences (Thierry, A. and B. Dujon, Nucleic Acids Res., 1992, 20, 5625-5631). These proteins can cleave unique sites in living cells, thereby enhancing gene targeting by 1000-fold or more in the vicinity of the cleavage site (Puchta et al., Nucleic Acids Res., 1993, 21, 5034-5040; Rouet et al., Mol. Cell. Biol., 1994, 14, 8096-8106; Choulika et al., Mol. Cell. Biol., 1995, 15, 1968-1973; Puchta et al., Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 5055-5060; Sargent et al., Mol. Cell. Biol., 1997, 17, 267-277; Cohen-Tannoudji et al., Mol. Cell. Biol., 1998, 18, 1444-1448; Donoho, et al., Mol. Cell. Biol., 1998, 18, 4070-4078; Elliott et al., Mol. Cell. Biol., 1998, 18, 93-101).

[0006] However, although several hundreds of natural meganucleases, also referred to as "homing endonucleases" have been identified (Chevalier, B. S, and B. L. Stoddard, Nucleic Acids Res., 2001, 29, 3757-3774), the repertoire of cleavable sequences is too limited to address the complexity of the genomes, and there is usually no cleavable site in a chosen gene. Theoretically, the making of artificial sequence specific endonucleases with chosen specificities could alleviate this limit. Therefore, the making of meganucleases with tailored specificities is under intense investigation.

[0007] Recently, fusion of Zinc-Finger Proteins with the catalytic domain of the FokI, a class IIS restriction endonuclease, were used to make functional sequence-specific endonucleases (Smith et al., Nucleic Acids Res., 1999, 27, 674-681; Bibikova et al., Mol. Cell. Biol., 2001, 21, 289-297; Bibikova et al., Genetics, 2002, 161, 1169-1175; Bibikova et al., Science, 2003, 300, 764; Porteus, M. H. and D. Baltimore, Science, 2003, 300, 763-; Alwin et al., Mol. Ther., 2005, 12, 610-617; Urnov et al., Nature, 2005, 435, 646-651; Porteus, M. H., Mol. Ther., 2006, 13, 438-446; International PCT Application WO 2007/014275). Such nucleases could recently be used for the engineering of the ILR2G gene in human cells from the lymphoid lineage (Urnov et al., Nature, 2005, 435, 646-651).

[0008] The binding specificity of Cys2-His2 type Zinc-Finger Proteins (ZFP), is easy to manipulate, probably because they represent a simple (specificity driven by essentially four residues per finger), and modular system (Pabo et al., Annu. Rev. Biochem., 2001, 70, 313-340; Jamieson et al., Nat. Rev. Drug Discov., 2003, 2, 361-368. Studies from the Pabo (Rebar, E. J. and C. O. Pabo, Science, 1994, 263, 671-673; Kim, J. S, and C. O. Pabo, Proc. Natl. Acad. Sci. USA, 1998, 95, 2812-2817), Klug (Choo, Y. and A. Klug, Proc. Natl. Acad. Sci. USA, 1994, 91, 11163-11167; Isalan M. and A. Klug, Nat. Biotechnol., 2001, 19, 656-660) and Barbas (Choo, Y. and A. Klug, Proc. Natl. Acad. Sci. USA, 1994, 91, 11163-11167; Isalan M. and A. Klug, Nat. Biotechnol., 2001, 19, 656-660) laboratories resulted in a large repertoire of novel artificial ZFPs, able to bind most G/ANNG/ANNG/ANN sequences.

[0009] Nevertheless, ZFPs might have their limitations, especially for applications requiring a very high level of specificity, such as therapeutic applications. It was recently shown that FokI nuclease activity in fusion acts with either one recognition site or with two sites separated by varied distances via a DNA loop including in the presence of some DNA-binding defective mutants of FokI (Catto et al., Nucleic Acids Res., 2006, 34, 1711-1720). Thus, specificity might be very degenerate, as illustrated by toxicity in mammalian cells and Drosophila (Bibikova et al., Genetics, 2002, 161, 1169-1175; Bibikova et al., Science, 2003, 300, 764-).

[0010] In the wild, meganucleases are essentially represented by homing endonucleases. Homing Endonucleases (HEs) are a widespread family of natural meganucleases including hundreds of proteins families (Chevalier, B. S, and B. L. Stoddard, Nucleic Acids Res., 2001, 29, 3757-3774). These proteins are encoded by mobile genetic elements which propagate by a process called "homing": the endonuclease cleaves a cognate allele from which the mobile element is absent, thereby stimulating a homologous recombination event that duplicates the mobile DNA into the recipient locus. Given their exceptional cleavage properties in terms of efficacy and specificity, they could represent ideal scaffold to derive novel, highly specific endonucleases.

[0011] HEs belong to four major families. The LAGLIDADG family, named after a conserved peptidic motif involved in the catalytic center, is the most widespread and the best characterized group. Seven structures are now available. Whereas most proteins from this family are monomeric and display two LAGLIDADG motifs, a few ones have only one motif, but dimerize to cleave palindromic or pseudo-palindromic target sequences.

[0012] Although the LAGLIDADG peptide is the only conserved region among members of the family, these proteins share a very similar architecture (FIG. 2). The catalytic core is flanked by two DNA-binding domains with a perfect two-fold symmetry for homodimers such as I-CreI (Chevalier, et al., Nat. Struct. Biol., 2001, 8, 312-316) and I-MsoI (Chevalier et al., J. Mol. Biol., 2003, 329, 253-269) and with a pseudo-symmetry fo monomers such as I-SceI (Moure et al., J. Mol. Biol., 2003, 334, 685-69, I-DmoI (Silva et al., J. Mol. Biol., 1999, 286, 1123-1136) or I-AniI (Bolduc et al., Genes Dev., 2003, 17, 2875-2888). Both monomers, or both domains (for monomeric proteins) contribute to the catalytic core, organized around divalent cations. Just above the catalytic core, the two LAGLIDADG peptides play also an essential role in the dimerization interface. DNA binding depends on two typical saddle-shaped .beta..beta..alpha..beta..beta. folds, sitting on the DNA major groove. Other domains can be found, for example in inteins such as PI-PfuI (Ichiyanagi et al., J. Mol. Biol., 2000, 300, 889-901) and PI-SceI (Moure et al., Nat. Struct. Biol., 2002, 9, 764-770), which protein splicing domain is also involved in DNA binding.

[0013] The making of functional chimeric meganucleases, by fusing the N-terminal I-DmoI domain with an I-CreI monomer (Chevalier et al., Mol. Cell., 2002, 10, 895-905; Epinat et al., Nucleic Acids Res, 2003, 31, 2952-62; International PCT Applications WO 03/078619 and WO 2004/031346) have demonstrasted the plasticity of LAGLIDADG proteins.

[0014] Besides, different groups have used a rational approach to locally alter the specificity of the I-CreI (Seligman et al., Genetics, 1997, 147, 1653-1664; Sussman et al., J. Mol. Biol., 2004, 342, 31-41; International PCT Applications WO 2006/097784, WO 2006/097853 and WO 2007/049156; Arnould et al., J. Mol. Biol., 2006, 355, 443-458; Rosen et al., Nucleic Acids Res., 2006, 34, 4791-4800; Smith et al., Nucleic Acids Res., Epub 27 Nov. 2006), I-SceI (Doyon et al., J. Am. Chem. Soc., 2006, 128, 2477-2484), PI-SceI (Gimble et al., J. Mol. Biol., 2003, 334, 993-1008) and I-MsoI (Ashworth et al., Nature, 2006, 441, 656-659).

[0015] In addition, hundreds of I-CreI derivatives with locally altered specificity were engineered by combining the semi-rational approach and High Throughput Screening: [0016] Residues Q44, R68 and R70 or Q44, R68, D75 and I77 of I-CreI were mutagenized and a collection of variants with altered specificity towards the nucleotides at positions .+-.3 to 5 of the DNA target (5NNN DNA target) were identified by screening (International PCT Applications WO 2006/097784 and WO 2006/097853; Arnould et al., J. Mol. Biol., 2006, 355, 443-458; Smith et al., Nucleic Acids Res., Epub 27 Nov. 2006).

[0017] Residues K28, N30 and Q38, N30, Y33 and Q38 or K28, Y33, Q38 and S40 of I-CreI were mutagenized and a collection of variants with altered specificity towards the nucleotides at positions .+-.8 to 10 of the DNA target (10NNN DNA target) were identified by screening (Smith et al., Nucleic Acids Res., Epub 27 Nov. 2006; International PCT Application WO 2007/049156).

[0018] Residues 28 to 40 and 44 to 77 of I-CreI were shown to form two separable functional subdomains, able to bind distinct parts of a homing endonuclease half-site (Smith et al. Nucleic Acids Res., Epub 27 Nov. 2006; International PCT Application WO 2007/049095).

[0019] The combination of mutations from the two subdomains of I-CreI within the same monomer allowed the design of novel chimeric molecules (homodimers) able to cleave a palindromic combined DNA target sequence comprising the nucleotides at positions .+-.3 to 5 and .+-.8 to 10 which are bound by each subdomain (Smith et al., Nucleic Acids Res., Epub 27 Nov. 2006; International PCT Application WO 2007/049156).

[0020] Two different variants were combined and assembled in a functional heterodimeric endonuclease able to cleave a chimeric target resulting from the fusion of a different half of each variant DNA target sequence (Arnould et al., precited; International PCT Application WO 2006/097854). Interestingly, the novel proteins had kept proper folding and stability, high activity, and a narrow specificity

[0021] The combination of the two former steps allows a larger combinatorial approach, involving four different subdomains. The different subdomains can be modified separately and combined to obtain an entirely redesigned meganuclease variant (heterodimer or single-chain molecule) with chosen specificity, as illustrated on FIG. 3. In a first step, couples of novel meganucleases are combined in new molecules ("half-meganucleases") cleaving palindromic targets derived from the target one wants to cleave. Then, the combination of such "half-meganuclease" can result in a heterodimeric species cleaving the target of interest. The assembly of four set of mutations into heterodimeric endonucleases cleaving a model target sequence or a sequence from the human RAG1 gene has been described in Smith et al. (Nucleic Acids Res., Epub 27 Nov. 2006).

[0022] However, the targets tested in this report were identical to the original sequence of the palindromic I-CreI site (C1221; FIG. 5) at the positions .+-.2 and .+-.1. Even though the base-pairs .+-.1 and .+-.2 do not display any contact with the protein, it has been shown that these positions are not devoid of content information (Chevalier et al., J. Mol. Biol., 2003, 329, 253-269), especially for the base-pair .+-.1 and could be a source of additional substrate specificity (Argast et al., J. Mol. Biol., 1998, 280, 345-353; Jurica et al., Mol. Cell., 1998, 2, 469-476; Chevalier, B. S, and B. L. Stoddard, Nucleic Acids Res., 2001, 29, 3757-3774). In vitro selection of cleavable I-CreI target (Argast et al., precited) randomly mutagenized, revealed the importance of these four base-pairs on protein binding and cleavage activity. It has been suggested that the network of ordered water molecules found in the active site was important for positioning the DNA target (Chevalier et al., Biochemistry, 2004, 43, 14015-14026). In addition, the extensive conformational changes that appear in this region upon I-CreI binding suggest that the four central nucleotides could contribute to the substrate specificity, possibly by sequence dependent conformational preferences (Chevalier et al., 2003, precited).

[0023] Thus, it was not clear if mutants identified on 10NNN and 5NNN DNA targets as homodimers cleaving a palindromic sequence with the four central nucleotides being gtac, would allow the design of new endonucleases that would cleave targets containing changes in the four central nucleotides.

[0024] The Inventors have identified a series of DNA targets in the mouse ROSA26 locus that could be cleaved by I-CreI variants (FIG. 17). The combinatorial approach described in FIG. 3 was used to entirely redesign the DNA binding domain of the I-CreI protein and thereby engineer novel meganucleases with fully engineered specificity, to cleave a DNA target from the mouse ROSA26 locus (rosa1) which differs from the I-CreI C1221 22 bp palindromic site by 13 nucleotides including one (position +1) of the four central nucleotides (FIG. 5).

[0025] Even though the combined variants were initially identified towards nucleotides 10NNN and 5NNN respectively, and a strong impact of the four central nucleotides of the target on the activity of the engineered meganuclease was observed, functional meganucleases with a profound change in specificity were selected. Furthermore, the activity of the engineered protein could be significantly improved by two successive rounds of random mutagenesis and screening, to compare with the activity of the I-CreI protein.

[0026] The ability to generate a double-strand break at the ROSA26 locus provides a means to significantly enhance homologous recombination at the locus. Thus, a meganuclease targeting the ROSA26 locus will allow efficient gene insertions in mouse cells (FIG. 4). The ability to efficiently insert genes (knock-in) at this locus has the advantage of allowing reproducible expression levels as well as predictable time lines for generating insertions. Potential applications include the production of recombinant proteins in mouse cells and the engineering of transgenic mice and recombinant mouse cell lines, that can be used, for example, for protein production, gene function studies, drug screening, or as disease model.

[0027] The invention relates to an I-CreI variant wherein at least one of the two I-CreI monomers has at least two substitutions one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, and is able to cleave a DNA target sequence from the mouse ROSA26 locus.

[0028] The cleavage activity of the variant according to the invention may be measured by any well-known, in vitro or in vivo cleavage assay, such as those described in the International PCT Application WO 2004/067736; Epinat et al., Nucleic Acids Res., 2003, 31, 2952-2962; Chames et al., Nucleic Acids Res., 2005, 33, e178 and Arnould et al., J. Mol. Biol., 2006, 355, 443-458. For example, the cleavage activity of the variant of the invention may be measured by a direct repeat recombination assay, in yeast or mammalian cells, using a reporter vector. The reporter vector comprises two truncated, non-functional copies of a reporter gene (direct repeats) and the genomic DNA target sequence within the intervening sequence, cloned in a yeast or a mammalian expression vector. Expression of the variant results in a functional endonuclease which is able to cleave the genomic DNA target sequence. This cleavage induces homologous recombination between the direct repeats, resulting in a functional reporter gene, whose expression can be monitored by appropriate assay.

DEFINITIONS

[0029] Amino acid refers to a natural or synthetic amino acid including enantiomers and stereoisomers of the preceding amino acids. [0030] Amino acid residues in a polypeptide sequence are designated herein according to the one-letter code, in which, for example, Q means Gln or Glutamine residue, R means Arg or Arginine residue and D means Asp or Aspartic acid residue. [0031] Acidic amino acid refers to aspartic acid (D) and Glutamic acid (E). [0032] Basic amino acid refers to lysine (K), arginine (R) and histidine (H). [0033] Small amino acid refers to glycine (G) and alanine (A). [0034] Aromatic amino acid refers to phenylalanine (F), tryptophane (W) and tyrosine (Y). [0035] Nucleotides are designated as follows: one-letter code is used for designating the base of a nucleoside: a is adenine, t is thymine, c is cytosine, and g is guanine. For the degenerated nucleotides, r represents g or a (purine nucleotides), k represents g or t, s represents g or c, w represents a or t, m represents a or c, y represents t or c (pyrimidine nucleotides), d represents g, a or t, v represents g, a or c, b represents g, t or c, h represents a, t or c, and n represents g, a, t or c. [0036] by "meganuclease", is intended an endonuclease having a double-stranded DNA target sequence of 12 to 45 bp. Said meganuclease is either a dimeric enzyme, wherein each domain is on a monomer or a monomeric enzyme comprising the two domains on a single polypeptide. [0037] by "meganuclease domain" is intended the region which interacts with one half of the DNA target of a meganuclease and is able to associate with the other domain of the same meganuclease which interacts with the other half of the DNA target to form a functional meganuclease able to cleave said DNA target. [0038] by "meganuclease variant" or "variant" is intented a meganuclease obtained by replacement of at least one residue in the amino acid sequence of the wild-type meganuclease (natural meganuclease) with a different amino acid. [0039] by "functional variant" is intended a variant which is able to cleave a DNA target sequence, preferably said target is a new target which is not cleaved by the parent meganuclease. For example, such variants have amino acid variation at positions contacting the DNA target sequence or interacting directly or indirectly with said DNA target. [0040] by "meganuclease variant with novel specificity" is intended a variant having a pattern of cleaved targets different from that of the parent meganuclease. The terms "novel specificity", "modified specificity", "novel cleavage specificity", "novel substrate specificity" which are equivalent and used indifferently, refer to the specificity of the variant towards the nucleotides of the DNA target sequence. [0041] by "I-CreI" is intended the wild-type I-CreI having the sequence SWISSPROT P05725, corresponding to the sequence SEQ ID NO: 1 in the sequence listing or the sequence pdb accession code 1g9y, corresponding to the sequence SEQ ID NO: 133 in the sequence listing. [0042] by "domain" or "core domain" is intended the "LAGLIDADG homing endonuclease core domain" which is the characteristic .alpha..sub.1.beta..sub.1.beta..sub.2.alpha..sub.2.beta..sub.3.beta..sub.- 4.alpha..sub.3 fold of the homing endonucleases of the LAGLIDADG family, corresponding to a sequence of about one hundred amino acid residues. Said domain comprises four beta-strands (.beta..sub.1.beta..sub.2.beta..sub.3.beta..sub.4) folded in an antiparallel beta-sheet which interacts with one half of the DNA target. This domain is able to associate with another LAGLIDADG homing endonuclease core domain which interacts with the other half of the DNA target to form a functional endonuclease able to cleave said DNA target. For example, in the case of the dimeric homing endonuclease I-CreI (163 amino acids), the LAGLIDADG homing endonuclease core domain corresponds to the residues 6 to 94. [0043] by "single-chain meganuclease" is intended a meganuclease comprising two LAGLIDADG homing endonuclease domains or core domains linked by a peptidic spacer. The single-chain meganuclease is able to cleave a chimeric DNA target sequence comprising one different half of each parent meganuclease target sequence. [0044] by "subdomain" is intended the region of a LAGLIDADG homing endonuclease core domain which interacts with a distinct part of a homing endonuclease DNA target half-site. Two different subdomains behave independently and the mutation in one subdomain does not alter the binding and cleavage properties of the other subdomain. Therefore, two subdomains bind distinct part of a homing endonuclease DNA target half-site. [0045] by "beta-hairpin" is intended two consecutive beta-strands of the antiparallel beta-sheet of a LAGLIDADG homing endonuclease core domain ((.beta..sub.1.beta..sub.2 or, .beta..sub.3.beta..sub.4) which are connected by a loop or a turn, [0046] by "I-CreI site" is intended a 22 to 24 bp double-stranded DNA sequence which is cleaved by I-CreI. I-CreI sites include the wild-type (natural) non-palindromic I-CreI homing site and the derived palindromic sequences such as the sequence 5'-t.sub.-12c.sub.-11a.sub.-10a.sub.-9a.sub.-8a.sub.-7c.sub.-6g.sub.-5t.s- ub.-4c.sub.-3g.sub.-2t.sub.-1a.sub.+1c.sub.+2g.sub.+3a.sub.+4c.sub.+5g.sub- .+6t.sub.+7t.sub.+8t.sub.+9t.sub.+10g.sub.+11a.sub.+12 also called C1221 (SEQ ID NO:2; FIG. 5). [0047] by "DNA target", "DNA target sequence", "target sequence", "target-site", "target", "site"; "site of interest"; "recognition site", "recognition sequence", "homing recognition site", "homing site", "cleavage site" is intended a 20 to 24 bp double-stranded palindromic, partially palindromic (pseudo-palindromic) or non-palindromic polynucleotide sequence that is recognized and cleaved by a LAGLIDADG homing endonuclease such as I-CreI, or a variant, or a single-chain chimeric meganuclease derived from I-CreI. These terms refer to a distinct DNA location, preferably a genomic location, at which a double stranded break (cleavage) is to be induced by the meganuclease. The DNA target is defined by the 5' to 3' sequence of one strand of the double-stranded polynucleotide, as indicate above for C1221. Cleavage of the DNA target occurs at the nucleotides at positions +2 and -2, respectively for the sense and the antisense strand. Unless otherwise indicated, the position at which cleavage of the DNA target by an I-Cre I meganuclease variant occurs, corresponds to the cleavage site on the sense strand of the DNA target. [0048] by "DNA target half-site", "half cleavage site" or half-site" is intended the portion of the DNA target which is bound by each LAGLIDADG homing endonuclease core domain. [0049] by "chimeric DNA target" or "hybrid DNA target" is intended the fusion of a different half of two parent meganuclease target sequences. In addition at least one half of said target may comprise the combination of nucleotides which are bound by at least two separate subdomains (combined DNA target). [0050] by "mouse ROSA26 locus" is intended the locus located in mouse chromosome 6 and having the sequence corresponding to EMBL accession number CQ880114 (SEQ ID NO: 3; 13139 bp). The ROSA26 produces three transcripts (FIG. 1): two transcripts originate from a common promoter share identical 5' ends (exon 1 and exon 2 start), but neither contains a significant ORF. And a third one originated from the reverse strand. [0051] by "DNA target sequence from the mouse ROSA26 locus", "genomic DNA target sequence", "genomic DNA cleavage site", "genomic DNA target" or "genomic target" is intended a 20 to 24 bp sequence of the mouse ROSA26 locus which is recognized and cleaved by a meganuclease variant. [0052] by "vector" is intended a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. [0053] by "homologous" is intended a sequence with enough identity to another one to lead to a homologous recombination between sequences, more particularly having at least 95% identity, preferably 97% identity and more preferably 99%. [0054] "identity" refers to sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base, then the molecules are identical at that position. A degree of similarity or identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default settings. [0055] "individual" includes mammals, as well as other vertebrates (e.g., birds, fish and reptiles). The terms "mammal" and "mammalian", as used herein, refer to any vertebrate animal, including monotremes, marsupials and placental, that suckle their young and either give birth to living young (eutharian or placental mammals) or are egg-laying (metatharian or nonplacental mammals). Examples of mammalian species include humans and other primates (e.g., monkeys, chimpanzees), rodents (e.g., rats, mice, guinea pigs) and others such as for example: cows, pigs and horses. [0056] by mutation is intended the substitution, deletion, insertion of one or more nucleotides/amino acids in a polynucleotide (cDNA, gene) or a polypeptide sequence. Said mutation can affect the coding sequence of a gene or its regulatory sequence. It may also affect the structure of the genomic sequence or the structure/stability of the encoded mRNA.

[0057] The variant according to the present invention may be a homodimer or a heterodimer. Preferably, both monomers of the heterodimer are mutated at positions 26 to 40 and/or 44 to 77. More preferably, both monomers have different substitutions both at positions 26 to 40 and 44 to 77 of I-CreI

[0058] In a preferred embodiment of said variant, said substitution(s) in the subdomain situated from positions 44 to 77 of I-CreI are at positions 44, 68, 70, 75 and/or 77.

[0059] In another preferred embodiment of said variant, said substitution(s) in the subdomain situated from positions 26 to 40 of I-CreI are at positions 26, 28, 30, 32, 33, 38 and/or 40.

[0060] In another preferred embodiment of said variant, said substitutions are replacement of the initial amino acids with amino acids selected from the group consisting of: A, D, E, G, H, K, N, P, Q, R, S, T, Y, C, V, L and W.

[0061] In another preferred embodiment of said variant, it comprises one or more mutations at positions of other amino acid residues which contact the DNA target sequence or interact with the DNA backbone or with the nucleotide bases, directly or via a water molecule; these residues are well-known in the art (Jurica et al., Molecular Cell., 1998, 2, 469-476; Chevalier et al., J. Mol. Biol., 2003, 329, 253-269).

[0062] In particular, additional substitutions may be introduced at positions contacting the phosphate backbone, for example in the final C-terminal loop (positions 137 to 143; Prieto et al., Nucleic Acids Res., Epub 22 Apr. 2007). Preferably said residues are involved in binding and cleavage of said DNA cleavage site. More preferably, said residues are at positions 138, 139, 142 or 143 of I-CreI. Two residues may be mutated in one variant provided that each mutation is in a different pair of residues chosen from the pair of residues at positions 138 and 139 and the pair of residues at positions 142 and 143. The mutations which are introduced modify the interaction(s) of said amino acid(s) of the final C-terminal loop with the phosphate backbone of the I-CreI site. Preferably, the residue at position 138 or 139 is substituted by an hydrophobic amino acid to avoid the formation of hydrogen bonds with the phosphate backbone of the DNA cleavage site. For example, the residue at position 138 is substituted by an alanine or the residue at position 139 is substituted by a methionine. The residue at position 142 or 143 is advantageously substituted by a small amino acid, for example a glycine, to decrease the size of the side chains of these amino acid residues. More, preferably, said substitution in the final C-terminal loop modify the specificity of the variant towards the nucleotide at positions .+-.1 to 2, .+-.6 to 7 and/or .+-.11 to 12 of the I-CreI site.

[0063] In another preferred embodiment of said variant, it comprises one or more additional mutations that improve the binding and/or the cleavage properties of the variant towards the DNA target sequence from the mouse ROSA26 locus.

[0064] The additional residues which are mutated may be on the entire I-CreI sequence, and in particular in the C-terminal half of I-CreI (positions 80 to 163). For example, the variant comprises one or more additional substitution at positions 19, 24, 79, 105, 107, 151, 153, 158. Said substitutions are advantageously selected from the group consisting of: G19S, I24V, S79G, V105A, K107R, V151A, D153G and K158E.

[0065] The variant of the invention may be derived from the wild-type I-CreI (SEQ ID NO: 1 or 133) or an I-CreI scaffold protein having at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity with SEQ ID NO: 133, such as the scaffold of SEQ ID NO: 4 (167 amino acids) having the insertion of an alanine at position 2, the substitutionD75N, and the insertion of AAD at the C-terminus (positions 164 to 166) of the I-CreI sequence.

[0066] In addition, the variants of the invention may include one or more residues inserted at the NH.sub.2 terminus and/or COOH terminus of the sequence. For example, a tag (epitope (HA-tag (YPYDVPDYA; SEQ ID NO: 135) or S-tag (KETAAAKFERQHMDS; SEQ ID NO: 136) or polyhistidine sequence) is introduced at the NH.sub.2 terminus and/or COOH terminus; said tag is useful for the detection and/or the purification of said variant. When the tag is introduced at the NH.sub.2 terminus, the sequence of the tag may either replace the first amino acids of the variant (at least the first methionine and eventually the second amino acid of the variant; tag starting with a methionine) or be inserted between the first (methionine) and the second amino acids or the first and the third amino acids of the variant (tag with no methionine).

[0067] The variant may also comprise a nuclear localization signal (NLS); said NLS is useful for the importation of said variant into the cell nucleus. An example of NLS is KKKRK (SEQ ID NO: 134). The NLS may be inserted just after the first methionine of the variant or just after an N-terminal tag.

[0068] The variant according to the present invention may be ahomodimer which is able to cleave a palindromic or pseudo-palindromic DNA target sequence.

[0069] Alternatively, said variant is a heterodimer, resulting from the association of a first and a second monomer having different substitutions at positions 26 to 40 and/or 44 to 77 of I-CreI, said heterodimer being able to cleave a non-palindromic DNA target sequence from the mouse ROSA26 locus.

[0070] The DNA target sequence which is cleaved by said variant may be in an exon or in an intron of the mouse ROSA26 locus.

[0071] In another preferred embodiment of said variant, said DNA target is selected from the group consisting of the sequences SEQ ID NO: 5 to 30 (FIG. 17) which cover all of the mouse ROSA26 locus.

TABLE-US-00001 TABLE I ROSA26 locus target sequences SEQ ID Target NO: Target sequence position* Target location 5 cgcccctgcgcaacgtggcagg 3220 Intron 1 6 ccgcacccttctccggaggggg 3490 Intron 1 7 tggactggcttgactcatggca 4717 Intron 1 8 ccagcctggtctacacatcaag 5584 Intron 1 9 ctatctaggatagccaggaata 5608 Intron 1 10 cagcctgatttccagggtgggg 5906 Intron 1 11 taaacctcataaaatagttatg 5992 Intron 1 12 tcagattcttttataggggaca 6409 Intron 1 13 ttgtatatctcaaataatgctg 7394 Intron 1 14 tgagccactgagaatggtctca 8070 Intron 1 15 caacatgatgttcataatccca 8304 Exon 2 16 ttaaatgttgctatgcagtttg 8394 Exon 2 17 ttccccaaagttccaaattata 8583 Exon 2 18 taacaccgtttgtgttataata 8678 Exon 2 19 tatactgtctttagagagttta 8749 Exon 2 20 tgtaatagcttagaaaatttaa 9010 Exon 2 21 tttaatctattggtttgtctag 9280 Intron 2 22 ttgtacattgttaggagtgtga 9556 Intron 2 23 tgcactggtacacataatttca 10263 Intron 2 24 tgagatgatacaaagaatttag 11558 Intron 2 and antisense transcript 25 ccatcctataaaagaaggtcaa 12391 Exon 3 or antisense transcript 26 tttaatctattgcaaaaggtaa 12414 Exon 3 or antisense transcript 27 tagtccagtgttatagagttag 12535 Exon 3 or antisense transcript 28 ttctacctttttccaaatggca 12791 Exon 3 or antisense transcript 29 ttttctgtggagacaaaggtaa 12904 Exon 3 or antisense transcript 30 tgagatggctcagcaaataatg 12954 Exon 3 or antisense transcript *the indicated position is that of the first nucleotide of the target

[0072] More preferably, the monomers of the variant have at least the following substitutions, respectively for the first and the second monomer: [0073] N30H, Y33S, Q44E, R68C, R70S and D75N (first monomer), and N30D, Y33R, Q38T, Q44K, R68E, R70S, and I77R (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 5 which is located in the first intron (FIGS. 1 and 17; Table I), [0074] S32N, Y33G, Q44K, R70E and D75N (first monomer), and S32T, Q38W, Q44K, R68E, R70S and I77R (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 6 which is located in the first intron (FIGS. 1 and 17; Table I), [0075] Y33R, Q38N, S40Q, Q44N, R70S, D75R and I77D (first monomer), and N30H, Y33S, Q44A, R70S, D75Q and I77E (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 7 which is located in the first intron (FIGS. 1 and 17; Table I), [0076] K28S, Q38R, S40K, Q44D, R68Y, R70S, D75S and I77R (first monomer), and Y33C, Q38A, R68A, R70K and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 8 which is located in the first intron (FIGS. 1 and 17; Table I), [0077] Y33C, Q44T, R70S and D75Y (first monomer), and S32D, Q38C, Q44D, R68Y, R70S, D75S and I77R (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 9 which is located in the first intron (FIGS. 1 and 17; Table I), [0078] S32T, Y33C, R68T, R70N and D75N (first monomer), and S32T, Q38W, Q44K, R70E and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 10 which is located in the first intron (FIGS. 1 and 17; Table I), [0079] R70S, D75R and I77Y ((first monomer), and Y33R, Q38A, S40Q, Q44A, R70S and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 11 which is located in the first intron (FIGS. 1 and 17; Table I), [0080] K28S, Q38R, S40K, Q44T, R68N, R70N and D75N (first monomer), and Y33H, Q38S, Q44K, R68Y, R70S, D75Q and I77N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 12 which is located in the first intron (FIGS. 1 and 17; Table I), [0081] K28A, Y33S, Q38R, S40K, Q44N, R68Y, R70S, D75R, I77V (first monomer), and S32T, Y33C, Q44A, R70S and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 13 which is located in the first intron (FIGS. 1 and 17; Table I), [0082] S32D, Y33H, Q44K, R68E, R70S and I77R (first monomer), and S32D, Y33H, Q44D, R68N, R70S and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 14 which is located in the first intron (FIGS. 1 and 17; Table I), [0083] N30R, S32D, R68S, R70K and D75N (first monomer), and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 16 which is located in the second exon (FIGS. 1 and 17; Table I), [0084] K28R, Y33A, Q38Y, S40Q, R68Y, R70S, D75R and I77Q (first monomer), and Y33R, Q38A, S40Q, R70S and I77K (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 17 which is located in the second exon (FIGS. 1 and 17; Table I), [0085] K28R, N30D, D75E and I77R (first monomer), and S32D, Q38C, Q44A, R70S, D75R and I77Y (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 18 which is located in the second exon (FIGS. 1 and 17; Table I), [0086] Y33R, Q38A, S40Q, R70S, and D75N (first monomer), and R70S, D75Y and I77R (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 19 which is located in the second exon (FIGS. 1 and 17; Table I), [0087] Y33R, Q38A, S40Q, Q44N, R68Y, R70S, D75R and I77V (first monomer), and N30R, S32D, Q44T, R68H, R70H and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 20 which is located in the second exon (FIGS. 1 and 17; Table I), [0088] Y33P, S40Q, Q44K, R68Y, R70S, D75Q and I77N (first monomer), and S32A, Y33C, R68Y, R70S, D75R and I77Q (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 21 which is located in the second intron (FIGS. 1 and 17; Table I), [0089] K28A, Y33S, Q38R, S40K, R68N, R70S, D75N and I77R (first monomer), and S32N, Y33G, Q44A, R68A, R70K and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 22 which is located in the second intron (FIGS. 1 and 17; Table I), [0090] N30H, Y33S, Q44Y, R70S and I77V (first monomer), and Y33R, S40Q, Q44A, R70S and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 23 which is located in the second intron (FIGS. 1 and 17; Table I), [0091] S32D, Y33H, R68T, R70N and D75N (first monomer), and N30R, S32D, Q44T, R68N, R70N and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 24 which is located in the second intron and in the antisense transcript (FIGS. 1 and 17; Table I), [0092] S32R, Y33D, Q44A, R70S and D75N (first monomer), and Y33S, Q38R, S40H, R68H, R70H and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 25 which is located in the third exon or the antisense transcript (FIGS. 1 and 17; Table I), [0093] Y33P, S40Q, Q44K, R68Y, R70S, D75Q and I77N (first monomer), and K28R, Y33A, Q38Y, S40Q, Q44T, R68H, R70H and D75N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 26 which is located in the third exon or the antisense transcript (FIGS. 1 and 17; Table I), [0094] K28Q, Q38R, S40K, Q44A, R70S, D75E and I77R (first monomer), and N30R, S32D, Q44K, R68Y, R70S, D75Q and I77N (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 27 which is located in the third exon or the antisense transcript (FIGS. 1 and 17; Table I), [0095] Y33T, Q38A, R68H, R70H and D75N (first monomer), and N30H, Y33S, R70S and I77K (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 28 which is located in the third exon or the antisense transcript (FIGS. 1 and 17; Table I), [0096] Y33T, S40T, R68A, R70K and D75N (first monomer), and K28R, Y33A, Q38Y, S40Q, R70S and I77K (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 29 which is located in the third exon or the antisense transcript (FIGS. 1 and 17; Table I), and [0097] S32D, Y33H, Q44N, R70S, D75R and I77D (first monomer), and S32D, Q38C, R70S and I77K (second monomer); this variant cleaves the ROSA26 target SEQ ID NO: 30 which is located in the third exon or the antisense transcript (FIGS. 1 and 17; Table I).

[0098] Examples of said variants cleaving the ROSA26 DNA targets of Table I (nucleotide sequences SEQ ID NO: 5 to 14 and 16 to 30) include the variants having a first monomer of any of the amino acid sequences SEQ ID NO: 82 to 106 and a second monomer of any of the amino acid sequences SEQ ID NO: 107 to 116, 4, 117 to 130, respectively (FIG. 17).

[0099] In addition, the following variants are able to cleave the ROSA26 DNA target, named rosa1, which is located in the second exon (FIGS. 1 and 17; Table I): [0100] the fourty variants having a first monomer selected from the group consisting of: I24V, Q44Y, R70S and D75N; I24V, Q44Y, R68Y, R70S, D75Y and I77R; I24V, Q44Y, R70S, D75N and I77V; I24V, Q44Y, R68N, R70S and D75R; I24V, Q44Y, R68S, R70S and D75R; I24V, Q44Y, R70S and D75Q; I24V, Q44Y, R68Y, R70S, D75R and I77V; I24V, Q44Y, R70S, D75Y and I77T, and a second monomer selected in the group consisting of: K28E, Y33R, Q38R, S40R, Q44A, R68H, R70Q and D75N; K28E, Y33R, Q38R, S40R, Q44A, R70N and D75N; K28E, Y33R, Q38R, S40K, Q44A, R68H, R70Q and D75N; K28E, Y33R, Q38R, S40K, Q44V, R70A and D75N; K28E, Y33R, Q38R, S40K, Q44A, R70G and D75N; examples of these variants are presented in Table V (first monomer: m2, m6, m8, m12, m13, m14, m16 or m17 (SEQ ID NO: 39, 43, 45, 49, 50, 51, 53 and 54); second monomer any of the SEQ ID NO: 60, 61, 63, 65 and 66) [0101] the variant having a first monomer comprising I24V, Q44Y, R70S, D75Y and I77T and K28E, Y33R, Q38R, S40R, Q44A, R68S, R70Q and D75N (second monomer); an example of this variant is presented in Table V (first monomer m17 (SEQ ID NO:54) and second monomer SEQ ID NO: 62). [0102] the ten variants having a first monomer selected from the group consisting of I24V, Q44Y, R68N, R70S and D75R; I24V, Q44Y, R68S, R70S and D75R; I24V, Q44Y, R70S and D75Q; I24V, Q44Y, R68Y, R70S, D75R and I77V; I24V, Q44Y, R70S, D75Y and I77T, and a second monomer selected in the group consisting of: K28E, Y33R, Q38R, S40K, Q44A, R70S and D75N and K28E, Y33R, Q38R, S40K, Q44A, R68T, R70N and D75N; examples of these variants are presented in Table V (first monomer: m12, m13, m14, m16 or m17 (SEQ ID NO: 49, 50, 51, 53 and 54); second monomer any of the SEQ ID NO: 64 and 67). [0103] the variants having a first monomer consisting of the sequence SEQ ID NO: 72 (MO.sub.--1; Tables VI and VII) or SEQ ID NO: 73 (MO.sub.--2; Tables VI and VII) and a second monomer consisting of any of the sequences SEQ ID NO: 74 to 77 (mO.sub.--1 to mO.sub.--4; Table VII); these eight variants have additional substitutions that increase the cleavage activity of the variants for the rosa1 target.

[0104] The invention encompasses I-CreI variants having at least 85% identity, preferably at least 90% identity, more preferably at least 95% (96%, 97%, 98%, 99%) identity with the sequences as defined above, said variant being able to cleave a DNA target from the mouse ROSA26 locus.

[0105] For example, the invention encompasses the I-CreI variants derived from MO.sub.--1 and mO.sub.--2 by insertion of a NLS, a tag or both, which are selected from the group consisting of the sequences SEQ ID NO: 140 to 145.

[0106] The heterodimeric variant is advantageously an obligate heterodimer variant having at least one pair of mutations interesting corresponding residues of the first and the second monomers which make an intermolecular interaction between the two I-CreI monomers, wherein the first mutation of said pair(s) is in the first monomer and the second mutation of said pair(s) is in the second monomer and said pair(s) of mutations prevent the formation of functional homodimers from each monomer and allow the formation of a functional heterodimer, able to cleave the genomic DNA target from the mouse ROSA26 locus.

[0107] To form an obligate heterodimer, the monomers have advantageously at least one of the following pairs of mutations, respectively for the first and the second monomer:

[0108] a) the substitution of the glutamic acid at position 8 with a basic amino acid, preferably an arginine (first monomer) and the substitution of the lysine at position 7 with an acidic amino acid, preferably a glutamic acid (second monomer); the first monomer may further comprise the substitution of at least one of the lysine residues at positions 7 and 96, by an arginine.

[0109] b) the substitution of the glutamic acid at position 61 with a basic amino acid, preferably an arginine (first monomer) and the substitution of the lysine at position 96 with an acidic amino acid, preferably a glutamic acid (second monomer); the first monomer may further comprise the substitution of at least one of the lysine residues at positions 7 and 96, by an arginine

[0110] c) the substitution of the leucine at position 97 with an aromatic amino acid, preferably a phenylalanine (first monomer) and the substitution of the phenylalanine at position 54 with a small amino acid, preferably a glycine (second monomer); the first monomer may further comprise the substitution of the phenylalanine at position 54 by a tryptophane and the second monomer may further comprise the substitution of the leucine at position 58 or lysine at position 57, by a methionine, and

[0111] d) the substitution of the aspartic acid at position 137 with a basic amino acid, preferably an arginine (first monomer) and the substitution of the arginine at position 51 with an acidic amino acid, preferably a glutamic acid (second monomer).

[0112] For example, the first monomer may have the mutation D137R and the second monomer, the mutation R51D. The obligate heterodimer meganuclease comprises advantageously, at least two pairs of mutations as defined in a), b) c) or d), above; one of the pairs of mutation is advantageously as defined in c) or d). Preferably, one monomer comprises the substitution of the lysine residues at positions 7 and 96 by an acidic amino acid (aspartic acid (D) or glutamic acid (E)), preferably an aspartic acid (K7E and K96E) and the other monomer comprises the substitution of the glutamic acid residues at positions 8 and 61 by a basic amino acid (arginine (R) or lysine (K); for example, E8K and E61R). More preferably, the obligate heterodimer meganuclease, comprises three pairs of mutations as defined in a), b) and c), above. The obligate heterodimer meganuclease consists advantageously of (i) E8R, E8K or E8H, E61R, E61K or E61H and L97F, L97W or L97Y; (ii) K7R, E8R, E61R, K96R and L97F, or (iii) K7R, E8R, F54W, E61R, K96R and L97F and a second monomer (B) having at least the mutations (iv) K7E or K7D, F54G or F54A and K96D or K96E; (v) K7E, F54G, L58M and K96E, or (vi) K7E, F54G, K57M and K96E. For example, the first monomer may have the mutations K7R, E8R or E8K, E61R, K96R and L97F or K7R, E8R or E8K, F54W, E61R, K96R and L97F and the second monomer, the mutations K7E, F54G, L58M and K96E or K7E, F54G, K57M and K96E. An example of heterodimer is SEQ ID NO: 147 and SEQ ID NO: 148. The obligate heterodimer may comprise at least one NLS and/or one tag as defined above; said NLS and/or tag may be in the first and/or the second monomer.

[0113] The subject-matter of the present invention is also a single-chain chimeric meganuclease (fusion protein) derived from an I-CreI variant as defined above. The single-chain meganuclease may comprise two I-CreI monomers, two I-CreI core domains (positions 6 to 94 of I-CreI) or a combination of both. Preferably, the two monomers/core domains or the combination of both, are connected by a peptidic linker. An example of peptidic linker is SEQ ID NO: 149. An example of single-chain chimeric meganuclease is SEQ ID NO: 146. The single-chain chimeric meganuclease may further comprise at least one NLS and/or one tag as defined above; said NLS and/or tag may be in the first and/or the second monomer.

[0114] The subject-matter of the present invention is also a polynucleotide fragment encoding a variant or a single-chain chimeric meganuclease as defined above; said polynucleotide may encode one monomer of a homodimeric or heterodimeric variant, or two domains/monomers of a single-chain chimeric meganuclease.

[0115] The subject-matter of the present invention is also a recombinant vector for the expression of a variant or a single-chain meganuclease according to the invention. The recombinant vector comprises at least one polynucleotide fragment encoding a variant or a single-chain meganuclease, as defined above. In a preferred embodiment, said vector comprises two different polynucleotide fragments, each encoding one of the monomers of a heterodimeric variant.

[0116] A vector which can be used in the present invention includes, but is not limited to, a viral vector, a plasmid, a RNA vector or a linear or circular DNA or RNA molecule which may consists of a chromosomal, non chromosomal, semi-synthetic or synthetic nucleic acids. Preferred vectors are those capable of autonomous replication (episomal vector) and/or expression of nucleic acids to which they are linked (expression vectors). Large numbers of suitable vectors are known to those of skill in the art and commercially available.

[0117] Viral vectors include retrovirus, adenovirus, parvovirus (e.g. adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox). Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).

[0118] Preferred vectors include lentiviral vectors, and particularly self inactivating lentiviral vectors.

[0119] Vectors can comprise selectable markers, for example: neomycin phosphotransferase, histidinol dehydrogenase, dihydrofolate reductase, hygromycin phosphotransferase, herpes simplex virus thymidine kinase, adenosine deaminase, glutamine synthetase, and hypoxanthine-guanine phosphoribosyl transferase for eukaryotic cell culture; TRP 1 for S. cerevisiae; tetracycline, rifampicin or ampicillin resistance in E. coli.

[0120] Preferably said vectors are expression vectors, wherein the sequence(s) encoding the variant/single-chain meganuclease of the invention is placed under control of appropriate transcriptional and translational control elements to permit production or synthesis of said variant. Therefore, said polynucleotide is comprised in an expression cassette. More particularly, the vector comprises a replication origin, a promoter operatively linked to said encoding polynucleotide, a ribosome-binding site, an RNA-splicing site (when genomic DNA is used), a polyadenylation site and a transcription termination site. It also can comprise an enhancer. Selection of the promoter will depend upon the cell in which the polypeptide is expressed. Preferably, when said variant is a heterodimer, the two polynucleotides encoding each of the monomers are included in one vector which is able to drive the expression of both polynucleotides, simultaneously. Suitable promoters include tissue specific and/or inducible promoters. Examples of inducible promoters are: eukaryotic metallothionine promoter which is induced by increased levels of heavy metals, prokaryotic lacZ promoter which is induced in response to isopropyl-.beta.-D-thiogalacto-pyranoside (IPTG) and eukaryotic heat shock promoter which is induced by increased temperature. Examples of tissue specific promoters are skeletal muscle creatine kinase, prostate-specific antigen (PSA), .alpha.-antitrypsin protease, human surfactant (SP) A and B proteins, .beta.-casein and acidic whey protein genes.

[0121] According to another advantageous embodiment of said vector, it includes a targeting construct comprising sequences sharing homologies with the region surrounding the genomic DNA cleavage site as defined above.

[0122] Alternatively, the vector coding for an I-CreI variant/single-chain meganuclease and the vector comprising the targeting construct are different vectors.

[0123] More preferably, the targeting DNA construct comprises:

[0124] a) sequences sharing homologies with the region surrounding the genomic DNA cleavage site as defined above, and

[0125] b) a sequence to be introduced flanked by sequences as in a).

[0126] For gene knock-in at the mouse the ROSA26 locus, the sequence to be introduced comprises an exogenous gene expression cassette or part thereof and eventually a selection marker, such as the HPRT gene.

[0127] Alternatively, the sequence to be introduced can be any other sequence used to alter the mouse ROSA26 locus in some specific way including a sequence used to modify a specific sequence in the mouse ROSA26 locus, to attenuate or activate the mouse ROSA26 locus or part thereof, to introduce a mutation into a site of interest of the mouse ROSA26 locus, or to inactivate or delete the mouse ROSA26 locus or a part thereof.

[0128] Preferably, homologous sequences of at least 50 bp, preferably more than 100 bp and more preferably more than 200 bp are used for repairing the cleavage site. Indeed, shared DNA homologies are located in regions flanking upstream and downstream the site of the break and the DNA sequence to be introduced should be located between the two arms.

[0129] Therefore, the targeting construct is preferably from 200 pb to 6000 pb, more preferably from 1000 pb to 2000 pb.

[0130] For the insertion of a sequence, DNA homologies are generally located in regions directly upstream and downstream to the site of the break (sequences immediately adjacent to the break; minimal repair matrix). However, when the insertion is associated with a deletion of sequences flanking the cleavage site, shared DNA homologies are located in regions upstream and downstream the region of the deletion.

[0131] For example, the mouse ROSA 26 DNA targets which are cleaved by the variants as defined above and the minimal matrix for repairing each of the cleavage generated by each variant, are indicated in FIG. 17.

[0132] The subject-matter of the present invention is also a composition characterized in that it comprises at least one meganuclease as defined above (variant or single-chain derived chimeric meganuclease) and/or at least one expression vector encoding said meganuclease, as defined above.

[0133] In a preferred embodiment of said composition, it comprises a targeting DNA construct as defined above.

[0134] Preferably, said targeting DNA construct is either included in a recombinant vector or it is included in an expression vector comprising the polynucleotide(s) encoding the meganuclease according to the invention.

[0135] The subject-matter of the present invention is further the use of a meganuclease as defined above, one or two polynucleotide(s), preferably included in expression vector(s), for genome engineering at the mouse ROSA26 locus, for non-therapeutic purposes.

[0136] According to an advantageous embodiment of said use, it is for inducing a double-strand break in a site of interest of the mouse ROSA26 locus comprising a genomic DNA target sequence, thereby inducing a DNA recombination event, a DNA loss or cell death.

[0137] According to the invention, said double-strand break is for: modifying a specific sequence in the ROSA26 locus, attenuating or activating the endogenous ROSA26 locus, introducing a mutation into a site of interest of the ROSA26 locus, introducing an exogenous gene or a part thereof, inactivating or deleting the endogenous ROSA26 locus or a part thereof, translocating a chromosomal arm, or leaving the DNA unrepaired and degraded.

[0138] According to another advantageous embodiment of said use, said variant, polynucleotide(s), vector, are associated with a targeting DNA construct as defined above.

[0139] In a preferred embodiment of the use of the meganuclease according to the present invention, it comprises at least the following steps: 1) introducing a double-strand break at a site of interest of the mouse ROSA26 locus comprising at least one recognition and cleavage site of said meganuclease, by contacting said cleavage site with said meganuclease; 2) providing a targeting DNA construct comprising the sequence to be introduced flanked by sequences sharing homologies to the targeted locus. Said meganuclease can be provided directly to the cell or through an expression vector comprising the polynucleotide sequence encoding said meganuclease and suitable for its expression in the used cell. This strategy is used to introduce a DNA sequence at the target site, for example to generate knock-in transgenic mice or recombinant mouse cell lines that can be used for protein production, gene function studies, drug development (drug screening) or as disease model.

[0140] The subject-matter of the present invention is also a method for making a transgenic mouse expressing a product of interest, comprising at least the step of:

[0141] (a) introducing into a mouse pluripotent precursor cell or a mouse embryo, a meganuclease, as defined above, so as to into induce a double stranded cleavage at a site of interest of the ROSA26 locus comprising a DNA recognition and cleavage site of said meganuclease; simultaneously or consecutively,

[0142] (b) introducing into the mouse precursor cell or embryo of step (a) a targeting DNA, comprising at least a sequence encoding a product of interest flanked by sequences sharing homologies to the region surrounding the cleavage site, so as to generate a genomically modified mouse precursor cell or embryo having inserted the sequence of interest by homologous recombination between the targeting DNA and the chromosomal DNA,

[0143] (c) developing the genomically modified mouse precursor cell or embryo of step (b) into a chimeric mouse, and

[0144] (d) deriving a transgenic mouse from the chimeric mouse of step (c).

[0145] Preferably, step (c) comprises the introduction of the genomically modified precursor cell generated in step (b) into blastocysts so as to generate chimeric mice.

[0146] According to a preferred embodiment of said method, it comprises a further step (e) of recovering the product of interest from the transgenic mouse, by any means.

[0147] The subject-matter of the present invention is also a method for making a recombinant mouse cell expressing a product of interest, comprising at least the step of:

[0148] (a) introducing into a mouse cell, a meganuclease, as defined above, so as to into induce a double stranded cleavage at a site of interest of the ROSA26 locus comprising a DNA recognition and cleavage site for said meganuclease, simultaneously or consecutively,

[0149] (b) introducing into the cell of step (a), a targeting DNA, wherein said targeting DNA comprising at least a sequence encoding a product of interest flanked by sequences sharing homologies to the region surrounding the cleavage site, so as to generate a recombinant mouse cell having inserted the sequence of interest by homologous recombination between the targeting DNA and the chromosomal DNA,

[0150] (c) isolating the recombinant mouse cell of step (b), by any appropriate mean.

[0151] According to a preferred embodiment of said method, it comprises a further step (d) of recovering the product of interest from the recombinany mouse cell, by any means.

[0152] The targeting DNA is introduced into the cell under conditions appropriate for introduction of the targeting DNA into the site of interest.

[0153] In a preferred embodiment, said targeting DNA construct is inserted in a vector.

[0154] The cell which is modified may be any cell of interest. For making transgenic mice, the cells are pluripotent precursor cells such as embryo-derived stem (ES) cells, which are well-known in the art. For making recombinant mouse cell lines, the cells may advantageously be NSO, SP2/0 (BALB/c myeloma; ECACC #85110503 and #85072401), or L (ATCC # CRL-2648) cells. Said meganuclease can be provided directly to the cell or through an expression vector comprising the polynucleotide sequence encoding said meganuclease and suitable for its expression in the used cell.

[0155] For making transgenic animals/recombinant cell lines expressing a product of interest, the targeting DNA comprises a sequence encoding the product of interest (protein or RNA), and eventually a selectable marker gene, flanked by sequences upstream and downsteam the meganuclease site in the mouse ROSA26 locus, as defined above, so as to generate genomically modified cells (animal precursor cell or embryo/animal or human cell) having integrated the exogenous sequence of interest at the meganuclease site in the ROSA26 locus, by homologous recombination.

[0156] The sequence of interest may be any gene coding for a certain protein/peptide of interest, included but not limited to: reporter genes, receptors, signaling molecules, transcription factors, pharmaceutically active proteins and peptides, disease causing gene products and toxins. The sequence may also encode an RNA molecule of interest including for example a siRNA.

[0157] The expression of the exogenous sequence may be driven, either by the endogenous ROSA26 promoter or by an heterologous promoter, preferably a ubiquitous or tissue specific promoter, either constitutive or inducible, as defined above. In addition, the expression of the sequence of interest may be conditional; the expression may be induced by a site-specific recombinase (Cre, FLP . . . ).

[0158] Thus, the sequence of interest is inserted in an appropriate cassette that may comprise an heterologous promoter operatively linked to said gene of interest and one or more functional sequences including but mot limited to (selectable) marker genes, recombinase recognition sites, polyadenylation signals, splice acceptor sequences, introns, tags for protein detection and enhancers.

[0159] Alternatively, the appropriate cassette may comprise an Internal Ribosomal Entry site (IRES) operatively linked to said gene of interest and one or more functional sequences including but n events with the IRES-Hygro matrix (pCLS1675).ot limited to (selectable) marker genes, recombinase recognition sites, polyadenylation signals, splice acceptor sequences, introns, tags for protein detection and enhancers.

[0160] The meganuclease can be used either as a polypeptide or as a polynucleotide construct encoding said polypeptide. It is introduced into mouse cells, by any convenient means well-known to those in the art, which are appropriate for the particular cell type, alone or in association with either at least an appropriate vehicle or carrier and/or with the targeting DNA.

[0161] According to an advantageous embodiment of the uses according to the invention, the meganuclease (polypeptide) is associated with: [0162] liposomes, polyethyleneimine (PEI); in such a case said association is administered and therefore introduced into somatic target cells. [0163] membrane translocating peptides (Bonetta, The Scientist, 2002, 16, 38; Ford et al., Gene Ther., 2001, 8, 1-4; Wadia and Dowdy, Curr. Opin. Biotechnol., 2002, 13, 52-56); in such a case, the sequence of the variant/single-chain meganuclease is fused with the sequence of a membrane translocating peptide (fusion protein).

[0164] According to another advantageous embodiment of the uses according to the invention, the meganuclease (polynucleotide encoding said meganuclease) and/or the targeting DNA is inserted in a vector. Vectors comprising targeting DNA and/or nucleic acid encoding a meganuclease can be introduced into a cell by a variety of methods (e.g., injection, direct uptake, projectile bombardment, liposomes, electroporation). Meganucleases can be stably or transiently expressed into cells using expression vectors. Techniques of expression in eukaryotic cells are well known to those in the art. (See Current Protocols in Human Genetics: Chapter 12 "Vectors For Gene Therapy" & Chapter 13 "Delivery Systems for Gene Therapy"). Optionally, it may be preferable to incorporate a nuclear localization signal into the recombinant protein to be sure that it is expressed within the nucleus.

[0165] Once in a cell, the meganuclease and if present, the vector comprising targeting DNA and/or nucleic acid encoding a meganuclease are imported or translocated by the cell from the cytoplasm to the site of action in the nucleus.

[0166] In one embodiment of the uses according to the present invention, the meganuclease is substantially non-immunogenic, i.e., engender little or no adverse immunological response. A variety of methods for ameliorating or eliminating deleterious immunological reactions of this sort can be used in accordance with the invention. In a preferred embodiment, the meganuclease is substantially free of N-formyl methionine. Another way to avoid unwanted immunological reactions is to conjugate meganucleases to polyethylene glycol ("PEG") or polypropylene glycol ("PPG") (preferably of 500 to 20,000 daltons average molecular weight (MW)). Conjugation with PEG or PPG, as described by Davis et al. (U.S. Pat. No. 4,179,337) for example, can provide non-immunogenic, physiologically active, water soluble endonuclease conjugates with anti-viral activity. Similar methods also using a polyethylene-polypropylene glycol copolymer are described in Saifer et al. (U.S. Pat. No. 5,006,333).

[0167] The invention also concerns a prokaryotic or eukaryotic host cell which is modified by a polynucleotide or a vector as defined above, preferably an expression vector.

[0168] The invention also concerns a non-human transgenic animal or a transgenic plant, characterized in that all or parts of their cells are modified by a polynucleotide or a vector as defined above.

[0169] As used herein, a cell refers to a prokaryotic cell, such as a bacterial cell, or an eukaryotic cell, such as an animal, plant or yeast cell.

[0170] The subject-matter of the present invention is also the use of at least one meganuclease variant, as defined above, as a scaffold for making other meganucleases. For example a third round of mutagenesis and selection/screening can be performed on said variants, for the purpose of making novel, third generation meganucleases.

[0171] The different uses of the meganuclease and the methods of using said meganuclease according to the present invention include the use of the I-CreI variant, the single-chain chimeric meganuclease derived from said variant, the polynucleotide(s), vector, cell, transgenic plant or non-human transgenic mammal encoding said variant or single-chain chimeric meganuclease, as defined above.

[0172] The I-CreI variant according to the invention may be obtained by a method for engineering I-CreI variants able to cleave a genomic DNA target sequence from the mouse ROSA26 locus, comprising at least the steps of:

[0173] (a) constructing a first series of I-CreI variants having at least one substitution in a first functional subdomain of the LAGLIDADG core domain situated from positions 26 to 40 of I-CreI,

[0174] (b) constructing a second series of I-CreI variants having at least one substitution in a second functional subdomain of the LAGLIDADG core domain situated from positions 44 to 77 of I-CreI,

[0175] (c) selecting and/or screening the variants from the first series of step (a) which are able to cleave a mutant I-CreI site wherein at least (i) the nucleotide triplet at positions -10 to -8 of the I-CreI site has been replaced with the nucleotide triplet which is present at positions -10 to -8 of said genomic target and (ii) the nucleotide triplet at positions +8 to +10 has been replaced with the reverse complementary sequence of the nucleotide triplet which is present at positions -10 to -8 of said genomic target,

[0176] (d) selecting and/or screening the variants from the second series of step (b) which are able to cleave a mutant I-CreI site wherein at least (i) the nucleotide triplet at positions -5 to -3 of the I-CreI site has been replaced with the nucleotide triplet which is present at positions -5 to -3 of said genomic target and (ii) the nucleotide triplet at positions +3 to +5 has been replaced with the reverse complementary sequence of the nucleotide triplet which is present at positions -5 to -3 of said genomic target,

[0177] (e) selecting and/or screening the variants from the first series of step (a) which are able to cleave a mutant I-CreI site wherein at least (i) the nucleotide triplet at positions +8 to +10 of the I-CreI site has been replaced with the nucleotide triplet which is present at positions +8 to +10 of said genomic target and (ii) the nucleotide triplet at positions -10 to -8 has been replaced with the reverse complementary sequence of the nucleotide triplet which is present at positions +8 to +10 of said genomic target,

[0178] (f) selecting and/or screening the variants from the second series of step (b) which are able to cleave a mutant I-CreI site wherein at least (i) the nucleotide triplet at positions +3 to +5 of the I-CreI site has been replaced with the nucleotide triplet which is present at positions +3 to +5 of said genomic target and (ii) the nucleotide triplet at positions -5 to -3 has been replaced with the reverse complementary sequence of the nucleotide triplet which is present at positions +3 to +5 of said genomic target,

[0179] (g) combining in a single variant, the mutation(s) at positions 26 to 40 and 44 to 77 of two variants from step (c) and step (d), to obtain a novel homodimeric I-CreI variant which cleaves a sequence wherein (i) the nucleotide triplet at positions -10 to -8 is identical to the nucleotide triplet which is present at positions -10 to -8 of said genomic target, (ii) the nucleotide triplet at positions +8 to +10 is identical to the reverse complementary sequence of the nucleotide triplet which is present at positions -10 to -8 of said genomic target, (iii) the nucleotide triplet at positions -5 to -3 is identical to the nucleotide triplet which is present at positions -5 to -3 of said genomic target and (iv) the nucleotide triplet at positions +3 to +5 is identical to the reverse complementary sequence of the nucleotide triplet which is present at positions -5 to -3 of said genomic target, and/or

[0180] (h) combining in a single variant, the mutation(s) at positions 26 to 40 and 44 to 77 of two variants from step (e) and step (f), to obtain a novel homodimeric I-CreI variant which cleaves a sequence wherein (i) the nucleotide triplet at positions +3 to +5 is identical to the nucleotide triplet which is present at positions +3 to +5 of said genomic target, (ii) the nucleotide triplet at positions -5 to -3 is identical to the reverse complementary sequence of the nucleotide triplet which is present at positions +3 to +5 of said genomic target, (iii) the nucleotide triplet at positions +8 to +10 of the I-CreI site has been replaced with the nucleotide triplet which is present at positions +8 to +10 of said genomic target and (iv) the nucleotide triplet at positions -10 to -8 is identical to the reverse complementary sequence of the nucleotide triplet at positions +8 to +10 of said genomic target,

[0181] (i) combining the variants obtained in steps (g) and (h) to form heterodimers, and

[0182] (j) selecting and/or screening the heterodimers from step (i) which are able to cleave said genomic DNA target from the mouse ROSA26 locus.

[0183] One of the step(s) (c), (d), (e) or (f) may be omitted. For example, if step (c) is omitted, step (d) is performed with a mutant I-CreI site wherein both nucleotide triplets at positions -10 to -8 and -5 to -3 have been replaced with the nucleotide triplets which are present at positions -10 to -8 and -5 to -3, respectively of said genomic target, and the nucleotide triplets at positions +3 to +5 and +8 to +10 have been replaced with the reverse complementary sequence of the nucleotide triplets which are present at positions -5 to -3 and -10 to -8, respectively of said genomic target.

[0184] Steps (a), (b), (g), (h) and (i) may further comprise the introduction of additional mutations at other positions contacting the DNA target sequence or interacting directly or indirectly with said DNA target, at positions which improve the binding and/or cleavage properties of the mutants, or at positions which prevent the formation of functional homodimers, as defined above. This may be performed by generating a combinatorial library as described in the International PCT Application WO 2004/067736.

[0185] The method for engineering I-CreI variants of the invention advantageously comprise the introduction of random mutations on the whole variant or in a part of the variant, in particular the C-terminal half of the variant (positions 80 to 163) to improve the binding and/or cleavage properties of the mutants towards the DNA target from the gene of interest. The mutagenesis may be performed by generating random mutagenesis libraries on a pool of variants, according to standard mutagenesis methods which are well-known in the art and commercially available. Preferably, the mutagenesis is performed on the entire sequence of one monomer of the heterodimer formed in step (i) or obtained in step (j), advantageously on a pool of monomers, preferably on both monomers of the heterodimer of step (i) or (j).

[0186] Preferably, two rounds of selection/screening are performed according to the process illustrated by FIG. 4 of Arnould et al., J. Mol. Biol., Epub 10 May 2007. In the first round, one of the monomers of the heterodimer is mutagenised (monomer Y in FIG. 4), co-expressed with the other monomer (monomer X in FIG. 4) to form heterodimers, and the improved monomers Y.sup.+ are selected against the target from the gene of interest. In the second round, the other monomer (monomer X) is mutagenised, co-expressed with the improved monomers Y.sup.+ to form heterodimers, and selected against the target from the gene of interest to obtain meganucleases (X.sup.+ Y.sup.+) with improved activity.

[0187] The (intramolecular) combination of mutations in steps (g) and (h) may be performed by amplifying overlapping fragments comprising each of the two subdomains, according to well-known overlapping PCR techniques.

[0188] The (intermolecular) combination of the variants in step (i) is performed by co-expressing one variant from step (g) with one variant from step (h), so as to allow the formation of heterodimers. For example, host cells may be modified by one or two recombinant expression vector(s) encoding said variant(s). The cells are then cultured under conditions allowing the expression of the variant(s), so that heterodimers are formed in the host cells, as described previously in the International PCT Application WO 2006/097854 and Arnould et al., J. Mol. Biol., 2006, 355, 443-458.

[0189] The selection and/or screening in steps (c), (d), (e), (f) and/or (j) may be performed by using a cleavage assay in vitro or in vivo, as described in the International PCT Application WO 2004/067736, Arnould et al., J. Mol. Biol., 2006, 355, 443-458, Epinat et al., Nucleic Acids Res., 2003, 31, 2952-2962 and Chames et al., Nucleic Acids Res., 2005, 33, e178.

[0190] According to another advantageous embodiment of said method, steps (c), (d), (e), (f) and/or (j) are performed in vivo, under conditions where the double-strand break in the mutated DNA target sequence which is generated by said variant leads to the activation of a positive selection marker or a reporter gene, or the inactivation of a negative selection marker or a reporter gene, by recombination-mediated repair of said DNA double-strand break.

[0191] The subject matter of the present invention is also an I-CreI variant having mutations at positions 26 to 40 and/or 44 to 77 of I-CreI that is useful for engineering the variants able to cleave a DNA target from the mouse ROSA26 locus, according to the present invention. In particular, the invention encompasses the I-CreI variants as defined in step (c) to (f) of the method for engineering I-CreI variants, as defined above, including the variants m1 to m18 (Table II, SEQ ID NO: 38 to 55), the variant comprising Q44V, R70A and D75N (SEQ ID NO: 131; Table III) and the variant comprising K28E, Y33R, Q38R, S40R and D75N (SEQ ID NO: 132; Table III). The invention encompasses also the I-CreI variants as defined in step (g) and (h) of the method for engineering I-CreI variants, as defined above, including the variants of the sequence SEQ ID NO:60 to 67 (combined variants of Table III).

[0192] Single-chain chimeric meganucleases able to cleave a DNA target from the gene of interest are derived from the variants according to the invention by methods well-known in the art (Epinat et al., Nucleic Acids Res., 2003, 31, 2952-62; Chevalier et al., Mol. Cell., 2002, 10, 895-905; Steuer et al., Chembiochem., 2004, 5, 206-13; International PCT Applications WO 03/078619 and WO 2004/031346). Any of such methods, may be applied for constructing single-chain chimeric meganucleases derived from the variants as defined in the present invention.

[0193] The polynucleotide sequence(s) encoding the variant as defined in the present invention may be prepared by any method known by the man skilled in the art. For example, they are amplified from a cDNA template, by polymerase chain reaction with specific primers. Preferably the codons of said cDNA are chosen to favour the expression of said protein in the desired expression system.

[0194] The recombinant vector comprising said polynucleotides may be obtained and introduced in a host cell by the well-known recombinant DNA and genetic engineering techniques.

[0195] The I-CreI variant or single-chain derivative as defined in the present the invention are produced by expressing the polypeptide(s) as defined above; preferably said polypeptide(s) are expressed or co-expressed (in the case of the variant only) in a host cell or a transgenic animal/plant modified by one expression vector or two expression vectors (in the case of the variant only), under conditions suitable for the expression or co-expression of the polypeptide(s), and the variant or single-chain derivative is recovered from the host cell culture or from the transgenic animal/plant.

[0196] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and son Inc, Library of Congress, USA); Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et al, 2001, Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Harries & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the series, Methods In ENZYMOLOGY (J. Abelson and M. Simon, eds.-in-chief, Academic Press, Inc., New York), specifically, Vols. 154 and 155 (Wu et al. eds.) and Vol. 185, "Gene Expression Technology" (D. Goeddel, ed.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

[0197] In addition to the preceding features, the invention further comprises other features which will emerge from the description which follows, which refers to examples illustrating the I-CreI meganuclease variants and their uses according to the invention, as well as to the appended drawings in which:

[0198] FIG. 1 represents the mouse ROSA26 locus (accession number EMBL CQ880114; SEQ ID NO: 3). The Exons are boxed (Exon 1: positions 2490 to 2599; Exon 2 from transcript 1: positions 8228 to 9248; Exon 3 from transcript 2 starts at position 11845, and largely overlaps with the antisense transcript, which ends art position 11505. The three transcripts identified so far are indicated as well as the sequence and position of target rosa1 (SEQ ID NO: 15).

[0199] FIG. 2 represents the tridimensional structure of the I-CreI homing endonuclease bound to its DNA target. The catalytic core is surrounded by two .alpha..beta..beta..alpha..beta..beta..alpha. folds forming a saddle-shaped interaction interface above the DNA major groove.

[0200] FIG. 3 illustrates a two-step approach to engineer the specificity of I-CreI and other LAGLIDADG homing endonucleases. A large collection of I-CreI derivatives is generated by semi-rational mutagenesis of an initial scaffold and screening for functional variants with locally altered specificity. Then, a combinatorial approach is used to assemble these mutants into meganucleases with fully redesigned specificity. Homodimeric proteins ("half-meganucleases") are created by combinations of two sets of mutations within a same .alpha..beta..beta..alpha..beta..beta..alpha. fold, and the co-expression of two such `half-meganucleases" can result in a heterodimeric species ("custom-meganuclease") cleaving the target of interest.

[0201] FIG. 4 represents a strategy for the use of a meganuclease cleaving the mouse ROSA26 locus. Gene insertion using meganuclease-induced homologous recombination will knock-in a gene of interest in the mouse ROSA26 locus. Introns and exons sequences can be used as homologous regions.

[0202] FIG. 5 represents the rosa1 target sequence and derivatives. 10GGG_P, 5GAT_P and 5TAT_P are close derivatives found to be cleaved by previously obtained I-CreI mutants. They differ from C1221 (palindromic sequence cleaved by the I-CreI scaffold protein) by the boxed motives. C1221, 10GGG_P, 5GAT_P and 5TAT_P were first described as 24 bp sequences, but structural data suggest that only the 22 bp are relevant for protein/DNA interaction. However, positions .+-.12 are indicated in parenthesis. rosa1 is the DNA sequence located in the mouse ROSA26 locus at position 8304. In the rosa1.2 target, the GTTC sequence in the middle of the target is replaced with GTAC, the bases found in C1221. rosa1.3 is the palindromic sequence derived from the left part of rosa1.2, and rosa1.4 is the palindromic sequence derived from the right part of rosa1.2. As shown in the figure, the boxed motives from 10GGG_P, 5GAT_P and 5TAT_P are found in the rosa1 series of targets.

[0203] FIG. 6 represents the pCLS1055 vector map.

[0204] FIG. 7 represents the pCLS0542 vector map.

[0205] FIG. 8 illustrates the cleavage of the rosa1.3 DNA target by I-CreI mutants. The 63 positives found in primary screen were rearranged in one 96-well plate and validated by a secondary screen (in a quadraplicate format). The 22 mutants chosen in example 2 are circled.

[0206] FIG. 9 illustrates the cleavage of the rosa1.4 target by I-CreI combinatorial mutants. The 69 positives found in primary screen were rearranged in one 96-well plate and validated by a secondary screen (in a quadraplicate format). The 15 chosen mutants in example 3 are circled.

[0207] FIG. 10 represents the pCLS1107 vector map.

[0208] FIG. 11 illustrates the cleavage of the rosa1.2 and rosa1 targets by heterodimeric I-CreI combinatorial mutants. A. Example of screening of combinations of I-CreI mutants with the rosa1.2 target. B. Screening of the same combinations of I-CreI mutants with the rosa1 target. B5, B6, D5, D6, F5, F6, H5 and H6: yeast strains expressing rosa1.3 cutting I-CreI mutants transformed with pCLS1107 empty plasmid DNA.

[0209] FIG. 12 illustrates the cleavage of the rosa1 target. A series of 1-CreI mutants cutting rosa1.4 were randomly mutagenized and co-expressed with a mutant cutting rosa1.3. Cleavage is tested with the rosa1 target. In each four dots cluster, the two dots on the right correspond to one of the original heterodimers cleaving rosa1 in duplicate, whereas the tow left dots correspond to a same mutated rosa1.4 cleaver co-expressed with a non mutated rosa1.3 cleaver (mutant m13, described in Tables IV and V). The two optimized mutants displaying improved cleavage of rosa1 are circled, and correspond to co-expression of mutants m13 and MO.sub.--1 (C10) or of m13 and MO.sub.--2 (E2). MO.sub.--1 and MO.sub.--2 are further described in Table VI.

[0210] FIG. 13 illustrates the cleavage of the rosa1 target. A series of 1-CreI mutants cutting rosa1.3 were randomly mutagenized and co-expressed with a refined mutant cutting rosa1.4. Cleavage is tested with the rosa1 target. Mutants displaying efficient cleavage of rosa1 are circled. In the filter:

[0211] B11 corresponds to the heterodimer S19, V24, Y44, R68, S70, N75, V77+E28, R33, R38, K40, A44, H68, Q70, A105, R107, A151, G153, E158;

[0212] C9 corresponds to the heterodimer S19, V24, Y44, R68, S70, Q75, I77+E28, R33, R38, K40, A44, H68, Q70, A105, R107, A151, G153, E158;

[0213] C11 and E8 correspond to the heterodimer V24, Y44, S68, S70, R75, I77, A105+E28, R33, R38, K40, A44, H68, Q70, A105, R107, A151, G153, E158; and

[0214] E6 corresponds to the heterodimer V24, Y44, S68, S70, R75, I77, G79+E28, R33, R38, K40, A44, H68, Q70, A105, R107, A151, G153, E158.

[0215] H10 is a negative control, H11 and H12 are positive controls of different intensity. To compare the activity of the heterodimers against the rosa1 target before and after the improvement of mutants cutting the rosa1.3 target: in each cluster, the two right points are one of the heterodimers described in example 5 and the two left points are heterodimers with mutants described in example 6.

[0216] FIG. 14 represents the pCLS1058 vector map.

[0217] FIG. 15 represents the pCLS1069 vector map.

[0218] FIG. 16 illustrates the cleavage of the rosa1 target by I-CreI refined mutants in an extrachromosomic model in CHO cells. Values from two transfection experiments are shown. Cleavage of I-CreI and I-SceI targets by I-CreI N75 and I-SceI in the same experiments are shown as positive controls.

[0219] FIG. 17 represents meganuclease target sequences found in the mouse ROSA26 and the corresponding I-CreI variant which is able to cleave each of said DNA targets. The sequence of the DNA target is presented (column 1), with its position (column 2). The minimum repair matrix for repairing the cleavage at the target site is indicated by its first nucleotide (start, column 5) and last nucleotide (end, column 6). The sequence of each variant is defined by the residues at the indicated positions. For example, the first heterodimeric variant of FIG. 17 consists of a first monomer having K, H, S, S, Q, S, E, C, S, N and I at positions 28, 30, 32, 33, 38, 40, 44, 68, 70, 75 and 77, respectively and a second monomer having K, D, S, R, T, S, K, E, S, D, R at positions 28, 30, 32, 33, 38, 40, 44, 68, 70, 75 and 77, respectively. The positions are indicated by reference to I-CreI sequence SWISSPROT P05725 (SEQ ID NO: 1); I-CreI has K, N, S, Y, Q, S, Q, R, R, D and I, at positions 28, 30, 32, 33, 38, 40, 44, 68, 70, 75 and 77 respectively.

[0220] FIG. 18 represents the pCLS1675 vector map.

[0221] FIG. 19 represents the pCLS1761 vector map.

[0222] FIG. 20 represents the pCLS1762 vector map.

[0223] FIG. 21 illustrates PCR analysis of knock-in (KI) events with the IRES-Hygro matrix (pCLS1675). events with the IRES-Hygro matrix (pCLS1675). Clones wild-type for the ROSA26 locus and clones having a random insertion of the hygromycin CDS are negatives in PCR. Clones having a KI event at the ROSA26 locus are positives in PCR. Clones having KI event and random insertion are also positives in PCR.

EXAMPLE 1

Strategy for Engineering Novel Meganucleases Cleaving the Mouse ROSA26 Locus

[0224] The combinatorial approach described in Smith et al., Nucleic Acids Res., 2006 and illustrated in FIG. 3, was used to engineer the DNA binding domain of I-CreI, and cleave a 22 bp (non-palindromic) sequence named rosa1 (FIG. 5) and located at position 8304, in exon 2 of the mouse ROSA26 locus (accession number CQ880114; SEQ ID NO: 3). Meganucleases cleaving the rosa1 sequence could be used to knock-in genes in the mouse ROSA26 locus (FIG. 4). Applications are in the following fields: production of recombinant proteins in mouse cells, engineering of recombinant cell lines, for example for drug screening purpose, and engineering of transgenic mice, for example for use as animal models.

[0225] The rosa1 sequence is partly a patchwork of the 10GGG_P, 5GAT_P and 5TAT_P targets (FIG. 5), which are cleaved by previously identified meganucleases, obtained as described in International PCT Applications WO 2006/097784, WO 2006/097853 and WO 2007/049156; Arnould et al., J. Mol. Biol., 2006, 355, 443-458 and Smith et al., Nucleic Acids Res., Epub 27 Nov. 2006. Thus rosa1 could be cleaved by meganucleases combining the mutations found in the I-CreI derivatives cleaving these three targets.

[0226] The 10GGG_P, 5GAT_P and 5TAT_P sequences are 24 bp derivatives of C1221, a palindromic sequence cleaved by I-CreI (International PCT Applications WO 2006/097784, WO 2006/097853 and WO 2007/049156; Arnould et al., J. Mol. Biol., 2006, 355, 443-458 and Smith et al., Nucleic Acids Res., Epub 27 Nov. 2006). However, the structure of I-CreI bound to its DNA target suggests that the two external base pairs of these targets (positions -12 and 12) have no impact on binding and cleavage (Chevalier et al., Nat. Struct. Biol., 2001, 8, 312-316; Chevalier B. S, and Stoddard B. L., Nucleic Acids Res., 2001, 29, 3757-3754; Chevalier et al., J. Mol. Biol., 2003, 329, 253-269), and in this study, only positions -11 to 11 were considered. Consequently, the rosa1 series of targets were defined as 22 bp sequences instead of 24 bp.

[0227] Rosa1 differs from C1221 in one base pair of the 4 bp central region. According to the structure of the I-CreI protein bound to its target, there is no contact between the 4 central base pairs (positions -2 to 2) and the I-CreI protein (Chevalier et al., Nat. Struct. Biol., 2001, 8, 312-316; Chevalier B. S, and Stoddard B. L., Nucleic Acids Res., 2001, 29, 3757-3754; Chevalier et al., J. Mol. Biol., 2003, 329, 253-269). Thus, the bases at these positions are not supposed to impact the binding efficiency. However, they could affect cleavage, which results from two nicks at the edge of this region. Thus, the GTTC sequence in -2 to 2 were first substituted with the GTAC sequence from C1221, resulting in target rosa1.2 (FIG. 5)

[0228] Then, two palindromic targets, rosa1.3 and rosa1.4, were derived from rosa1.2 (FIG. 5). Since rosa1.3 and rosa1.4 are palindromic, they should be cleaved by homodimeric proteins.

[0229] Thus proteins able to cleave the rosa1.3 and rosa1.4 sequences as homodimers, were first designed (examples 2 and 3), and then coexpressed to obtain heterodimers cleaving rosa1 (example 4). Heterodimers cleaving the rosa1.2 and rosa1 targets could be identified. In order to improve cleavage activity for the rosa1 target, we chose a series of chosen mutants cleaving rosa1.3 and rosa1.4 was then refined; the chosen mutants were randomly mutagenized, and used to form novel heterodimers that were screened against the rosa1 target (examples 5 and 6). Finally, heterodimers cleaving the rosa1 target could be identified, displaying a high cleavage activity in yeast and CHO cells.

EXAMPLE 2

Making of Meganucleases Cleaving Rosa1.3

[0230] This example shows that I-CreI mutants can cut the rosa1.3 DNA target sequence derived from the left part of the rosa1 target in a palindromic form (FIG. 5).

[0231] Target sequences described in this example are 22 bp palindromic sequences. Therefore, they will be described only by the first 11 nucleotides, followed by the suffix_P. For example, target rosa1.3 will be noted also caacatgatgt_P; SEQ ID NO: 35)).

[0232] The rosa1.3 target is similar to 5GAT_P at positions .+-.1, .+-.2, .+-.3, .+-.4, .+-.5, .+-.7, .+-.9, .+-.10 and .+-.11, the two sequences differing only at positions .+-.6 and .+-.8. It was hypothesized that positions .+-.6 would have little effect on the binding and cleavage activity. Mutants able to cleave 5GAT_P (caaaacgatgt_P; SEQ ID NO: 32) were previously obtained by mutagenesis on I-CreI N75 at positions 24, 44, 68, 70, 75 and 77, as described in Arnould et al., J. Mol. Biol., 2006, 355, 443-458 and International PCT Applications WO 2006/097784 and WO 2006/097853. In this example, it was checked whether mutants cleaving the 5GAT_P target could also cleave the rosa1.3 target.

1) Material and Methods

[0233] The method for producing meganuclease variants and the assays based on cleavage-induced recombination in mammal or yeast cells, which are used for screening variants with altered specificity are described in the International PCT Application WO 2004/067736; Epinat et al., Nucleic Acids Res., 2003, 31, 2952-2962; Chames et al., Nucleic Acids Res., 2005, 33, e178, and Arnould et al., J. Mol. Biol., 2006, 355, 443-458. These assays result in a functional LacZ reporter gene which can be monitored by standard methods.

a) Construction of Target Vector

[0234] The target was cloned as follow: oligonucleotide corresponding to the target sequence flanked by gateway cloning sequence was ordered from PROLIGO: 5' 5' tggcatacaagtttcaacatgatgtacatcatgttgacaatcgtctgtca 3'(SEQ ID NO: 37). Double-stranded target DNA, generated by PCR amplification of the single stranded oligonucleotide, was cloned using the Gateway protocol (INVITROGEN) into yeast reporter vector (pCLS1055, FIG. 6). Yeast reporter vector was transformed into S. cerevisiae strain FYBL2-7B (MAT .alpha., ura3.DELTA.851, trp1.DELTA.63, leu2.DELTA.1, lys2.DELTA.202).

b) I-CreI Mutants

[0235] I-CreI mutants cleaving 5GAT_P were identified in a library where positions 24, 44, 68, 70, 75 and 77 of I-CreI are mutated, as described previously in Arnould et al., J. Mol. Biol., 2006, 355, 443-458 and International PCT Applications WO 2006/097784 and WO 2006/097853. They are cloned in the DNA vector (pCLS0542, FIG. 7) and expressed in the yeast Saccharomyces cerevisiae strain FYC2-6A (MAT.alpha., trp1.DELTA.63, leu2.DELTA.1, his3.DELTA.200).

c) Mating of Meganuclease Expressing Clones and Screening in Yeast:

[0236] Screening was performed as described previously (Arnould et al., J. Mol. Biol., 2006, 355, 443-458). Mating was performed using a colony gridder (QpixII, Genetix). Mutants were gridded on nylon filters covering YPD plates, using a low gridding density (about 4 spots/cm.sup.2). A second gridding process was performed on the same filters to spot a second layer consisting of different reporter-harboring yeast strains for each target. Membranes were placed on solid agar YPD rich medium, and incubated at 30.degree. C. for one night, to allow mating. Next, filters were transferred to synthetic medium, lacking leucine and tryptophan, with galactose (2%) as a carbon source, and incubated for five days at 37.degree. C., to select for diploids carrying the expression and target vectors. After 5 days, filters were placed on solid agarose medium with 0.02% X-Gal in 0.5 M sodium phosphate buffer, pH 7.0, 0.1% SDS, 6% dimethyl formamide (DMF), 7 mM .beta.-mercaptoethanol, 1% agarose, and incubated at 37.degree. C., to monitor .beta.-galactosidase activity. Results were analyzed by scanning and quantification was performed using appropriate software.

d) Sequencing of Mutants

[0237] To recover the mutant expressing plasmids, yeast DNA was extracted using standard protocols and used to transform E. coli. Sequence of mutant ORF were then performed on the plasmids by MILLEGEN SA. Alternatively, ORFs were amplified from yeast DNA by PCR (Akada et al., Biotechniques, 2000, 28, 668-670), and sequence was performed directly on PCR product by MILLEGEN SA.

2) Results

[0238] I-CreI mutants cleaving the 5GAT_P target, previously identified in a library where positions 24, 44, 68, 70, 75 and 77 of I-CreI are mutated, were screened for cleavage against the rosa1.3 DNA target (caacatgatgt_P; SEQ ID NO: 35). A total of 63 positive clones were found, rearranged in a 96-well plate and validated by secondary screening (FIG. 8). Among those positive clones, 22 (circled in FIG. 8) were chosen. Those 22 positives clones were sequenced. They turned out to correspond to 18 different novel endonucleases cleaving the rosa1.3 target (named m1 to m18: SEQ ID NO: 38 to 55; Table II).

TABLE-US-00002 TABLE II I-CreI mutants capable of cleaving the rosa1.3 DNA target Amino acids at positions 24, 44, 68, 70, 75 and Sequence 77 (ex: VYRSYI stands Position on SEQ ID for V24, Y44, R68, S70, FIG. 8 Name NO: Y75 and 177) A1 and F3 m1 38 VYRSYI A3 m2 39 VYRSNI A5 and B1 m3 40 VYDSRR A9 m4 41 ITYSYR A11 m5 42 VYRSYQ B3, D5 and E6 m6 43 VYYSYR B8 m7 44 VYYSRA B9 m8 45 VYRSNV B10 m9 46 VNYSYR B11 m10 47 VNYSYR + 82T* C3 m11 48 VYSSRV C8 m12 49 VYNSRI C11 ml3 50 VYSSRI D6 m14 51 VYRSQI D9 m15 52 IYRSNI D12 m16 53 VYYSRV E1 m17 54 VYRSYT E11 m18 55 VNSSRV *82T in m10 is an unexpected mutation that may be due to an error introduced by the PCR reaction before sequencing of yeast DNA.

EXAMPLE 3

Making of Meganucleases Cleaving Rosa1.4

[0239] This example shows that I-CreI mutants can cut the rosa1.4 DNA target sequence derived from the right part of the rosa1 target in a palindromic form (FIG. 5). All targets sequences described in this example are 22 bp palindromic sequences. Therefore, they will be described only by the first 11 nucleotides, followed by the suffix_P. For example, rosa1.4 will be called tgggattatgt_P (SEQ ID NO: 36).

[0240] The rosa1.4 target is similar to 5TAT_P at positions .+-.1, .+-.2, .+-.3, .+-.4, .+-.5 and .+-.7 and to 10GGG_P at positions .+-.1, .+-.2, .+-.7, .+-.8, .+-.9 and .+-.10. It was hypothesized that positions .+-.6 and .+-.11 would have little effect on the binding and cleavage activity. Mutants able to cleave 5TAT_P were previously obtained by mutagenesis on I-CreI N75 at positions 44, 68, 70, as described in Arnould et al., J. Mol. Biol., 2006, 355, 443-458 and International PCT Applications WO 2006/097784 and WO 2006/097853. Mutants able to cleave the 10GGG_P target were obtained by mutagenesis on I-CreI N75 at positions 28, 30, 33, 38, 40 and 70, as described in Smith et al., Nucleic Acids Res., Epub 27 Nov. 2006 and International PCT Application WO 2007/049156.

[0241] Both sets of proteins are mutated at position 70. However, it was hypothesized that two separable functional subdomains exist. That implies that this position has little impact on the specificity towards the bases .+-.8 to 10 of the target.

[0242] Therefore, to check whether combined mutants could cleave the rosa1.4 target, mutations at positions 44, 68 and 70 from proteins cleaving 5TAT_P (caaaactatgt_P; SEQ ID NO: 33) were combined with the 28, 30, 33, 38 and 40 mutations from proteins cleaving 10GGG_P (cgggacgtcgt_P; SEQ ID NO: 31).

1) Material and Methods

[0243] The experimental procedures are as described in example 2 and as follows:

Construction of Combinatorial Mutants

[0244] I-CreI mutants cleaving 10GGG_P or 5TAT_P were identified in Smith et al, Nucleic Acids Res. Epub 27 Nov. 2006; International PCT Application WO 2007/049156, and Amould et al., J. Mol. Biol., 2006, 355, 443-458; International PCT Applications WO 2006/097784 and WO 2006/097853, respectively for the 10GGG_P or 5TAT_P targets. In order to generate I-CreI derived coding sequence containing mutations from both series, separate overlapping PCR reactions were carried out that amplify the 5' end (aa positions 1-43) or the 3' end (positions 39-167) of the I-CreI coding sequence. For both the 5' and 3' end, PCR amplification is carried out using primers Gal10F 5'-gcaactttagtgctgacacatacagg-3' (SEQ ID NO: 56) or Gal10R 5'-acaaccttgattggagacttgacc-3'(SEQ ID NO: 57), specific to the vector (pCLS0542, FIG. 7) and primers assF 5'-ctannnttgaccttt-3' (SEQ ID NO: 58) or assR 5'-aaaggtcaannntag-3' (SEQ ID NO: 59) where mm code for residue 40, specific to the I-CreI coding sequence for amino acids 39-43. The PCR fragments resulting from the amplification reaction realized with the same primers and with the same coding sequence for residue 40 were pooled. Then, each pool of PCR fragments resulting from the reaction with primers Gal10F and assR or assF and Gal10R was mixed in an equimolar ratio. Finally, approximately 25 ng of each final pool of the two overlapping PCR fragments and 75 ng of vector DNA (pCLS0542) linearized by digestion with NcoI and EagI were used to transform the yeast Saccharomyces cerevisiae strain FYC2-6A (MAT.alpha., trp1.DELTA.63, leu.DELTA.1, his3.DELTA.200) using a high efficiency LiAc transformation protocol (Gietz and Woods, Methods Enzymol., 2002, 350, 87-96). An intact coding sequence containing both groups of mutations is generated by in vivo homologous recombination in yeast.

2) Results

[0245] I-CreI combinatorial mutants were constructed by associating mutations at positions 44, 68 and 70 with the 28, 30, 33, 38 and 40 mutations on the I-CreI N75 scaffold, resulting in a library of complexity 2208. Examples of combinatorial mutants are displayed in Table III. This library was transformed into yeast and 3456 clones (1.5 times the diversity) were screened for cleavage against the rosa1.4 DNA target (tgggattatgt_P; SEQ ID NO: 36). A total of 69 positive clones were found and were rearranged in a 96-well plate and validated by secondary screening (FIG. 9). Among those positives, 15 clones (circled in FIG. 9) were chosen. After sequencing, these 15 clones turned out to correspond to 8 different novel endonucleases cleaving the rosa1.4 DNA target (SEQ ID NO: 60 to 67; Table III).

TABLE-US-00003 TABLE III Cleavage of the rosa1.4 target by the combinatorial variants Amino acids at positions 28, 30, 33, 38 and 40 (ex: ENRRR stands for E28, N30, R33, R38 and R40) ENRRR ENRRK KNHAS KNHSS KNHQS KNRAT RNRDR Amino acids at positions 44, 68 and 70 AHQ + + (ex: AHQ stands for A44, H68 and Q70) ARN + ARS + VRA + ARG + ASQ + ATN + RAG ANN AQH ARH ARL ART NRN AQA Only 105 out of the 2208 combinations are displayed). + indicates that a functional combinatorial mutant was found among the sequenced positives.

EXAMPLE 4

Making of Meganucleases Cleaving Rosa1

[0246] I-CreI mutants able to cleave each of the palindromic rosa1 derived targets (rosa1.3 and rosa1.4) were identified in examples 2 and 3. Pairs of such mutants (one cutting rosa1.3 and one cutting rosa1.4) were co-expressed in yeast. Upon coexpression, there should be three active molecular species, two homodimers, and one heterodimer. It was assayed whether the heterodimers that should be formed cut the non palindromic rosa1 and rosa1.2 DNA targets.

1) Material and Methods

a) Cloning of Mutants in Kanamycin Resistant Vector

[0247] To co-express two I-CreI mutants in yeast, mutants cutting the rosa1.4 sequence were subcloned in a yeast expression vector marked with a kanamycin resistance gene (pCLS1107, FIG. 10). Mutants were amplified by PCR reaction using primers common for pCLS0542 and pCLS1107: Gal10F 5'-gcaactttagtgctgacacatacagg-3' (SEQ ID NO: 56) and Gal10R 5'-acaaccttgattggagacttgacc-3'(SEQ ID NO: 57). Approximately 25 ng of PCR fragment and 25 ng of vector DNA (pCLS1107) linearized by digestion with DraIII and NgoMIV are used to transform the yeast Saccharomyces cerevisiae strain FYC2-6A (MAT.alpha., trp1.DELTA.63, leu2.DELTA.1, his3.DELTA.200) using a high efficiency LiAc transformation protocol. An intact coding sequence for the I-CreI mutant is generated by in vivo homologous recombination in yeast. Each yeast strain containing a mutant cutting the rosa1.4 target subcloned in pCLS1107 vector was then mated with yeast expressing the rosa1.4 target to validate it. To recover the mutant expressing plasmids, yeast DNA was extracted using standard protocols and used to transform E. coli. and prepare E. coli DNA.

b) Mutants Coexpression

[0248] Yeast strain expressing a mutant cutting the rosa1.3 target in pCLS0542 expression vector was transformed with DNA coding for a mutant cutting the rosa1.4 target in pCLS1107 expression vector. Transformants were selected on -L Glu+G418 medium.

c) Mating of Meganucleases Coexpressing Clones and Screening in Yeast

[0249] Mating was performed using a colony gridder (QpixII, Genetix). Mutants were gridded on nylon filters covering YPD plates, using a low gridding density (about 4 spots/cm.sup.2). A second gridding process was performed on the same filters to spot a second layer consisting of different reporter-harbouring yeast strains for each target. Membranes were placed on solid agar YPD rich medium, and incubated at 30.degree. C. for one night, to allow mating. Next, filters were transferred to synthetic medium, lacking leucine and tryptophan, adding G418, with galactose (1%) as a carbon source, and incubated for five days at 37.degree. C., to select for diploids carrying the expression and target vectors. After 5 days, filters were placed on solid agarose medium with 0.02% X-Gal in 0.5 M sodium phosphate buffer, pH 7.0, 0.1% SDS, 6% dimethyl formamide (DMF), 7 mM .beta.-mercaptoethanol, 1% agarose, and incubated at 37.degree. C., to monitor .beta.-galactosidase activity. Results were analyzed by scanning and quantification was performed using appropriate software.

Results

[0250] Coexpression of mutants cleaving the rosa1.3 target (m1 to m18 described in Table II) and the eight mutants cleaving the rosa1.4 target (described in Table III) resulted in efficient cleavage of the rosa1.2 target in all the cases (screen examples are shown in FIG. 11A). All combinations tested are summarized in Table IV. Most of these combinations are also able to cut the rosa1 natural target that differs from the rosa1.2 sequence just by 1 bp at position +1 (FIG. 5). As shown on FIG. 11B, the signal observed on rosa1 natural target is weak compared to the one observed on rosa1.2 target. The combinations cleaving the rosa1 DNA target are presented in Table V.

TABLE-US-00004 TABLE IV Combinations that resulted in cleavage of the rosa1.2 target Mutants cutting rosa1.4 amino acids at positions 28, 30, 33, 38, 40/44, 68 and 70 (ex: ENRRR/AHQ stands for E28, N30, R33, R38, R40/A44, H68 and Q70) ENRRR/ ENRRR/ ENRRR/ ENRRK/ ENRRK/ ENRRK/ ENRRK/ ENRRK/ AHQ ARN ASQ AHQ ARS VRA ARG ATN Mutants cutting rosa1.3 amino m1 VYRSYI + + + + + + + + acids at positions 24, 44, 68, 70, m2 VYRSNI + + + + + + + + 75 and 77 m3 VYDSRR + + + + + + + + (ex: VYRSYI stands for V24, m4 ITYSYR + + + + + + + + Y44, R68, S70, Y75 and I77) m5 VYRSYQ + + + + + + + + m6 VYYSYR + + + + + + + + m7 VYYSRA + + + + + + + + m8 VYRSNV + + + + + + + + m9 VNYSYR + + + + + + + + m10 VNYSYR + + + + + + + + + 82T m11 VYSSRV + + + + + + + + m12 VYNSRI + + + + + + + + m13 VYSSRI + + + + + + + + m14 VYRSQI + + + + + + + + m15 IYRSNI + + + + + + + + m16 VYYSRV + + + + + + + + m17 VYRSYT + + + + + + + + m18 VNSSRV + + + + + + + + + indicates that the heterodimeric mutant cleaves the rosa1.2 target.

TABLE-US-00005 TABLE V Combinations that resulted in cleavage of the rosa1 target Mutants cutting rosa1.4 amino acids at positions 28, 30, 33, 38, 40/44, 68 and 70 (ex: ENRRR/AHQ stands for E28, N30, R33, R38, R40/A44, H68 and Q70) ENRRR/ ENRRR/ ENRRR/ ENRRK/ ENRRK/ ENRRK/ ENRRK/ ENRRK/ AHQ ARN ASQ AHQ ARS VRA ARG ATN Mutants cutting rosa1.3 m1 VYRSYI amino acids at positions 24, 44, m2 VYRSNI + + + + + 68, 70, 75 and 77 m3 VYDSRR (ex: VYRSYI stands for V24, m4 ITYSYR Y44, R68, S70, Y75 and I77) m5 VYRSYQ m6 VYYSYR + + + + + m7 VYYSRA m8 VYRSNV + + + + + m9 VNYSYR m10 VNYSYR + 82T m11 VYSSRV m12 VYNSRI + + + + + + + m13 VYSSRI + + + + + + + m14 VYRSQI + + + + + + + m15 IYRSNI m16 VYYSRV + + + + + + + m17 VYRSYT + + + + + + + + m18 VNSSRV + indicates that the heterodimeric mutant cleaves the rosa1.2 target.

EXAMPLE 5

Refinement of Meganucleases Cleaving Rosa1 by Random Mutagenesis of Proteins Cleaving Rosa1.4 and Assembly with Proteins Cleaving Rosa1.3

[0251] I-CreI mutants able to cleave the non palindromic rosa1.2 and rosa1 targets were identified by assembly of mutants cleaving the palindromic rosa1.3 and rosa1.4 targets. However, the combinations were able to efficiency cleave rosa1.2 but weakly cleave rosa1, which differs from rosa1.2 only by 1 bp at position 1. The signal observed on rosa1 is not sufficient.

[0252] Therefore protein combinations cleaving rosa1 were mutagenized, and mutants cleaving rosa1 efficiently were screened. According to the structure of the I-CreI protein bound to its target, there is no contact between the 4 central base pairs (positions -2 to 2) and the I-CreI protein (Chevalier et al., Nat. Struct. Biol., 2001, 8, 312-316; Chevalier B. S, and Stoddard B. L., Nucleic Acids Res., 2001, 29, 3757-3754; Chevalier et al., J. Mol. Biol., 2003, 329, 253-269). Thus, it is difficult to rationally choose a set of positions to mutagenize, and mutagenesis was done on the C-terminal part of the protein (83 last amino acids) or on the whole protein. Random mutagenesis results in high complexity libraries, and the complexity of the variants libraries to be tested was limited by mutagenizing only one of the two components of the heterodimers cleaving rosa1.

[0253] Thus, proteins cleaving rosa1.4 were mutagenized, and it was tested whether they could efficiency cleave rosa1 when co-expressed with proteins cleaving rosa1.3.

1) Material and Methods

a) Random Mutagenesis:

[0254] Random mutagenesis libraries were created on pools of chosen mutants, by PCR using Mn.sup.2+ or derivatives of dNTPs as 8-oxo-dGTP and dPTP in two-step PCR process as described in the protocol from JENA BIOSCIENCE GmbH in JBS dNTP-Mutageneis kit. For random mutagenesis on the whole protein, primers used are: preATGCreFor (5'-gcataaattactatacttctatagacacgcaaacacaaatacacagcggccttgccacc-3'; SEQ ID NO: 68) and ICreIpostRev (5'-ggctcgaggagctcgtctagaggatcgctcgagttatcagtcggccgc-3'; SEQ ID NO: 69). For random mutagenesis on the C-terminal part of the protein, primers used are: AA78a83For (5'-ttaagcgaaatcaagccg-3'; SEQ ID NO: 70) and ICreIpostRev with dNTPs derivatives; the rest of the protein is amplified with a high fidelity taq polymerase and without dNTPs derivatives using primers preATGCreFor and AA78a83Rev (5'-cggcttgatttcgcttaa-3'; SEQ ID NO: 71).

[0255] Pools of mutants were amplified by PCR reaction using these primers common for pCLS0542 (FIG. 7) and pCLS1107 (FIG. 10). Approximately 75 ng of PCR fragment and 75 ng of vector DNA (pCLS1107) linearized by digestion with DraIII and NgoMIV are used to transform the yeast Saccharomyces cerevisiae strain FYC2-6A (MAT.alpha., trp1.DELTA.63, leu2.DELTA.1, his3.DELTA.200) using a high efficiency LiAc transformation protocol. A library of intact coding sequence for the I-CreI mutant is generated by in vivo homologous recombination in yeast. Positives resulting clones were verified by sequencing as described in example 2.

b) Cloning of Mutants in Leucine Expression Vector in the Yeast Strain Containing the Rosa1 Target:

[0256] The yeast strain FYBL2-7B (MAT a, ura3.DELTA.851, trp1.DELTA.63, leu2.DELTA.1, lys2.DELTA.202) containing the rosa1 target into yeast reporter vector (pCLS1055, FIG. 6) is transformed with mutants cutting rosa1.3 target, in the pCLS0542 vector, marked with LEU2 gene, using a high efficiency LiAc transformation protocol. The resulting yeast strains are used as targets for mating assays as described in example 4.

2) Results

[0257] Four mutants cleaving rosa1.4 (ERRR/AHQ, ERRR/ARN, ERRK/AHQ and ERRK/VRA according to Table V) were pooled, randomly mutagenized on all proteins or on the C terminal part of proteins and transformed into yeast. 4464 transformed clones were then mated with a yeast strain that (i) contains the rosa1 target in a reporter plasmid (ii) expresses a variant cleaving the rosa1.3 target, chosen among those described in example 2. Three such strains were used, expressing the I-CreI V24 Y44 S68 S70 R75 I77 (or VYSSRI) mutant, the I-CreI V24 Y44 R68 S70 Q75 I77 (or VYRSQI) mutant, or the I-CreI V24 Y44 R68 S70 Y75 T77 (or VYRSYT) mutant (see Table II). Two clones were found to trigger a better cleavage of the rosa1 target when mated with such yeast strain compared to the mutants before mutagenesis with the same yeast strain. In conclusion, two proteins able to efficiently cleave rosa1 when forming heterodimers with VYSSRI, VYRSQI or VYRSYT (Table VI) were identified. (FIG. 12)

TABLE-US-00006 TABLE VI Functional mutant combinations displaying strong cleavage activity for rosa1 DNA target Optimized mutant rosa1.4* (SEQ ID NO: 72, 73) Mutant cutting rosa1.3 VYSSRI MO_1: E28 R33 R38 R40 A44 H68 Q70 N75 A105 R107 amino acids at positions (m13) MO_2: E28 R33 R38 K40 A44 H68 Q70N75 A105 R107 A151 G153 24, 44, 68, 70, 75 and 77 E158 (ex: VYRSYI stands for V24, VYRSQI MO_1: E28 R33 R38 R40 A44 H68 Q70 N75 A105 R107 Y44, R68, S70, Y75 and I77) (m14) MO_2: E28 R33 R38 K40 A44 H68 Q70 N75 A105 R107 A151 G153 E158 VYRSYT MO_1: E28 R33 R38 R40 A44 H68 Q70 N75 A105 R107 (m17) MO_2: E28 R33 R38 K40 A44 H68 Q70 N75 A105 R107 A151 G153 E158 *mutations resulting from random mutagnenesis are in bold.

EXAMPLE 6

Refinement of Meganucleases Cleaving Rosa1 by Random Mutagenesis of Proteins Cleaving Rosa1.3 and Assembly with Refined Proteins Cleaving Rosa1.4

[0258] I-CreI mutants able to cleave the rosa1 target were identified by assembly of mutants cleaving rosa1.3 and refined mutants cleaving rosa1.4. To increase the activity of the meganucleases, the second component of the heterodimers cleaving rosa1 was mutagenized. In this example, mutants cleaving rosa1.3 were mutagenized, followed by screening of more efficient variants cleaving rosa1 in combination with the refined mutants cleaving rosa1.4 identified in example 5.

1) Material and Method

a) Random Mutagenesis:

[0259] Random mutagenesis libraries were created on pools of chosen mutants, by PCR using Mn.sup.2+ or derivatives of dNTPs as 8-oxo-dGTP and dPTP in two-step PCR process as described in the protocol from JENA BIOSCIENCE GmbH in JBS dNTP-Mutageneis kit. For random mutagenesis on the whole protein, primers used are: preATGCreFor (5'-gcataaattactatacttctatagacacgcaaacacaaatacacagcggccttgccacc-3'; SEQ ID NO: 68) and ICreIpostRev (5'-ggctcgaggagctcgtctagaggatcgctcgagttatcagtcggccgc-3'; SEQ ID NO: 69). For random mutagenesis on the C-terminal part of the protein primer used are AA78a83For (5'-ttaagcgaaatcaagccg-3'; SEQ ID NO: 70) and ICreIpostRev with dNTPs derivatives; the rest of the protein is amplified with a high fidelity taq polymerase and without dNTPs derivatives using primers preATGCreFor and AA78a83Rev (5'-cggcttgatttcgcttaa-3'; SEQ ID NO: 71).

[0260] Pools of mutants were amplified by PCR reaction using these primers common for pCLS0542 (FIG. 7) and pCLS1107 (FIG. 10). Approximately 75 ng of PCR fragment and 75 ng of vector DNA (pCLS0542) linearized by digestion with NcoI and EagI are used to transform the yeast Saccharomyces cerevisiae strain FYC2-6A (MAT.alpha., trp1.DELTA.63, leu2.DELTA.1, his3.DELTA.200) using a high efficiency LiAc transformation protocol. A library of intact coding sequence for the I-CreI mutant is generated by in vivo homologous recombination in yeast. Positives resulting clones were verified by sequencing as described in example 2.

b) Cloning of Mutants in Kanamycin Expression Vector in the Yeast Strain Containing the Rosa1 Target

[0261] The yeast strain FYBL2-7B (MAT a, ura3.DELTA.851, trp1.DELTA.63, leu2.DELTA.1, lys2.DELTA.202) containing the rosa1 target into yeast reporter vector (pCLS1055, FIG. 6) is transformed with MO.sub.--1 and MO.sub.--2 refined mutants, cutting rosa1.4 target, in pCLS1107 vector, using a high efficiency LiAc transformation protocol. Mutant-target yeasts are used as targets for mating assays as described in example 4.

2) Results

[0262] Two pools of four mutants cleaving rosa1.3 (pool 1: VYRSNI, VYYSYR, VYRSNV and VYNSRI and pool 2: VYYSYR, VYSSRI, VYRSQI and VYRSYT according to Table V) were randomly mutagenized on all proteins or on the C terminal part of proteins and transformed into yeast. 8928 transformed clones were then mated with a yeast strain that (i) contains the rosa1 target in a reporter plasmid (ii) expresses a variant cleaving the rosa1.4 target. Two such strains were used expressing either the I-CreI E28 R33 R38 R40 A44 H68 Q70 N75 A105 R107 (or MO.sub.--1) mutant, either the I-CreI E28 R33 R38 K40 A44 H68 Q70 N75 A105 R107 A151 G153 E158 (or MO.sub.--2) mutant. Five clones were found to trigger a better cleavage of the rosa1 target when mated with such yeast strain compared to the mutants before mutagenesis with the same yeast strain (FIG. 13). After sequencing they turn out to correspond to four proteins. In conclusion, four proteins able to efficiently cleave rosa1 when forming heterodimers with MO.sub.--1 or MO.sub.--2, were identified (Table VII).

TABLE-US-00007 TABLE VII Functional mutant combinations displaying strong cleavage activity for rosa1 DNA target. Optimized mutant rosa1.3* (SEQ ID NO: 74 to 77) Optimized MO_1 mO_1: S19 V24 Y44 R68 S70 N75 V77 mutant E28 R33 R38 mO_2: S19 V24 Y44 R68 S70 Q75 I77 rosa1.4 R40 A44 mO_3: V24 Y44 S68 S70 R75 I77 A105 H68 Q70 N75 mO_4: V24 Y44 S68 S70 R75 I77 G79 A105 R107 MO_2 mO_1: S19 V24 Y44 R68 S70 N75 V77 E28 R33 R38 mO_2: S19 V24 Y44 R68 S70 Q75 I77 K40 A44 H68 mO_3: V24 Y44 S68 S70 R75 I77 A105 Q70 N75 A105 mO_4: V24 Y44 S68 S70 R75 I77 G79 R107 A151 G153 E158 *mutations resulting from random mutagenesis are in bold

EXAMPLE 7

Validation of Rosa1 Target Cleavage in an Extrachromosomic Model in CHO Cells

[0263] In example 6, I-CreI refined mutants able to efficiently cleave the rosa1 target in yeast were identified. In this example, the ability of two combinations of mutants to cut the rosa1 target in CHO cells was tested using an extrachromosomal essay in mammalian cells.

1) Materials and Methods

a) Cloning of Rosa1 Target in a Vector for CHO Screen

[0264] The target was cloned as follow: oligonucleotide corresponding to the target sequence flanked by gateway cloning sequence was ordered from Proligo: 5' tggcatacaagtttcaacatgatgtacatcatgttgacaatcgtctgtca 3' (SEQ ID NO: 37). Double-stranded target DNA, generated by PCR amplification of the single stranded oligonucleotide, was cloned using the Gateway protocol (INVITROGEN) into CHO reporter vector (pCLS1058, FIG. 14).

b) Re-Cloning of Meganucleases

[0265] The ORF of I-CreI N75, I-SceI and I-CreI mutants identified in example 6 were amplified by PCR and sequenced (MILLEGEN). Then, ORFs were recloned using the Gateway protocol (INVITROGEN). ORFs were amplified by PCR of yeast DNA using the primers B1F: 5' ggggacaagtttgtacaaaaaagcaggatcgaaggagatagaaccatggccaataccaaatataacaaagagt- tcc 3' (SEQ ID NO: 78) and B2R: 5' ggggaccactttgtacaagaaagctgggtttagtcggccgccggggaggatttcttcttctcgc 3' (SEQ ID NO: 79) from Proligo. PCR products were cloned in CHO gateway expression vector pcDNA6.2 from Invitrogen (pCLS1069, FIG. 15). Resulting clones were verified by sequencing as described in example 2.

c) Extrachromosomal Assay in Mammalian Cells

[0266] CHO cells were transfected with Polyfect transfection reagent according to the supplier's (QIAGEN) protocol. 72 hours after transfection, culture medium was removed and 150 .mu.l of lysis/revelation buffer added for .beta.-galactosidase liquid assay (typically, 1 liter of buffer contains 100 ml of lysis buffer (Tris-HCl 10 mM pH 7.5, NaCl 150 mM, Triton X100 0.1%, BSA 0.1 mg/ml, protease inhibitors), 10 ml of Mg 100.times. buffer (MgCl.sub.2 100 mM, .beta.-mercaptoethanol 35%), 110 ml ONPG 8 mg/ml and 780 ml of sodium phosphate 0.1 M pH7.5). After incubation at 37.degree. C., optical density was measured at 420 nm. The entire process is performed on an automated BioCel.RTM. platform (VELOCITY11).

2) Results

[0267] The results of two experiments presented in FIG. 16, show that two combinations of I-CreI mutants (mO.sub.--2/MO.sub.--1 and mO.sub.--2/MO.sub.--2) are able to cut the rosa1 target in CHO cells with an activity similar as the activity of I-CreI N75 against the I-CreI target (tcaaaacgtcgtgagacagtttgg, SEQ ID NO: 80) or I-SceI against the I-SceI target (tagggataacagggtaat, SEQ ID NO: 81).

EXAMPLE 8

Genome Engineering at the ROSA26 Locus in Mouse Cells

[0268] I-CreI refined mutants able to efficiently cleave the rosa1 target in yeast and in an extrachromosomal assay in mammalian cells (CHO K1 cells) have been identified in examples 6 and 7. The ability of one combination of two I-CreI refined mutants to induce homologous recombination at the ROSA26 locus in mouse L cells was tested in this example.

1) Materials and Methods

a) Knock-In (KI) Matrices

[0269] Two knock-in matrices comprising the hygromycin resistance gene coding sequence (CDS) cloned between two mouse ROSA26 homology arms, HG ROSA26 from 6283 to 8317 and HD ROSA26 from 8313 to 10319 in CQ880114 sequence (corresponding to SEQ ID NO: 3 in the sequence listing), were constructed. The resulting plasmids are pCLS1679 and pCLS1675 (plasmid map in FIG. 18). In pCLS1679, the coding sequence of the hygromycin resistance gene (hygro CDS) operatively linked to the SV40 polyA was cloned in pBR322 vector (PROMEGA) between HG ROSA26 and HD ROSA26. pCLS1675 differs from pCLS1679 by the insertion of an Internal Ribosomal Entry site (IRES; SEQ ID NO: 139) just upstream of the hygro CDS.

b) Cloning of Meganucleases

[0270] The ORF of I-CreI refined mutants mO.sub.--2 and MO.sub.--1 are described in example 6 (Table VII). Mutants expression was made in two expression vectors under the control of the human elongation factor 1 alpha (EF1.alpha.) promoter or cytomegalovirus immediate early (CMV) promoter (pCLS1069, FIG. 15). Mutants were cloned in pCLS1069 under CMV promoter as described in example 7. The resulting plasmids were verified by sequencing (MILLEGEN). In pCLS1761 (FIG. 19) and pCLS1762 (FIG. 20), the mO.sub.--2 and MO.sub.--1 I-CreI mutants, respectively, are under the control of the EF1.alpha. promoter.

c) Knock-In Experiment in Mouse L Cells

[0271] Mouse L cells (ATCC # CRL-2648) are cultivated in complete DMEM medium (DMEM Glutamax, GIBCO) supplemented with 10% fetal calf serum, penicillin, streptomycin and fungizon. Cells are transfected using lipofectamin reagent (INVITROGEN) according to the procedure recommended by the manufacturer. Two days after transfection, selection is performed using Hygromycin at 0.6 mg/ml in complete medium. After two weeks of selection, resistant clones are picked using a ClonePix robot (GENETIX). Clones are amplified one week in 96 wells plates in complete medium supplemented with hygromycin at 0.6 mg/ml. Genomic DNA is extracted from resistant clones cultured in 96 well plates using the ZR96 kit (ZYMO RESEARCH).

c) PCR Analysis of Knock-In Events

[0272] Knock-in events are detected by PCR analysis on genomic DNA using the pair of primers KI_GHG_S5 (5' tagtatacagaaactgttgcatcgc 3'; SEQ ID NO: 137) and HygSeqRev (5' cgtctgctgctccatacaag 3'; SEQ ID NO: 138), located respectively in the mouse ROSA26 sequence upstream of the HG ROSA26 homology arm and in the hygromycin CDS, to obtain a KI specific PCR amplification (FIG. 21).

2) Results

[0273] ROSA26 meganucleases used in this example are mO.sub.--2 and MO.sub.--1 described in example 6 (Table VII) and cloned in two expression vectors, under the control of the human elongation factor 1 alpha (EF1.alpha.) promoter (pCLS1761 and pCLS1762) or cytomegalovirus immediate early (CMV) promoter (pCLS1069, FIG. 15). Mouse L cells were cotransfected with three vectors: two plasmids expressing the mO.sub.--2 and MO.sub.--1 ROSA26 meganucleases and the KI matrix. The meganucleases were cloned in pCLS1761 and pCLS1762, respectively EF1.alpha. promoter and the KI matrix was pCLS1675.

[0274] A total of 2600000 mouse L cells were cotransfected with 2 .mu.g of KI matrix vector and 5 .mu.g or 10 .mu.g of each meganuclease expression vector. As control of spontaneous KI frequency, the same number of cells was transfected with 2 .mu.g of KI matrix vector alone. The transfection efficacy (40%) was determined by FACS analysing using a fluorescent marker expressing plasmid. The frequency of resistant clones was determined by counting the total number of hygromycin resistant clones and corrected by transfection efficacy. 2605, 1197 and 1902 hygromycin resistant clones were obtained, respectively (Table VIII). 92 or 184 clones were picked per condition and analysed by PCR as described in materials and methods. Results are presented in Table VIII.

TABLE-US-00008 TABLE VIII PCR result and frequency of KI events at the ROSA26 locus in mouse L cells Total Number of number PCR positives/ of Corrected Hygro.sup.R Vectors Hygro.sup.R Hygro.sup.R picked KI events transfected clones frequency clones frequency 2 .mu.g pCLS1675 2605 2.5 .times. 10.sup.-3 18/92 4.9 .times. 10.sup.-4 5 .mu.g pCLS1761 5 .mu.g pCLS1762 2 .mu.g pCLS1675 1197 1.1 .times. 10.sup.-3 28/92 3.5 .times. 10.sup.-4 10 .mu.g pCLS1761 10 .mu.g pCLS1762 2 .mu.g pCLS1675 1902 1.8 .times. 10.sup.-3 0/184 0

[0275] Cotransfection of ROSA26 meganucleases and KI matrix induced homologous recombination at the mouse ROSA26 locus in L cells at a maximal frequency of 4.9.times.10.sup.-4. No spontaneous homologous recombination was observed with transfection of the KI matrix alone. This example illustrates the ability of ROSA26 meganucleases to induce homologous recombination at the mouse ROSA26 locus in mouse L cells.

EXAMPLE 9

Meganucleases Derived from mO.sub.--2 and MO.sub.--1

[0276] Meganuclease constructs were engineered from mO.sub.--2 (SEQ ID NO: 75) and MO.sub.--1 (SEQ ID NO: 72) by using conventional techniques of molecular biology and recombinant DNA, which are explained fully in Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and son Inc, Library of Congress, USA); Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et al, 2001, Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press).

[0277] A NLS (KKKRK; SEQ ID NO: 134) was inserted between the first (M.sub.1) and the second (A.sub.2) amino acids of MO.sub.--1 and mO.sub.--2; the resulting variants are SEQ ID NO: 140 and 141, respectively.

[0278] A tag (TagHA; YPYDVPDYA; SEQ ID NO: 135) was inserted between the first (M.sub.1) and the third amino acid (N.sub.3) of mO.sub.--2; the resulting variant is SEQ ID NO: 142.

[0279] A tag (STag; KETAAAKFERQHMDS; SEQ ID NO: 136) was inserted between the first (M.sub.1) and the second (A.sub.2) amino acids of MO.sub.--1; the resulting variant is SEQ ID NO: 143.

[0280] A tag (TagHA; YPYDVPDYA; SEQ ID NO: 135) and a NLS (KKKRK; SEQ ID NO: 134) were inserted between the first (M.sub.1) and the second amino acid (A.sub.2) of mO.sub.--2; the resulting variant is SEQ ID NO: 144.

[0281] A tag (STag; KETAAAKFERQHMDS; SEQ ID NO: 136) and a NLS (KKKRK; SEQ ID NO: 134) were inserted between the first (M.sub.1) and the second (A.sub.2) amino acids of MO.sub.--1; the resulting variant is SEQ ID NO: 145.

[0282] A single-chain meganuclease comprising an MO.sub.--1 monomer (positions 1 to 166 of SEQ ID NO: 72) separated from a mO.sub.--2 monomer (positions 3 to 164 of SEQ ID NO: 75) by a linker (GGSDKYNQALSKYNQALSKYNQALSGGGGS; SEQ ID NO: 149) was constructed: the resulting single-chain meganuclease is SEQ ID NO: 146.

[0283] An obligate heterodimer derived from mO.sub.--2/MO.sub.--1 was engineered by introducing the E8K and E61R mutations in a mO.sub.--2 monomer and the K7E and K96E mutations in a MO.sub.--1 monomer; the resulting heterodimer consists of SEQ ID NO: 147 and SEQ ID NO: 148.

Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 150 <210> SEQ ID NO 1 <211> LENGTH: 163 <212> TYPE: PRT <213> ORGANISM: Chlamydomonas reinhardtii <400> SEQUENCE: 1 Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe 1 5 10 15 Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln Ser 20 25 30 Tyr Lys Phe Lys His Gln Leu Ser Leu Ala Phe Gln Val Thr Gln Lys 35 40 45 Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val 50 55 60 Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Asp Tyr Ile Leu Ser Glu 65 70 75 80 Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys 85 90 95 Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Trp Arg Leu 100 105 110 Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp 115 120 125 Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr 130 135 140 Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys 145 150 155 160 Ser Ser Pro <210> SEQ ID NO 2 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: C1221 DNA target <400> SEQUENCE: 2 tcaaaacgtc gtacgacgtt ttga 24 <210> SEQ ID NO 3 <211> LENGTH: 13139 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 3 aagcttctca cgtagcaacc agagctccag agccagcagc tgctgccgcc ttgtatactc 60 actcctgtga tccaacacag gagcaacctt ttctttaccc cacccccact tcttaacaca 120 cttttttttg gggggggggg gggaacaagt gctccatgct ggaaggattg gaactatgct 180 tttagaaagg aacaatccta aggtcacttt taaattgagg tctttgattt gaaaatcaac 240 aaataccaaa ttccaaatat tcgttttaat taaaccagca atgtggatat aagcattaag 300 ttttagtttt aaaaaggtca attttccaaa cattcagcaa tcatatttaa atttacagct 360 aggaacaaga gccttgggtc atgtcctacc aaagaacata actcaatatt ctacacatga 420 caatctgaat aaccttaaag cctctaatcc cataacaggc cacaaatttt ggacagagaa 480 ctaatgatcc tcctgagaaa actggaagaa atccagggaa aagaaattcc tgtgtcctcc 540 aaactcagaa atctctaatt atgtcagtat tctctgcttt agtcctaggt cagattgcac 600 acatctaaaa taacctctta aagttttcct cctagcgacc taaaccatta ttaatatcaa 660 attaaccatc aaaacacttt cctctcaata tgctgcacac aaacctcctc ctggaacctc 720 ctccatctgg atcctcccca atcaaaagta taggtattta acatataagc aaggaagtaa 780 tgtaaacatg accttggtca caaatatgtc atctaaaaac aatttagtca aggtatggag 840 gaaattcgag aacctgaatc tttttaagta ttttgagcac aggaacaatt ggcaaaagga 900 atccaggtat agacaaaacc cagagcccag agctctgggc gaaaaatgag ttgctggtga 960 agacgttaca caagtaacat gagaaagcag aaaatgcagg tcatccacgc acccctgacc 1020 caggccagca gggcgggctg cagcatcagt acacaggaga aagatcctta ttcctaagaa 1080 tgagaaaggc aaaggcgccc gatagaataa attagcatag aaggggcttt cccaggagtt 1140 aaaactttcc ttctgagcga ttacctacta aaaccagggc ttttgcccac taccatttac 1200 ctaggatctt ggcttgcacg gattcatagg ggcatatccc tccccctctt ctttagagtc 1260 gttcttaaaa gatcgctctc cacgccctag gcagggaaaa cgacaaaatc tggctcaatt 1320 ccaggctaga accctacaaa ttcaacaggg atatcgcaag gatactgggg catacgccac 1380 agggagtcca agaatgtgag gtgggggtgg cgaaggtaat gtctttggtg tgggaaaagc 1440 agcagccatc tgagatagga actggaaaac cagaggagag gcgttcagga agattatgga 1500 ggggaggact gggcccccac gagcgaccag agttgtcaca aggccgcaag aacaggggag 1560 gtggggggct cagggacaga aaaaaaagta tgtgtatttt gagagcaggg ttgggaggcc 1620 tctcctgaaa agggtataaa cgtggagtag gcaataccca ggcaaaaagg ggagaccaga 1680 gtagggggag gggaagagtc ctgacccagg gaagacatta aaaaggtagt ggggtcgact 1740 agatgaagga gagcctttct ctctgggcaa gagcggtgca atggtgtgta aaggtagctg 1800 agaagacgaa aagggcaagc atcttcctgc taccaggctg gggaggccca ggcccacgac 1860 cccgaggaga gggaacgcag ggagactgag gtgacccttc tttcccccgg ggcccggtcg 1920 tgtggttcgg tgtctctttt ctgttggacc cttaccttga cccaggcgct gccggggcct 1980 gggcccgggc tgcggcgcac ggcactcccg ggaggcagcg agactcgagt taggcccaac 2040 gcggcgccac ggcgtttcct ggccgggaat ggcccgtacc cgtgaggtgg gggtgggggg 2100 cagaaaaggc ggagcgagcc cgagcgggga gggggagggc caggggcgga gggggccggc 2160 actactgtgt tggcggactg gcgggactag ggctgcgtga gtctctgagc gcaggcgggc 2220 ggcggccgcc cctcccccgg cggcggcagc ggcggcagcg gcggcagctc actcagcccg 2280 ctgcccgagc ggaaacgcca ctgaccgcac ggggattccc agtgccggcg ccaggggcac 2340 gcgggacacg ccccctcccg ccgcgccatt ggcctctccg cccaccgccc cacacttatt 2400 ggccggtgcg ccgccaatca gcggaggctg ccggggccgc ctaaagaaga ggctgtgctt 2460 tggggctccg gctcctcaga gagcctcggc taggtagggg atcgggactc tggcgggagg 2520 gcggcttggt gcgtttgcgg ggatgggcgg ccgcggcagg ccctccgagc gtggtggagc 2580 cgttctgtga gacagccggg tacgagtcgt gacgctggaa ggggcaagcg ggtggtgggc 2640 aggaatgcgg tccgccctgc agcaaccgga gggggaggga gaagggagcg gaaaagtctc 2700 caccggacgc ggccatggct cggggggggg ggggcagcgg aggagcgctt ccggccgacg 2760 tctcgtcgct gattggcttc ttttcctccc gccgtgtgtg aaaacacaaa tggcgtgttt 2820 tggttggcgt aaggcgcctg tcagttaacg gcagccggag tgcgcagccg ccggcagcct 2880 cgctctgccc actgggtggg gcgggaggta ggtggggtga ggcgagctgg acgtgcgggc 2940 gcggtcggcc tctggcgggg cgggggaggg gagggagggt cagcgaaagt agctcgcgcg 3000 cgagcggccg cccaccctcc ccttcctctg ggggagtcgt tttacccgcc gccggccggg 3060 cctcgtcgtc tgattggctc tcggggccca gaaaactggc ccttgccatt ggctcgtgtt 3120 cgtgcaagtt gagtccatcc gccggccagc gggggcggcg aggaggcgct cccaggttcc 3180 ggccctcccc tcggccccgc gccgcagagt ctggccgcgc gcccctgcgc aacgtggcag 3240 gaagcgcgcg ctgggggcgg ggacgggcag tagggctgag cggctgcggg gcgggtgcaa 3300 gcacgtttcc gacttgagtt gcctcaagag gggcgtgctg agccagacct ccatcgcgca 3360 ctccggggag tggagggaag gagcgagggc tcagttgggc tgttttggag gcaggaagca 3420 cttgctctcc caaagtcgct ctgagttgtt atcagtaagg gagctgcagt ggagtaggcg 3480 gggagaaggc cgcacccttc tccggagggg ggaggggagt gttgcaatac ctttctggga 3540 gttctctgct gcctcctggc ttctgaggac cgccctgggc ctgggagaat cccttccccc 3600 tcttccctcg tgatctgcaa ctccagtctt tctagaagat gggcgggagt cttctgggca 3660 ggcttaaagg ctaacctggt gtgtgggcgt tgtcctgcag gggaattgaa caggtgtaaa 3720 attggaggga caagacttcc cacagatttt cggttttgtc gggaagtttt ttaatagggg 3780 caaataagga aaatgggagg ataggtagtc atctggggtt ttatgcagca aaactacagg 3840 ttattattgc ttgtgatccg cctcggagta ttttccatcg aggtagatta aagacatgct 3900 cacccgagtt ttatactctc ctgcttgaga tccttactac agtatgaaat tacagtgtcg 3960 cgagttagac tatgtaagca gaattttaat catttttaaa gagcccagta cttcatatcc 4020 atttctcccg ctccttctgc agccttatca aaaggtattt tagaacactc attttagccc 4080 cattttcatt tattatactg gcttatccaa cccctagaca gagcattggc attttccctt 4140 tcctgatctt agaagtctga tgactcatga aaccagacag attagttaca tacaccacaa 4200 atcgaggctg tagctggggc ctcaacactg cagttctttt ataactcctt agtacacttt 4260 ttgttgatcc tttgccttga tccttaattt tcagtgtcta tcacctctcc cgtcagtggt 4320 gttccacatt tgggcctatt ctcagtccag ggagttttac aacaatagat gtattgagaa 4380 tccaacctaa agcttaactt tccactccca tgaatgcctc tctccttttt ctccatttat 4440 aaactgagct attaaccatt aatggttcca ggtggatgtc tcctccccat attacctgat 4500 gtatcttaca tattgccagg ctgatatttt aagacattaa aaggtatatt tcattattga 4560 gccacatggt attgattact gcttactaaa attttgtcat tgtacacatc tgtaaaaggt 4620 ggttcctttt ggaatgcaaa gttcaggtgt ttgttgtctt tcctgaccta aggtcttgtg 4680 agcttgtatt ttttctattt aagcagtgct ttctcttgga ctggcttgac tcatggcatt 4740 ctacacgtta ttgctggtct aaatgtgatt ttgccaagct tcttcaggac ctataatttt 4800 gcttgacttg tagccaaaca caagtaaaat gattaagcaa caaatgtatt tgtgaagctt 4860 ggtttttagg ttgttgtgtt gtgtgtgctt gtgctctata ataatactat ccaggggctg 4920 gagaggtggc tcggagttca agagcacaga ctgctcttcc agaagtcctg agttcaattc 4980 ccagcaacca catggtggct cacaaccatc tgtaatggga tctgatgccc tcttctggtg 5040 tgtctgaaga ccacaagtgt attcacatta aataaataaa tcctccttct tcttcttttt 5100 ttttttttta aagagaatac tgtctccagt agaatttact gaagtaatga aatactttgt 5160 gtttgttcca atatggtagc caataatcaa attactcttt aagcactgga aatgttacca 5220 aggaactaat ttttatttga agtgtaactg tggacagagg agccataact gcagacttgt 5280 gggatacaga agaccaatgc agactttaat gtcttttctc ttacactaag caataaagaa 5340 ataaaaattg aacttctagt atcctatttg tttaaactgc tagctttact taacttttgt 5400 gcttcatcta tacaaagctg aaagctaagt ctgcagccat tactaaacat gaaagcaagt 5460 aatgataatt ttggatttca aaaatgtagg gccagagttt agccagccag tggtggtgct 5520 tgcctttatg cctttaatcc cagcactctg gaggcagaga caggcagatc tctgagtttg 5580 agcccagcct ggtctacaca tcaagttcta tctaggatag ccaggaatac acacagaaac 5640 cctgttgggg aggggggctc tgagatttca taaaattata attgaagcat tccctaatga 5700 gccactatgg atgtggctaa atccgtctac ctttctgatg agatttgggt attatttttt 5760 ctgtctctgc tgttggttgg gtcttttgac actgtgggct ttctttaaag cctccttcct 5820 gccatgtggt ctcttgtttg ctactaactt cccatggctt aaatggcatg gctttttgcc 5880 ttctaagggc agctgctgag atttgcagcc tgatttccag ggtggggttg ggaaatcttt 5940 caaacactaa aattgtcctt taattttttt tttaaaaaat gggttatata ataaacctca 6000 taaaatagtt atgaggagtg aggtggacta atattaaatg agtccctccc ctataaaaga 6060 gctattaagg ctttttgtct tatacttaac ttttttttta aatgtggtat ctttagaacc 6120 aagggtctta gagttttagt atacagaaac tgttgcatcg cttaatcaga ttttctagtt 6180 tcaaatccag agaatccaaa ttcttcacag ccaaagtcaa attaagaatt tctgactttt 6240 aatgttaatt tgcttactgt gaatataaaa atgatagctt ttcctgaggc agggtctcac 6300 tatgtatctc tgcctgatct gcaacaagat atgtagacta aagttctgcc tgcttttgtc 6360 tcctgaatac taaggttaaa atgtagtaat acttttggaa cttgcaggtc agattctttt 6420 ataggggaca cactaaggga gcttgggtga tagttggtaa aatgtgtttc aagtgatgaa 6480 aacttgaatt attatcaccg caacctactt tttaaaaaaa aaagccaggc ctgttagagc 6540 atgcttaagg gatccctagg acttgctgag cacacaagag tagttacttg gcaggctcct 6600 ggtgagagca tatttcaaaa aacaaggcag acaaccaaga aactacagtt aaggttacct 6660 gtctttaaac catctgcata tacacaggga tattaaaata ttccaaataa tatttcattc 6720 aagttttccc ccatcaaatt gggacatgga tttctccggt gaataggcag agttggaaac 6780 taaacaaatg ttggttttgt gatttgtgaa attgttttca agtgatagtt aaagcccatg 6840 agatacagaa caaagctgct atttcgaggt ctcttggttt atactcagaa gcacttcttt 6900 gggtttccct gcactatcct gatcatgtgc taggcctacc ttaggctgat tgttgttcaa 6960 ataaacttaa gtttcctgtc aggtgatgtc atatgatttc atatatcaag gcaaaacatg 7020 ttatatatgt taaacatttg tacttaatgt gaaagttagg tctttgtggg tttgattttt 7080 aattttcaaa acctgagcta aataagtcat ttttacatgt cttacatttg gtggaattgt 7140 ataattgtgg tttgcaggca agactctctg acctagtaac cctacctata gagcactttg 7200 ctgggtcaca agtctaggag tcaagcattt caccttgaag ttgagacgtt ttgttagtgt 7260 atactagttt atatgttgga ggacatgttt atccagaaga tattcaggac tatttttgac 7320 tgggctaagg aattgattct gattagcact gttagtgagc attgagtggc ctttaggctt 7380 gaattggagt cacttgtata tctcaaataa tgctggcctt ttttaaaaag cccttgttct 7440 ttatcaccct gttttctaca taatttttgt tcaaagaaat acttgtttgg atctcctttt 7500 gacaacaata gcatgttttc aagccatatt ttttttcctt tttttttttt tttttggttt 7560 ttcgagacag ggtttctctg tatagccctg gctgtcctgg aactcacttt gtagaccagg 7620 ctggcctcga actcagaaat ccgcctgcct ctgcctcctg agtgccggga ttaaaggcgt 7680 gcaccaccac gcctggctaa gttggatatt ttgttatata actataacca atactaactc 7740 cactgggtgg atttttaatt cagtcagtag tcttaagtgg tctttattgg cccttcatta 7800 aaatctactg ttcactctaa cagaggctgt tggtactagt ggcacttaag caacttccta 7860 cggatatact agcagattaa gggtcaggga tagaaactag tctagcgttt tgtataccta 7920 ccagctttat actaccttgt tctgatagaa atatttcagg acatctagag tgtactataa 7980 ggttgatggt aagcttataa ggaacttgaa agtggagtaa ctactccatt tctctgaggg 8040 gagaattaaa atttttgacc aagtgttgtt gagccactga gaatggtctc agaacataac 8100 ttcttaagga accttcccag attgccctca acactgcacc acatttggtc ctgcttgaac 8160 attgccatgg ctcttaaagt cttaattaag aatattaatt gtgtaattat tgtttttcct 8220 cctttagatc attccttgag gacaggacag tgcttgttta aggctatatt tctgctgtct 8280 gagcagcaac aggtcttcga gatcaacatg atgttcataa tcccaagatg ttgccattta 8340 tgttctcaga agcaagcaga ggcatgatgg tcagtgacag taatgtcact gtgttaaatg 8400 ttgctatgca gtttggattt ttctaatgta gtgtaggtag aacatatgtg ttctgtatga 8460 attaaactct taagttacac cttgtataat ccatgcaatg tgttatgcaa ttaccatttt 8520 aagtattgta gctttctttg tatgtgagga taaaggtgtt tgtcataaaa tgttttgaac 8580 atttccccaa agttccaaat tataaaacca caacgttaga acttatttat gaacaatggt 8640 tgtagtttca tgcttttaaa atgcttaatt attcaattaa caccgtttgt gttataatat 8700 atataaaact gacatgtaga agtgtttgtc cagaacattt cttaaatgta tactgtcttt 8760 agagagttta atatagcatg tcttttgcaa catactaact tttgtgttgg tgcgagcaat 8820 attgtgtagt cattttgaaa ggagtcattt caatgagtgt cagattgttt tgaatgttat 8880 tgaacatttt aaatgcagac ttgttcgtgt tttagaaagc aaaactgtca gaagctttga 8940 actagaaatt aaaaagctga agtatttcag aagggaaata agctacttgc tgtattagtt 9000 gaaggaaagt gtaatagctt agaaaattta aaaccatata gttgtcattg ctgaatatct 9060 ggcagatgaa aagaaatact cagtggttct tttgagcaat ataacagctt gttatattaa 9120 aaattttccc cacagatata aactctaatc tataactcat aaatgttaca aatggatgaa 9180 gcttacaaat gtggcttgac ttgtcactgt gcttgtttta gttatgtgaa agtttggcaa 9240 taaacctatg tcctaaatag tcaaactgtg gaatgacttt ttaatctatt ggtttgtcta 9300 gaacagttat gttgccattt gccctaatgg tgaaagaaaa agtggggagt gccttggcac 9360 tgttcatttg tggtgtgaac caaagagggg ggcatgcact tacacttcaa acatcctttt 9420 gaaagactga caagtttggg tcttcacagt tggaattggg catccctttt gtcagggagg 9480 gagggaggga gggaggctgg cttgttatgc tgacaagtgt gattaaattc aaactttgag 9540 gtaagttgga ggaacttgta cattgttagg agtgtgacaa tttggactct taatgatttg 9600 gtcatacaaa atgaacctag accaacttct ggaagatgta tataataact ccatgttaca 9660 ttgatttcac ctgactaata cttatccctt atcaattaaa tacagaagat gccagccatc 9720 tgggcctttt aacccagaaa tttagtttca aactcctagg ttagtgttct cactgagcta 9780 catcctgatc tagtcctgaa aataggacca ccatcacccc caaaaaaatc tcaaataaga 9840 tttatgctag tgtttcaaaa ttttaggaat aggtaagatt agaaagtttt aaattttgag 9900 aaatggcttc tctagaaaga tgtacatagt gaacactgaa tggctcctaa agagcctaga 9960 aaactggtac tgagcacaca ggactgagag gtctttcttg aaaagcatgt attgctttac 10020 gtgggtcaca gaaggcaggc aggaagaact tgggctgaaa ctggtgtctt aagtggctaa 10080 catcttcaca actgatgagc aagaacttta tcctgatgca aaaaccatcc aaacaaacta 10140 agtgaaaggt ggcaatggat cccaggctgc tctagaggag gacttgactt ctcatcccat 10200 cacccacacc agatagctca tagactgcca attaacacca gcttctagcc tccacaggca 10260 cctgcactgg tacacataat ttcacacaaa cacagtaaga agccttccac ctggcatggt 10320 attgcttatc tttagttccc aacacttggg aggcagaggc cagccagggc tatgtgacaa 10380 aaaccttgtc tagaggagaa acttcatagc ttatttccta ttcacgtaac caggttagca 10440 aaatttacca gccagagatg aagctaacag tgtccactat atttgtagtg ttttaagtca 10500 attttttaaa tatacttaat agaattaaag ctatggtgaa ccaagtacaa acctggtgta 10560 ttaacttgag aacttagcat aaaaagtagt tcatttgttc agtaaatatt aaatgcttac 10620 tggcaaagat tatgtcagga acttggtaaa tggtgatgaa acaatcatag ttgtacatct 10680 tggttctgtg atcaccttgg tttgaggtaa aagtggttcc tttgatcaag gatggaattt 10740 taagtttata ttcaatcaat aatgtattat tttgtgattg caaaattgcc tatctagggt 10800 ataaaacctt taaaaatttc ataataccag ttcattctcc agttactaat tccaaaaagc 10860 cactgactat ggtgccaatg tggattctgt tctcaaagga aggattgtct gtgcccttta 10920 ttctaataga aacatcacac tgaaaatcta agctgaaaga agccagactt tcctaaataa 10980 ataactttcc ataaagctca aacaaggatt acttttagga ggcactgtta aggaactgat 11040 aagtaatgag gttacttata taatgatagt cccacaagac tatctgagga aaaatcagta 11100 caactcgaaa acagaacaac cagctaggca ggaataacag ggctcccaag tcaggaggtc 11160 tatccaacac ccttttctgt tgagggcccc agacctacat attgtataca aacagggagg 11220 tgggtgattt taactctcct gaggtacctt ggtaaatctt tgtcctgagt aagcagtaca 11280 gtgtacagtt tacattttca tttaaagata cattagctcc ctctaccccc taagactgac 11340 aggcactttg ggggtgggga gggctttgga aaataacgct tccatacact aaaagagaaa 11400 tttctttaat taggcttgtt ggttccatac atctactggt gtttctacta cttagtaata 11460 ttataatagt cacacaagca tctttgctct gtttaggttg tatatttatt ttaaggcaga 11520 tgataaaact gtagatctta agggatgctt ctgcttctga gatgatacaa agaatttaga 11580 ccataaaaca gtaggttgca caagcaatag aatatggcct aaagtgttct gacacttaga 11640 agccaagcag tgtaggcttc ttaagaaata ccattacaat caccttgcta gaaatcaagc 11700 attctggagt ggtcaagcag tgtaacctgt actgtaagtt acttttctgc tatttttctc 11760 ccaaagcaag ttctttatgc tgatatttcc agtgttagga actacaaata ttaataagtt 11820 gtcttcactc ttttctttac caaggagggt ctcttccttc atcttgatct gaaggatgaa 11880 caaaggcttg agcagtgcgc tttagaagat aaactgcagc atgaaggccc ccgatgttca 11940 cccagactac atggaccttt cgccacacat gtcccattcc agataaggcc tggcacacac 12000 aaaaaacata agtcattagg ctaccagtct gattctaaaa caacctaaaa tcttcccact 12060 taaatgctat gggtggtggg ttggaaagtt gactcagaaa atcacttgct gtttttagag 12120 aggatctggg ttcagtttct gatacattgt ggcttacaac tataactcca gttctagggg 12180 gtccatccaa catcctcttc tgttgagggc accaaataaa tgtattgtgt acaaacaggg 12240 aggtgagtga tttaactctc gtgtatagta ccttggtaaa acatttcttg tcctgagtaa 12300 gcagtacagc tctgcctgtc cctggtctac agacacggct catttcccga aggcaagctg 12360 gatagagatt ccaatttctc ttcttggatc ccatcctata aaagaaggtc aagtttaatc 12420 tattgcaaaa ggtaaatagg tagtttctta catgagacaa gaacaaatct taggtgtgaa 12480 gcagtcatct tttacaggcc agagcctcta ttctatgcca atgaaggaaa ctgttagtcc 12540 agtgttatag agttagtcca gtgtatagtt ttctatcaga acactttttt tttaaacaac 12600 tgcaacttag cttattgaag acaaaccacg agtagaaatc tgtccaagaa gcaagtgctt 12660 ctcagcctac aatgtggaat aggaccatgt aatggtacag tgagtgaaat gaattatggc 12720 atgtttttct gactgagaag acagtacaat aaaaggtaaa ctcatggtat ttatttaaaa 12780 agaatccaat ttctaccttt ttccaaatgg catatctgtt acaataatat ccacagaagc 12840 agttctcagt gggaggttgc agatatccca ctgaacagca tcaatgggca aaccccaggt 12900 tgtttttctg tggagacaaa ggtaagatat ttcaatatat tttcccaagc taatgagatg 12960 gctcagcaaa taatggtact ggccattaag tctcatgacc tgagcttgat cctcagggac 13020 catgtggtac aaggagagac ctaaatcctt cagttggact tcaatcttct accctcatgt 13080 ccacacacaa ataaatacaa taaaaaacat tctgcagtcg aatttctaaa agggcgaat 13139 <210> SEQ ID NO 4 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI N75 scaffold protein <400> SEQUENCE: 4 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 5 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 5 cgcccctgcg caacgtggca gg 22 <210> SEQ ID NO 6 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 6 ccgcaccctt ctccggaggg gg 22 <210> SEQ ID NO 7 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 7 tggactggct tgactcatgg ca 22 <210> SEQ ID NO 8 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 8 ccagcctggt ctacacatca ag 22 <210> SEQ ID NO 9 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 9 ctatctagga tagccaggaa ta 22 <210> SEQ ID NO 10 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 10 cagcctgatt tccagggtgg gg 22 <210> SEQ ID NO 11 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 11 taaacctcat aaaatagtta tg 22 <210> SEQ ID NO 12 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 12 tcagattctt ttatagggga ca 22 <210> SEQ ID NO 13 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 13 ttgtatatct caaataatgc tg 22 <210> SEQ ID NO 14 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA DNA target <400> SEQUENCE: 14 tgagccactg agaatggtct ca 22 <210> SEQ ID NO 15 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 15 caacatgatg ttcataatcc ca 22 <210> SEQ ID NO 16 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 16 ttaaatgttg ctatgcagtt tg 22 <210> SEQ ID NO 17 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 17 ttccccaaag ttccaaatta ta 22 <210> SEQ ID NO 18 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 18 taacaccgtt tgtgttataa ta 22 <210> SEQ ID NO 19 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 19 tatactgtct ttagagagtt ta 22 <210> SEQ ID NO 20 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA DNA target <400> SEQUENCE: 20 tgtaatagct tagaaaattt aa 22 <210> SEQ ID NO 21 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 21 tttaatctat tggtttgtct ag 22 <210> SEQ ID NO 22 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 22 ttgtacattg ttaggagtgt ga 22 <210> SEQ ID NO 23 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 23 tgcactggta cacataattt ca 22 <210> SEQ ID NO 24 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 24 tgagatgata caaagaattt ag 22 <210> SEQ ID NO 25 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 25 ccatcctata aaagaaggtc aa 22 <210> SEQ ID NO 26 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 26 tttaatctat tgcaaaaggt aa 22 <210> SEQ ID NO 27 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 27 tagtccagtg ttatagagtt ag 22 <210> SEQ ID NO 28 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 28 ttctaccttt ttccaaatgg ca 22 <210> SEQ ID NO 29 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 29 ttttctgtgg agacaaaggt aa 22 <210> SEQ ID NO 30 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 30 tgagatggct cagcaaataa tg 22 <210> SEQ ID NO 31 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: 10GGG_P DNA target <400> SEQUENCE: 31 tcgggacgtc gtacgacgtc ccga 24 <210> SEQ ID NO 32 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: 5GAT_P DNA target <400> SEQUENCE: 32 tcaaaacgat gtacatcgtt ttga 24 <210> SEQ ID NO 33 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: 5TAT_P DNA target <400> SEQUENCE: 33 tcaaaactat gtacatagtt ttga 24 <210> SEQ ID NO 34 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: rosa1.2 DNA target <400> SEQUENCE: 34 caacatgatg tacataatcc ca 22 <210> SEQ ID NO 35 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: rosa1.3 DNA target <400> SEQUENCE: 35 caacatgatg tacatcatgt tg 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: rosa1.4 DNA target <400> SEQUENCE: 36 tgggattatg tacataatcc ca 22 <210> SEQ ID NO 37 <211> LENGTH: 50 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: target oligonucleotide <400> SEQUENCE: 37 tggcatacaa gtttcaacat gatgtacatc atgttgacaa tcgtctgtca 50 <210> SEQ ID NO 38 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m1 variant <400> SEQUENCE: 38 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 39 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m2 variant <400> SEQUENCE: 39 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 40 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m3 variant <400> SEQUENCE: 40 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asp Asp Ser Gly Ser Val Ser Arg Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 41 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m4 variant <400> SEQUENCE: 41 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 42 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m5 variant <400> SEQUENCE: 42 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Gln Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 43 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m6 variant <400> SEQUENCE: 43 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 44 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m7 variant <400> SEQUENCE: 44 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Ala Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 45 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m8 variant <400> SEQUENCE: 45 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 46 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m9 variant <400> SEQUENCE: 46 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 47 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m10 variant <400> SEQUENCE: 47 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Thr Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 48 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m11 variant <400> SEQUENCE: 48 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 49 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m12 variant <400> SEQUENCE: 49 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Ser Gly Ser Val Ser Arg Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 50 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m13 variant <400> SEQUENCE: 50 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 51 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m14 variant <400> SEQUENCE: 51 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 52 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m15 variant <400> SEQUENCE: 52 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 53 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m16 variant <400> SEQUENCE: 53 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 54 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m17 variant <400> SEQUENCE: 54 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Thr Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 55 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m18 variant <400> SEQUENCE: 55 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 56 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 56 gcaactttag tgctgacaca tacagg 26 <210> SEQ ID NO 57 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 57 acaaccttga ttggagactt gacc 24 <210> SEQ ID NO 58 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <220> FEATURE: <221> NAME/KEY: modified_base <222> LOCATION: (4)..(6) <223> OTHER INFORMATION: a, c, t, g, unknown or other <400> SEQUENCE: 58 ctannnttga ccttt 15 <210> SEQ ID NO 59 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <220> FEATURE: <221> NAME/KEY: modified_base <222> LOCATION: (10)..(12) <223> OTHER INFORMATION: a, c, t, g, unknown or other <400> SEQUENCE: 59 aaaggtcaan nntag 15 <210> SEQ ID NO 60 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 60 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 61 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 61 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 62 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 62 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 63 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 63 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 64 <211> LENGTH: 166 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 64 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Val Thr Gln Lys 35 40 45 Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val 50 55 60 Gly Tyr Val Arg Asp Ala Gly Ser Val Ser Asn Tyr Ile Leu Ser Glu 65 70 75 80 Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys 85 90 95 Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu 100 105 110 Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp 115 120 125 Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr 130 135 140 Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys 145 150 155 160 Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 65 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 65 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Gly Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 66 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 66 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 67 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 67 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Thr Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 68 <211> LENGTH: 59 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 68 gcataaatta ctatacttct atagacacgc aaacacaaat acacagcggc cttgccacc 59 <210> SEQ ID NO 69 <211> LENGTH: 48 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 69 ggctcgagga gctcgtctag aggatcgctc gagttatcag tcggccgc 48 <210> SEQ ID NO 70 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 70 ttaagcgaaa tcaagccg 18 <210> SEQ ID NO 71 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 71 cggcttgatt tcgcttaa 18 <210> SEQ ID NO 72 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 72 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 73 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 73 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Ala Leu Gly Ser Leu Ser Glu Glu Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 74 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 74 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 75 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 75 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 76 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 76 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 77 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 77 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Ile Leu Gly 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 78 <211> LENGTH: 77 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 78 ggggacaagt ttgtacaaaa aagcaggctt cgaaggagat agaaccatgg ccaataccaa 60 atataacaaa gagttcc 77 <210> SEQ ID NO 79 <211> LENGTH: 64 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 79 ggggaccact ttgtacaaga aagctgggtt tagtcggccg ccggggagga tttcttcttc 60 tcgc 64 <210> SEQ ID NO 80 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI DNA target <400> SEQUENCE: 80 tcaaaacgtc gtgagacagt ttgg 24 <210> SEQ ID NO 81 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-SceI DNA target <400> SEQUENCE: 81 tagggataac agggtaat 18 <210> SEQ ID NO 82 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 82 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro His Gln 20 25 30 Ser Ser Lys Phe Lys His Gln Leu Ser Leu Thr Phe Glu Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Cys Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 83 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 83 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asn Gly Lys Phe Lys His Gln Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Glu Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 84 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 84 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Asn Leu Gln Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Arg Tyr Asp Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 85 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 85 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Ser Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Arg Leu Lys Leu Thr Phe Asp Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Ser Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 86 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 86 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Cys Lys Phe Lys His Gln Leu Ser Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 87 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 87 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Thr Cys Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Thr Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 88 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 88 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Arg Tyr Tyr Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 89 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 89 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Ser Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Arg Leu Lys Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 90 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 90 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Ala Pro Asn Gln 20 25 30 Ser Ser Lys Phe Lys His Arg Leu Lys Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 91 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 91 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp His Lys Phe Lys His Gln Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Glu Asp Ser Gly Ser Val Ser Asp Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 92 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 92 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Arg Gln 20 25 30 Asp Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Lys Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 93 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 93 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Arg Pro Asn Gln 20 25 30 Ser Ala Lys Phe Lys His Tyr Leu Gln Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Gln Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 94 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 94 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Arg Pro Asp Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Glu Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 95 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 95 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Ala Leu Gln Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 96 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 96 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Ala Leu Gln Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 97 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 97 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Pro Lys Phe Lys His Gln Leu Gln Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Gln Tyr Asn Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 98 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 98 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Ala Pro Asn Gln 20 25 30 Ser Ser Lys Phe Lys His Arg Leu Lys Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Ser Gly Ser Val Ser Asn Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 99 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 99 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro His Gln 20 25 30 Ser Ser Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 100 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 100 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp His Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Thr Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 101 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 101 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Arg Asp Lys Phe Lys His Gln Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 102 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 102 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Pro Lys Phe Lys His Gln Leu Gln Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Gln Tyr Asn Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 103 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 103 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Gln Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Glu Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 104 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 104 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Thr Lys Phe Lys His Ala Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp His Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 105 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 105 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Thr Lys Phe Lys His Gln Leu Thr Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ala Asp Lys Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 106 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 106 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp His Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Arg Tyr Asp Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 107 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 107 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asp Gln 20 25 30 Ser Arg Lys Phe Lys His Thr Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Glu Asp Ser Gly Ser Val Ser Asp Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 108 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 108 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Thr Tyr Lys Phe Lys His Trp Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Glu Asp Ser Gly Ser Val Ser Asp Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 109 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 109 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro His Gln 20 25 30 Ser Ser Lys Phe Lys His Gln Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Glu Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 110 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 110 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Cys Lys Phe Lys His Ala Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ala Asp Lys Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 111 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 111 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp Tyr Lys Phe Lys His Cys Leu Ser Leu Thr Phe Asp Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Ser Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 112 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 112 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Thr Tyr Lys Phe Lys His Trp Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Glu Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 113 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 113 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Ala Leu Gln Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 114 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 114 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser His Lys Phe Lys His Ser Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Gln Tyr Asn Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 115 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 115 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Thr Cys Lys Phe Lys His Gln Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 116 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 116 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp His Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asp Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 117 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 117 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Ala Leu Gln Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Lys Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 118 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 118 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp Tyr Lys Phe Lys His Cys Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Arg Tyr Tyr Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 119 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 119 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 120 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 120 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Arg Gln 20 25 30 Asp Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp His Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 121 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 121 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ala Cys Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Gln Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 122 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 122 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asn Gly Lys Phe Lys His Gln Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ala Asp Lys Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 123 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 123 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Gln Leu Gln Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 124 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 124 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Arg Gln 20 25 30 Asp Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 125 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 125 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Ser Lys Phe Lys His Arg Leu His Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp His Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 126 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 126 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Arg Pro Asn Gln 20 25 30 Ser Ala Lys Phe Lys His Tyr Leu Gln Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp His Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 127 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 127 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Arg Gln 20 25 30 Asp Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Gln Tyr Asn Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 128 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 128 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro His Gln 20 25 30 Ser Ser Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Lys Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 129 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 129 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Arg Pro Asn Gln 20 25 30 Ser Ala Lys Phe Lys His Tyr Leu Gln Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Lys Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 130 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 130 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp Tyr Lys Phe Lys His Cys Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Lys Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 131 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 131 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Val Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ala Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 132 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 132 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 133 <211> LENGTH: 163 <212> TYPE: PRT <213> ORGANISM: Chlamydomonas reinhardtii <400> SEQUENCE: 133 Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe 1 5 10 15 Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln Ser 20 25 30 Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln Lys 35 40 45 Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val 50 55 60 Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Asp Tyr Ile Leu Ser Glu 65 70 75 80 Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys 85 90 95 Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu 100 105 110 Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp 115 120 125 Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr 130 135 140 Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys 145 150 155 160 Ser Ser Pro <210> SEQ ID NO 134 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: NLS peptide <400> SEQUENCE: 134 Lys Lys Lys Arg Lys 1 5 <210> SEQ ID NO 135 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: HA-tag peptide <400> SEQUENCE: 135 Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 1 5 <210> SEQ ID NO 136 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: S-tag peptide <400> SEQUENCE: 136 Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser 1 5 10 15 <210> SEQ ID NO 137 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 137 tagtatacag aaactgttgc atcgc 25 <210> SEQ ID NO 138 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 138 cgtctgctgc tccatacaag 20 <210> SEQ ID NO 139 <211> LENGTH: 585 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: IRES polynucleotide <400> SEQUENCE: 139 gcccctctcc ctcccccccc cctaacgtta ctggccgaag ccgcttggaa taaggccggt 60 gtgcgtttgt ctatatgtta ttttccacca tattgccgtc ttttggcaat gtgagggccc 120 ggaaacctgg ccctgtcttc ttgacgagca ttcctagggg tctttcccct ctcgccaaag 180 gaatgcaagg tctgttgaat gtcgtgaagg aagcagttcc tctggaagct tcttgaagac 240 aaacaacgtc tgtagcgacc ctttgcaggc agcggaaccc cccacctggc gacaggtgcc 300 tctgcggcca aaagccacgt gtataagata cacctgcaaa ggcggcacaa ccccagtgcc 360 acgttgtgag ttggatagtt gtggaaagag tcaaatggct ctcctcaagc gtattcaaca 420 aggggctgaa ggatgcccag aaggtacccc attgtatggg atctgatctg gggcctcggt 480 gcacatgctt tacatgtgtt tagtcgaggt taaaaaaacg tctaggcccc ccgaaccacg 540 gggacgtggt tttcctttga aaaacacgat gataatatgg ccaca 585 <210> SEQ ID NO 140 <400> SEQUENCE: 140 000 <210> SEQ ID NO 141 <211> LENGTH: 172 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_1 NLS polypeptide <400> SEQUENCE: 141 Met Lys Lys Lys Arg Lys Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu 1 5 10 15 Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln 20 25 30 Ile Glu Pro Asn Gln Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr 35 40 45 Phe Ala Val Thr Gln Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu 50 55 60 Val Asp Glu Ile Gly Val Gly Tyr Val His Asp Gln Gly Ser Val Ser 65 70 75 80 Asn Tyr Ile Leu Ser Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln 85 90 95 Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu 100 105 110 Arg Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe 115 120 125 Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser 130 135 140 Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser 145 150 155 160 Leu Ser Glu Lys Lys Lys Ser Ser Pro Ala Ala Asp 165 170 <210> SEQ ID NO 142 <211> LENGTH: 175 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: mO_2 TagHA polypeptide <400> SEQUENCE: 142 Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Asn Thr Lys Tyr Asn Lys 1 5 10 15 Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Ser Asp Gly Ser Ile 20 25 30 Val Ala Gln Ile Lys Pro Asn Gln Ser Tyr Lys Phe Lys His Gln Leu 35 40 45 Ser Leu Thr Phe Tyr Val Thr Gln Lys Thr Gln Arg Arg Trp Phe Leu 50 55 60 Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Arg Asp Ser Gly 65 70 75 80 Ser Val Ser Gln Tyr Ile Leu Ser Glu Ile Lys Pro Leu His Asn Phe 85 90 95 Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala Asn 100 105 110 Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser Pro 115 120 125 Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala Leu 130 135 140 Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala Val 145 150 155 160 Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser Ser Pro Ala Ala Asp 165 170 175 <210> SEQ ID NO 143 <211> LENGTH: 182 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_1 Stag polypeptide <400> SEQUENCE: 143 Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser 1 5 10 15 Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe 20 25 30 Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln Ser 35 40 45 Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln Lys 50 55 60 Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val 65 70 75 80 Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser Glu 85 90 95 Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys 100 105 110 Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln Leu 115 120 125 Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp 130 135 140 Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr 145 150 155 160 Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys 165 170 175 Ser Ser Pro Ala Ala Asp 180 <210> SEQ ID NO 144 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_2 NLS+TagHA polypeptide <400> SEQUENCE: 144 Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Lys Lys Lys Arg Lys Ala 1 5 10 15 Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val 20 25 30 Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln Ser Tyr 35 40 45 Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln Lys Thr 50 55 60 Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly 65 70 75 80 Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser Glu Ile 85 90 95 Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu 100 105 110 Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro 115 120 125 Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val 130 135 140 Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser 145 150 155 160 Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser 165 170 175 Ser Pro Ala Ala Asp 180 <210> SEQ ID NO 145 <211> LENGTH: 187 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_1NLS+STag polypeptide <400> SEQUENCE: 145 Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser 1 5 10 15 Lys Lys Lys Arg Lys Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu 20 25 30 Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile 35 40 45 Glu Pro Asn Gln Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe 50 55 60 Ala Val Thr Gln Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val 65 70 75 80 Asp Glu Ile Gly Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn 85 90 95 Tyr Ile Leu Ser Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu 100 105 110 Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg 115 120 125 Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu 130 135 140 Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys 145 150 155 160 Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu 165 170 175 Ser Glu Lys Lys Lys Ser Ser Pro Ala Ala Asp 180 185 <210> SEQ ID NO 146 <211> LENGTH: 354 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Single-chain MO_1/mO_2 polypeptide <400> SEQUENCE: 146 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Gly Gly Ser Asp Lys Tyr Asn Gln Ala Leu 165 170 175 Ser Lys Tyr Asn Gln Ala Leu Ser Lys Tyr Asn Gln Ala Leu Ser Gly 180 185 190 Gly Gly Gly Ser Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val 195 200 205 Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln Ser Tyr 210 215 220 Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln Lys Thr 225 230 235 240 Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly 245 250 255 Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser Glu Ile 260 265 270 Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu 275 280 285 Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro 290 295 300 Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val 305 310 315 320 Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser 325 330 335 Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser 340 345 350 Ser Pro <210> SEQ ID NO 147 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_2 E8K+E61R polypeptide <400> SEQUENCE: 147 Met Ala Asn Thr Lys Tyr Asn Lys Lys Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Arg Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 148 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_1 K7E+K96E polypeptide <400> SEQUENCE: 148 Met Ala Asn Thr Lys Tyr Asn Glu Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Glu Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 149 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Single-chain meganuclease linker <400> SEQUENCE: 149 Gly Gly Ser Asp Lys Tyr Asn Gln Ala Leu Ser Lys Tyr Asn Gln Ala 1 5 10 15 Leu Ser Lys Tyr Asn Gln Ala Leu Ser Gly Gly Gly Gly Ser 20 25 30 <210> SEQ ID NO 150 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 150 Leu Ala Gly Leu Ile Asp Ala Asp Gly 1 5

1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 150 <210> SEQ ID NO 1 <211> LENGTH: 163 <212> TYPE: PRT <213> ORGANISM: Chlamydomonas reinhardtii <400> SEQUENCE: 1 Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe 1 5 10 15 Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln Ser 20 25 30 Tyr Lys Phe Lys His Gln Leu Ser Leu Ala Phe Gln Val Thr Gln Lys 35 40 45 Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val 50 55 60 Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Asp Tyr Ile Leu Ser Glu 65 70 75 80 Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys 85 90 95 Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Trp Arg Leu 100 105 110 Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp 115 120 125 Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr 130 135 140 Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys 145 150 155 160 Ser Ser Pro <210> SEQ ID NO 2 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: C1221 DNA target <400> SEQUENCE: 2 tcaaaacgtc gtacgacgtt ttga 24 <210> SEQ ID NO 3 <211> LENGTH: 13139 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 3 aagcttctca cgtagcaacc agagctccag agccagcagc tgctgccgcc ttgtatactc 60 actcctgtga tccaacacag gagcaacctt ttctttaccc cacccccact tcttaacaca 120 cttttttttg gggggggggg gggaacaagt gctccatgct ggaaggattg gaactatgct 180 tttagaaagg aacaatccta aggtcacttt taaattgagg tctttgattt gaaaatcaac 240 aaataccaaa ttccaaatat tcgttttaat taaaccagca atgtggatat aagcattaag 300 ttttagtttt aaaaaggtca attttccaaa cattcagcaa tcatatttaa atttacagct 360 aggaacaaga gccttgggtc atgtcctacc aaagaacata actcaatatt ctacacatga 420 caatctgaat aaccttaaag cctctaatcc cataacaggc cacaaatttt ggacagagaa 480 ctaatgatcc tcctgagaaa actggaagaa atccagggaa aagaaattcc tgtgtcctcc 540 aaactcagaa atctctaatt atgtcagtat tctctgcttt agtcctaggt cagattgcac 600 acatctaaaa taacctctta aagttttcct cctagcgacc taaaccatta ttaatatcaa 660 attaaccatc aaaacacttt cctctcaata tgctgcacac aaacctcctc ctggaacctc 720 ctccatctgg atcctcccca atcaaaagta taggtattta acatataagc aaggaagtaa 780 tgtaaacatg accttggtca caaatatgtc atctaaaaac aatttagtca aggtatggag 840 gaaattcgag aacctgaatc tttttaagta ttttgagcac aggaacaatt ggcaaaagga 900 atccaggtat agacaaaacc cagagcccag agctctgggc gaaaaatgag ttgctggtga 960 agacgttaca caagtaacat gagaaagcag aaaatgcagg tcatccacgc acccctgacc 1020 caggccagca gggcgggctg cagcatcagt acacaggaga aagatcctta ttcctaagaa 1080 tgagaaaggc aaaggcgccc gatagaataa attagcatag aaggggcttt cccaggagtt 1140 aaaactttcc ttctgagcga ttacctacta aaaccagggc ttttgcccac taccatttac 1200 ctaggatctt ggcttgcacg gattcatagg ggcatatccc tccccctctt ctttagagtc 1260 gttcttaaaa gatcgctctc cacgccctag gcagggaaaa cgacaaaatc tggctcaatt 1320 ccaggctaga accctacaaa ttcaacaggg atatcgcaag gatactgggg catacgccac 1380 agggagtcca agaatgtgag gtgggggtgg cgaaggtaat gtctttggtg tgggaaaagc 1440 agcagccatc tgagatagga actggaaaac cagaggagag gcgttcagga agattatgga 1500 ggggaggact gggcccccac gagcgaccag agttgtcaca aggccgcaag aacaggggag 1560 gtggggggct cagggacaga aaaaaaagta tgtgtatttt gagagcaggg ttgggaggcc 1620 tctcctgaaa agggtataaa cgtggagtag gcaataccca ggcaaaaagg ggagaccaga 1680 gtagggggag gggaagagtc ctgacccagg gaagacatta aaaaggtagt ggggtcgact 1740 agatgaagga gagcctttct ctctgggcaa gagcggtgca atggtgtgta aaggtagctg 1800 agaagacgaa aagggcaagc atcttcctgc taccaggctg gggaggccca ggcccacgac 1860 cccgaggaga gggaacgcag ggagactgag gtgacccttc tttcccccgg ggcccggtcg 1920 tgtggttcgg tgtctctttt ctgttggacc cttaccttga cccaggcgct gccggggcct 1980 gggcccgggc tgcggcgcac ggcactcccg ggaggcagcg agactcgagt taggcccaac 2040 gcggcgccac ggcgtttcct ggccgggaat ggcccgtacc cgtgaggtgg gggtgggggg 2100 cagaaaaggc ggagcgagcc cgagcgggga gggggagggc caggggcgga gggggccggc 2160 actactgtgt tggcggactg gcgggactag ggctgcgtga gtctctgagc gcaggcgggc 2220 ggcggccgcc cctcccccgg cggcggcagc ggcggcagcg gcggcagctc actcagcccg 2280 ctgcccgagc ggaaacgcca ctgaccgcac ggggattccc agtgccggcg ccaggggcac 2340 gcgggacacg ccccctcccg ccgcgccatt ggcctctccg cccaccgccc cacacttatt 2400 ggccggtgcg ccgccaatca gcggaggctg ccggggccgc ctaaagaaga ggctgtgctt 2460 tggggctccg gctcctcaga gagcctcggc taggtagggg atcgggactc tggcgggagg 2520 gcggcttggt gcgtttgcgg ggatgggcgg ccgcggcagg ccctccgagc gtggtggagc 2580 cgttctgtga gacagccggg tacgagtcgt gacgctggaa ggggcaagcg ggtggtgggc 2640 aggaatgcgg tccgccctgc agcaaccgga gggggaggga gaagggagcg gaaaagtctc 2700 caccggacgc ggccatggct cggggggggg ggggcagcgg aggagcgctt ccggccgacg 2760 tctcgtcgct gattggcttc ttttcctccc gccgtgtgtg aaaacacaaa tggcgtgttt 2820 tggttggcgt aaggcgcctg tcagttaacg gcagccggag tgcgcagccg ccggcagcct 2880 cgctctgccc actgggtggg gcgggaggta ggtggggtga ggcgagctgg acgtgcgggc 2940 gcggtcggcc tctggcgggg cgggggaggg gagggagggt cagcgaaagt agctcgcgcg 3000 cgagcggccg cccaccctcc ccttcctctg ggggagtcgt tttacccgcc gccggccggg 3060 cctcgtcgtc tgattggctc tcggggccca gaaaactggc ccttgccatt ggctcgtgtt 3120 cgtgcaagtt gagtccatcc gccggccagc gggggcggcg aggaggcgct cccaggttcc 3180 ggccctcccc tcggccccgc gccgcagagt ctggccgcgc gcccctgcgc aacgtggcag 3240 gaagcgcgcg ctgggggcgg ggacgggcag tagggctgag cggctgcggg gcgggtgcaa 3300 gcacgtttcc gacttgagtt gcctcaagag gggcgtgctg agccagacct ccatcgcgca 3360 ctccggggag tggagggaag gagcgagggc tcagttgggc tgttttggag gcaggaagca 3420 cttgctctcc caaagtcgct ctgagttgtt atcagtaagg gagctgcagt ggagtaggcg 3480 gggagaaggc cgcacccttc tccggagggg ggaggggagt gttgcaatac ctttctggga 3540 gttctctgct gcctcctggc ttctgaggac cgccctgggc ctgggagaat cccttccccc 3600 tcttccctcg tgatctgcaa ctccagtctt tctagaagat gggcgggagt cttctgggca 3660 ggcttaaagg ctaacctggt gtgtgggcgt tgtcctgcag gggaattgaa caggtgtaaa 3720 attggaggga caagacttcc cacagatttt cggttttgtc gggaagtttt ttaatagggg 3780 caaataagga aaatgggagg ataggtagtc atctggggtt ttatgcagca aaactacagg 3840 ttattattgc ttgtgatccg cctcggagta ttttccatcg aggtagatta aagacatgct 3900 cacccgagtt ttatactctc ctgcttgaga tccttactac agtatgaaat tacagtgtcg 3960 cgagttagac tatgtaagca gaattttaat catttttaaa gagcccagta cttcatatcc 4020 atttctcccg ctccttctgc agccttatca aaaggtattt tagaacactc attttagccc 4080 cattttcatt tattatactg gcttatccaa cccctagaca gagcattggc attttccctt 4140 tcctgatctt agaagtctga tgactcatga aaccagacag attagttaca tacaccacaa 4200 atcgaggctg tagctggggc ctcaacactg cagttctttt ataactcctt agtacacttt 4260 ttgttgatcc tttgccttga tccttaattt tcagtgtcta tcacctctcc cgtcagtggt 4320 gttccacatt tgggcctatt ctcagtccag ggagttttac aacaatagat gtattgagaa 4380 tccaacctaa agcttaactt tccactccca tgaatgcctc tctccttttt ctccatttat 4440 aaactgagct attaaccatt aatggttcca ggtggatgtc tcctccccat attacctgat 4500 gtatcttaca tattgccagg ctgatatttt aagacattaa aaggtatatt tcattattga 4560 gccacatggt attgattact gcttactaaa attttgtcat tgtacacatc tgtaaaaggt 4620 ggttcctttt ggaatgcaaa gttcaggtgt ttgttgtctt tcctgaccta aggtcttgtg 4680 agcttgtatt ttttctattt aagcagtgct ttctcttgga ctggcttgac tcatggcatt 4740 ctacacgtta ttgctggtct aaatgtgatt ttgccaagct tcttcaggac ctataatttt 4800 gcttgacttg tagccaaaca caagtaaaat gattaagcaa caaatgtatt tgtgaagctt 4860 ggtttttagg ttgttgtgtt gtgtgtgctt gtgctctata ataatactat ccaggggctg 4920 gagaggtggc tcggagttca agagcacaga ctgctcttcc agaagtcctg agttcaattc 4980 ccagcaacca catggtggct cacaaccatc tgtaatggga tctgatgccc tcttctggtg 5040 tgtctgaaga ccacaagtgt attcacatta aataaataaa tcctccttct tcttcttttt 5100 ttttttttta aagagaatac tgtctccagt agaatttact gaagtaatga aatactttgt 5160 gtttgttcca atatggtagc caataatcaa attactcttt aagcactgga aatgttacca 5220 aggaactaat ttttatttga agtgtaactg tggacagagg agccataact gcagacttgt 5280 gggatacaga agaccaatgc agactttaat gtcttttctc ttacactaag caataaagaa 5340 ataaaaattg aacttctagt atcctatttg tttaaactgc tagctttact taacttttgt 5400 gcttcatcta tacaaagctg aaagctaagt ctgcagccat tactaaacat gaaagcaagt 5460 aatgataatt ttggatttca aaaatgtagg gccagagttt agccagccag tggtggtgct 5520

tgcctttatg cctttaatcc cagcactctg gaggcagaga caggcagatc tctgagtttg 5580 agcccagcct ggtctacaca tcaagttcta tctaggatag ccaggaatac acacagaaac 5640 cctgttgggg aggggggctc tgagatttca taaaattata attgaagcat tccctaatga 5700 gccactatgg atgtggctaa atccgtctac ctttctgatg agatttgggt attatttttt 5760 ctgtctctgc tgttggttgg gtcttttgac actgtgggct ttctttaaag cctccttcct 5820 gccatgtggt ctcttgtttg ctactaactt cccatggctt aaatggcatg gctttttgcc 5880 ttctaagggc agctgctgag atttgcagcc tgatttccag ggtggggttg ggaaatcttt 5940 caaacactaa aattgtcctt taattttttt tttaaaaaat gggttatata ataaacctca 6000 taaaatagtt atgaggagtg aggtggacta atattaaatg agtccctccc ctataaaaga 6060 gctattaagg ctttttgtct tatacttaac ttttttttta aatgtggtat ctttagaacc 6120 aagggtctta gagttttagt atacagaaac tgttgcatcg cttaatcaga ttttctagtt 6180 tcaaatccag agaatccaaa ttcttcacag ccaaagtcaa attaagaatt tctgactttt 6240 aatgttaatt tgcttactgt gaatataaaa atgatagctt ttcctgaggc agggtctcac 6300 tatgtatctc tgcctgatct gcaacaagat atgtagacta aagttctgcc tgcttttgtc 6360 tcctgaatac taaggttaaa atgtagtaat acttttggaa cttgcaggtc agattctttt 6420 ataggggaca cactaaggga gcttgggtga tagttggtaa aatgtgtttc aagtgatgaa 6480 aacttgaatt attatcaccg caacctactt tttaaaaaaa aaagccaggc ctgttagagc 6540 atgcttaagg gatccctagg acttgctgag cacacaagag tagttacttg gcaggctcct 6600 ggtgagagca tatttcaaaa aacaaggcag acaaccaaga aactacagtt aaggttacct 6660 gtctttaaac catctgcata tacacaggga tattaaaata ttccaaataa tatttcattc 6720 aagttttccc ccatcaaatt gggacatgga tttctccggt gaataggcag agttggaaac 6780 taaacaaatg ttggttttgt gatttgtgaa attgttttca agtgatagtt aaagcccatg 6840 agatacagaa caaagctgct atttcgaggt ctcttggttt atactcagaa gcacttcttt 6900 gggtttccct gcactatcct gatcatgtgc taggcctacc ttaggctgat tgttgttcaa 6960 ataaacttaa gtttcctgtc aggtgatgtc atatgatttc atatatcaag gcaaaacatg 7020 ttatatatgt taaacatttg tacttaatgt gaaagttagg tctttgtggg tttgattttt 7080 aattttcaaa acctgagcta aataagtcat ttttacatgt cttacatttg gtggaattgt 7140 ataattgtgg tttgcaggca agactctctg acctagtaac cctacctata gagcactttg 7200 ctgggtcaca agtctaggag tcaagcattt caccttgaag ttgagacgtt ttgttagtgt 7260 atactagttt atatgttgga ggacatgttt atccagaaga tattcaggac tatttttgac 7320 tgggctaagg aattgattct gattagcact gttagtgagc attgagtggc ctttaggctt 7380 gaattggagt cacttgtata tctcaaataa tgctggcctt ttttaaaaag cccttgttct 7440 ttatcaccct gttttctaca taatttttgt tcaaagaaat acttgtttgg atctcctttt 7500 gacaacaata gcatgttttc aagccatatt ttttttcctt tttttttttt tttttggttt 7560 ttcgagacag ggtttctctg tatagccctg gctgtcctgg aactcacttt gtagaccagg 7620 ctggcctcga actcagaaat ccgcctgcct ctgcctcctg agtgccggga ttaaaggcgt 7680 gcaccaccac gcctggctaa gttggatatt ttgttatata actataacca atactaactc 7740 cactgggtgg atttttaatt cagtcagtag tcttaagtgg tctttattgg cccttcatta 7800 aaatctactg ttcactctaa cagaggctgt tggtactagt ggcacttaag caacttccta 7860 cggatatact agcagattaa gggtcaggga tagaaactag tctagcgttt tgtataccta 7920 ccagctttat actaccttgt tctgatagaa atatttcagg acatctagag tgtactataa 7980 ggttgatggt aagcttataa ggaacttgaa agtggagtaa ctactccatt tctctgaggg 8040 gagaattaaa atttttgacc aagtgttgtt gagccactga gaatggtctc agaacataac 8100 ttcttaagga accttcccag attgccctca acactgcacc acatttggtc ctgcttgaac 8160 attgccatgg ctcttaaagt cttaattaag aatattaatt gtgtaattat tgtttttcct 8220 cctttagatc attccttgag gacaggacag tgcttgttta aggctatatt tctgctgtct 8280 gagcagcaac aggtcttcga gatcaacatg atgttcataa tcccaagatg ttgccattta 8340 tgttctcaga agcaagcaga ggcatgatgg tcagtgacag taatgtcact gtgttaaatg 8400 ttgctatgca gtttggattt ttctaatgta gtgtaggtag aacatatgtg ttctgtatga 8460 attaaactct taagttacac cttgtataat ccatgcaatg tgttatgcaa ttaccatttt 8520 aagtattgta gctttctttg tatgtgagga taaaggtgtt tgtcataaaa tgttttgaac 8580 atttccccaa agttccaaat tataaaacca caacgttaga acttatttat gaacaatggt 8640 tgtagtttca tgcttttaaa atgcttaatt attcaattaa caccgtttgt gttataatat 8700 atataaaact gacatgtaga agtgtttgtc cagaacattt cttaaatgta tactgtcttt 8760 agagagttta atatagcatg tcttttgcaa catactaact tttgtgttgg tgcgagcaat 8820 attgtgtagt cattttgaaa ggagtcattt caatgagtgt cagattgttt tgaatgttat 8880 tgaacatttt aaatgcagac ttgttcgtgt tttagaaagc aaaactgtca gaagctttga 8940 actagaaatt aaaaagctga agtatttcag aagggaaata agctacttgc tgtattagtt 9000 gaaggaaagt gtaatagctt agaaaattta aaaccatata gttgtcattg ctgaatatct 9060 ggcagatgaa aagaaatact cagtggttct tttgagcaat ataacagctt gttatattaa 9120 aaattttccc cacagatata aactctaatc tataactcat aaatgttaca aatggatgaa 9180 gcttacaaat gtggcttgac ttgtcactgt gcttgtttta gttatgtgaa agtttggcaa 9240 taaacctatg tcctaaatag tcaaactgtg gaatgacttt ttaatctatt ggtttgtcta 9300 gaacagttat gttgccattt gccctaatgg tgaaagaaaa agtggggagt gccttggcac 9360 tgttcatttg tggtgtgaac caaagagggg ggcatgcact tacacttcaa acatcctttt 9420 gaaagactga caagtttggg tcttcacagt tggaattggg catccctttt gtcagggagg 9480 gagggaggga gggaggctgg cttgttatgc tgacaagtgt gattaaattc aaactttgag 9540 gtaagttgga ggaacttgta cattgttagg agtgtgacaa tttggactct taatgatttg 9600 gtcatacaaa atgaacctag accaacttct ggaagatgta tataataact ccatgttaca 9660 ttgatttcac ctgactaata cttatccctt atcaattaaa tacagaagat gccagccatc 9720 tgggcctttt aacccagaaa tttagtttca aactcctagg ttagtgttct cactgagcta 9780 catcctgatc tagtcctgaa aataggacca ccatcacccc caaaaaaatc tcaaataaga 9840 tttatgctag tgtttcaaaa ttttaggaat aggtaagatt agaaagtttt aaattttgag 9900 aaatggcttc tctagaaaga tgtacatagt gaacactgaa tggctcctaa agagcctaga 9960 aaactggtac tgagcacaca ggactgagag gtctttcttg aaaagcatgt attgctttac 10020 gtgggtcaca gaaggcaggc aggaagaact tgggctgaaa ctggtgtctt aagtggctaa 10080 catcttcaca actgatgagc aagaacttta tcctgatgca aaaaccatcc aaacaaacta 10140 agtgaaaggt ggcaatggat cccaggctgc tctagaggag gacttgactt ctcatcccat 10200 cacccacacc agatagctca tagactgcca attaacacca gcttctagcc tccacaggca 10260 cctgcactgg tacacataat ttcacacaaa cacagtaaga agccttccac ctggcatggt 10320 attgcttatc tttagttccc aacacttggg aggcagaggc cagccagggc tatgtgacaa 10380 aaaccttgtc tagaggagaa acttcatagc ttatttccta ttcacgtaac caggttagca 10440 aaatttacca gccagagatg aagctaacag tgtccactat atttgtagtg ttttaagtca 10500 attttttaaa tatacttaat agaattaaag ctatggtgaa ccaagtacaa acctggtgta 10560 ttaacttgag aacttagcat aaaaagtagt tcatttgttc agtaaatatt aaatgcttac 10620 tggcaaagat tatgtcagga acttggtaaa tggtgatgaa acaatcatag ttgtacatct 10680 tggttctgtg atcaccttgg tttgaggtaa aagtggttcc tttgatcaag gatggaattt 10740 taagtttata ttcaatcaat aatgtattat tttgtgattg caaaattgcc tatctagggt 10800 ataaaacctt taaaaatttc ataataccag ttcattctcc agttactaat tccaaaaagc 10860 cactgactat ggtgccaatg tggattctgt tctcaaagga aggattgtct gtgcccttta 10920 ttctaataga aacatcacac tgaaaatcta agctgaaaga agccagactt tcctaaataa 10980 ataactttcc ataaagctca aacaaggatt acttttagga ggcactgtta aggaactgat 11040 aagtaatgag gttacttata taatgatagt cccacaagac tatctgagga aaaatcagta 11100 caactcgaaa acagaacaac cagctaggca ggaataacag ggctcccaag tcaggaggtc 11160 tatccaacac ccttttctgt tgagggcccc agacctacat attgtataca aacagggagg 11220 tgggtgattt taactctcct gaggtacctt ggtaaatctt tgtcctgagt aagcagtaca 11280 gtgtacagtt tacattttca tttaaagata cattagctcc ctctaccccc taagactgac 11340 aggcactttg ggggtgggga gggctttgga aaataacgct tccatacact aaaagagaaa 11400 tttctttaat taggcttgtt ggttccatac atctactggt gtttctacta cttagtaata 11460 ttataatagt cacacaagca tctttgctct gtttaggttg tatatttatt ttaaggcaga 11520 tgataaaact gtagatctta agggatgctt ctgcttctga gatgatacaa agaatttaga 11580 ccataaaaca gtaggttgca caagcaatag aatatggcct aaagtgttct gacacttaga 11640 agccaagcag tgtaggcttc ttaagaaata ccattacaat caccttgcta gaaatcaagc 11700 attctggagt ggtcaagcag tgtaacctgt actgtaagtt acttttctgc tatttttctc 11760 ccaaagcaag ttctttatgc tgatatttcc agtgttagga actacaaata ttaataagtt 11820 gtcttcactc ttttctttac caaggagggt ctcttccttc atcttgatct gaaggatgaa 11880 caaaggcttg agcagtgcgc tttagaagat aaactgcagc atgaaggccc ccgatgttca 11940 cccagactac atggaccttt cgccacacat gtcccattcc agataaggcc tggcacacac 12000 aaaaaacata agtcattagg ctaccagtct gattctaaaa caacctaaaa tcttcccact 12060 taaatgctat gggtggtggg ttggaaagtt gactcagaaa atcacttgct gtttttagag 12120 aggatctggg ttcagtttct gatacattgt ggcttacaac tataactcca gttctagggg 12180 gtccatccaa catcctcttc tgttgagggc accaaataaa tgtattgtgt acaaacaggg 12240 aggtgagtga tttaactctc gtgtatagta ccttggtaaa acatttcttg tcctgagtaa 12300 gcagtacagc tctgcctgtc cctggtctac agacacggct catttcccga aggcaagctg 12360 gatagagatt ccaatttctc ttcttggatc ccatcctata aaagaaggtc aagtttaatc 12420 tattgcaaaa ggtaaatagg tagtttctta catgagacaa gaacaaatct taggtgtgaa 12480 gcagtcatct tttacaggcc agagcctcta ttctatgcca atgaaggaaa ctgttagtcc 12540 agtgttatag agttagtcca gtgtatagtt ttctatcaga acactttttt tttaaacaac 12600 tgcaacttag cttattgaag acaaaccacg agtagaaatc tgtccaagaa gcaagtgctt 12660 ctcagcctac aatgtggaat aggaccatgt aatggtacag tgagtgaaat gaattatggc 12720 atgtttttct gactgagaag acagtacaat aaaaggtaaa ctcatggtat ttatttaaaa 12780 agaatccaat ttctaccttt ttccaaatgg catatctgtt acaataatat ccacagaagc 12840 agttctcagt gggaggttgc agatatccca ctgaacagca tcaatgggca aaccccaggt 12900 tgtttttctg tggagacaaa ggtaagatat ttcaatatat tttcccaagc taatgagatg 12960 gctcagcaaa taatggtact ggccattaag tctcatgacc tgagcttgat cctcagggac 13020 catgtggtac aaggagagac ctaaatcctt cagttggact tcaatcttct accctcatgt 13080

ccacacacaa ataaatacaa taaaaaacat tctgcagtcg aatttctaaa agggcgaat 13139 <210> SEQ ID NO 4 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI N75 scaffold protein <400> SEQUENCE: 4 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 5 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 5 cgcccctgcg caacgtggca gg 22 <210> SEQ ID NO 6 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 6 ccgcaccctt ctccggaggg gg 22 <210> SEQ ID NO 7 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 7 tggactggct tgactcatgg ca 22 <210> SEQ ID NO 8 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 8 ccagcctggt ctacacatca ag 22 <210> SEQ ID NO 9 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 9 ctatctagga tagccaggaa ta 22 <210> SEQ ID NO 10 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 10 cagcctgatt tccagggtgg gg 22 <210> SEQ ID NO 11 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 11 taaacctcat aaaatagtta tg 22 <210> SEQ ID NO 12 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 12 tcagattctt ttatagggga ca 22 <210> SEQ ID NO 13 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 13 ttgtatatct caaataatgc tg 22 <210> SEQ ID NO 14 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA DNA target <400> SEQUENCE: 14 tgagccactg agaatggtct ca 22 <210> SEQ ID NO 15 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 15 caacatgatg ttcataatcc ca 22 <210> SEQ ID NO 16 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 16 ttaaatgttg ctatgcagtt tg 22 <210> SEQ ID NO 17 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 17 ttccccaaag ttccaaatta ta 22 <210> SEQ ID NO 18 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 18 taacaccgtt tgtgttataa ta 22 <210> SEQ ID NO 19 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 19 tatactgtct ttagagagtt ta 22 <210> SEQ ID NO 20 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA DNA target

<400> SEQUENCE: 20 tgtaatagct tagaaaattt aa 22 <210> SEQ ID NO 21 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 21 tttaatctat tggtttgtct ag 22 <210> SEQ ID NO 22 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 22 ttgtacattg ttaggagtgt ga 22 <210> SEQ ID NO 23 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 23 tgcactggta cacataattt ca 22 <210> SEQ ID NO 24 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 24 tgagatgata caaagaattt ag 22 <210> SEQ ID NO 25 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 25 ccatcctata aaagaaggtc aa 22 <210> SEQ ID NO 26 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 26 tttaatctat tgcaaaaggt aa 22 <210> SEQ ID NO 27 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 27 tagtccagtg ttatagagtt ag 22 <210> SEQ ID NO 28 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 28 ttctaccttt ttccaaatgg ca 22 <210> SEQ ID NO 29 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 29 ttttctgtgg agacaaaggt aa 22 <210> SEQ ID NO 30 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ROSA26 DNA target <400> SEQUENCE: 30 tgagatggct cagcaaataa tg 22 <210> SEQ ID NO 31 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: 10GGG_P DNA target <400> SEQUENCE: 31 tcgggacgtc gtacgacgtc ccga 24 <210> SEQ ID NO 32 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: 5GAT_P DNA target <400> SEQUENCE: 32 tcaaaacgat gtacatcgtt ttga 24 <210> SEQ ID NO 33 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: 5TAT_P DNA target <400> SEQUENCE: 33 tcaaaactat gtacatagtt ttga 24 <210> SEQ ID NO 34 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: rosa1.2 DNA target <400> SEQUENCE: 34 caacatgatg tacataatcc ca 22 <210> SEQ ID NO 35 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: rosa1.3 DNA target <400> SEQUENCE: 35 caacatgatg tacatcatgt tg 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: rosa1.4 DNA target <400> SEQUENCE: 36 tgggattatg tacataatcc ca 22 <210> SEQ ID NO 37 <211> LENGTH: 50 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: target oligonucleotide <400> SEQUENCE: 37 tggcatacaa gtttcaacat gatgtacatc atgttgacaa tcgtctgtca 50 <210> SEQ ID NO 38 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m1 variant <400> SEQUENCE: 38 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly

50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 39 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m2 variant <400> SEQUENCE: 39 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 40 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m3 variant <400> SEQUENCE: 40 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asp Asp Ser Gly Ser Val Ser Arg Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 41 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m4 variant <400> SEQUENCE: 41 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 42 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m5 variant <400> SEQUENCE: 42 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Gln Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 43 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m6 variant <400> SEQUENCE: 43 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 44 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m7 variant

<400> SEQUENCE: 44 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Ala Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 45 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m8 variant <400> SEQUENCE: 45 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 46 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m9 variant <400> SEQUENCE: 46 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 47 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m10 variant <400> SEQUENCE: 47 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Thr Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 48 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m11 variant <400> SEQUENCE: 48 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 49 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m12 variant <400> SEQUENCE: 49 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Ser Gly Ser Val Ser Arg Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys

145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 50 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m13 variant <400> SEQUENCE: 50 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 51 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m14 variant <400> SEQUENCE: 51 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 52 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m15 variant <400> SEQUENCE: 52 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 53 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m16 variant <400> SEQUENCE: 53 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 54 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m17 variant <400> SEQUENCE: 54 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Thr Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 55 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: m18 variant <400> SEQUENCE: 55 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80

Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 56 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 56 gcaactttag tgctgacaca tacagg 26 <210> SEQ ID NO 57 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 57 acaaccttga ttggagactt gacc 24 <210> SEQ ID NO 58 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <220> FEATURE: <221> NAME/KEY: modified_base <222> LOCATION: (4)..(6) <223> OTHER INFORMATION: a, c, t, g, unknown or other <400> SEQUENCE: 58 ctannnttga ccttt 15 <210> SEQ ID NO 59 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <220> FEATURE: <221> NAME/KEY: modified_base <222> LOCATION: (10)..(12) <223> OTHER INFORMATION: a, c, t, g, unknown or other <400> SEQUENCE: 59 aaaggtcaan nntag 15 <210> SEQ ID NO 60 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 60 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 61 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 61 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 62 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 62 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 63 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 63 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140

Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 64 <211> LENGTH: 166 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 64 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Val Thr Gln Lys 35 40 45 Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val 50 55 60 Gly Tyr Val Arg Asp Ala Gly Ser Val Ser Asn Tyr Ile Leu Ser Glu 65 70 75 80 Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys 85 90 95 Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu 100 105 110 Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp 115 120 125 Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr 130 135 140 Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys 145 150 155 160 Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 65 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 65 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Gly Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 66 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 66 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 67 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 67 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Thr Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 68 <211> LENGTH: 59 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 68 gcataaatta ctatacttct atagacacgc aaacacaaat acacagcggc cttgccacc 59 <210> SEQ ID NO 69 <211> LENGTH: 48 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 69 ggctcgagga gctcgtctag aggatcgctc gagttatcag tcggccgc 48 <210> SEQ ID NO 70 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 70 ttaagcgaaa tcaagccg 18 <210> SEQ ID NO 71 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 71 cggcttgatt tcgcttaa 18 <210> SEQ ID NO 72 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 72 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly

1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 73 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 73 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Ala Leu Gly Ser Leu Ser Glu Glu Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 74 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 74 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 75 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 75 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 76 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 76 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 77 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 77 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Ser Gly Ser Val Ser Arg Tyr Ile Leu Gly 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165

<210> SEQ ID NO 78 <211> LENGTH: 77 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 78 ggggacaagt ttgtacaaaa aagcaggctt cgaaggagat agaaccatgg ccaataccaa 60 atataacaaa gagttcc 77 <210> SEQ ID NO 79 <211> LENGTH: 64 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 79 ggggaccact ttgtacaaga aagctgggtt tagtcggccg ccggggagga tttcttcttc 60 tcgc 64 <210> SEQ ID NO 80 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI DNA target <400> SEQUENCE: 80 tcaaaacgtc gtgagacagt ttgg 24 <210> SEQ ID NO 81 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-SceI DNA target <400> SEQUENCE: 81 tagggataac agggtaat 18 <210> SEQ ID NO 82 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 82 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro His Gln 20 25 30 Ser Ser Lys Phe Lys His Gln Leu Ser Leu Thr Phe Glu Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Cys Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 83 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 83 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asn Gly Lys Phe Lys His Gln Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Glu Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 84 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 84 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Asn Leu Gln Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Arg Tyr Asp Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 85 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 85 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Ser Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Arg Leu Lys Leu Thr Phe Asp Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Ser Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 86 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 86 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30

Ser Cys Lys Phe Lys His Gln Leu Ser Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 87 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 87 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Thr Cys Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Thr Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 88 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 88 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Arg Tyr Tyr Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 89 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 89 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Ser Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Arg Leu Lys Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 90 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 90 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Ala Pro Asn Gln 20 25 30 Ser Ser Lys Phe Lys His Arg Leu Lys Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 91 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 91 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp His Lys Phe Lys His Gln Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Glu Asp Ser Gly Ser Val Ser Asp Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 92 <211> LENGTH: 167

<212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 92 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Arg Gln 20 25 30 Asp Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ser Asp Lys Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 93 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 93 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Arg Pro Asn Gln 20 25 30 Ser Ala Lys Phe Lys His Tyr Leu Gln Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Gln Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 94 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 94 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Arg Pro Asp Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Glu Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 95 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 95 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Ala Leu Gln Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 96 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 96 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Ala Leu Gln Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 97 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 97 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Pro Lys Phe Lys His Gln Leu Gln Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Gln Tyr Asn Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125

Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 98 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 98 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Ala Pro Asn Gln 20 25 30 Ser Ser Lys Phe Lys His Arg Leu Lys Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Ser Gly Ser Val Ser Asn Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 99 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 99 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro His Gln 20 25 30 Ser Ser Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Val Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 100 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 100 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp His Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Thr Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 101 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 101 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Arg Asp Lys Phe Lys His Gln Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 102 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 102 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Pro Lys Phe Lys His Gln Leu Gln Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Gln Tyr Asn Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 103 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 103 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Gln Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Arg Leu Lys Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly

50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Glu Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 104 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 104 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Thr Lys Phe Lys His Ala Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp His Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 105 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 105 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Thr Lys Phe Lys His Gln Leu Thr Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ala Asp Lys Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 106 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 106 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp His Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asn Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Arg Tyr Asp Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 107 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 107 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asp Gln 20 25 30 Ser Arg Lys Phe Lys His Thr Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Glu Asp Ser Gly Ser Val Ser Asp Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 108 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 108 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Thr Tyr Lys Phe Lys His Trp Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Glu Asp Ser Gly Ser Val Ser Asp Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 109 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant

<400> SEQUENCE: 109 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro His Gln 20 25 30 Ser Ser Lys Phe Lys His Gln Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Glu Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 110 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 110 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Cys Lys Phe Lys His Ala Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ala Asp Lys Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 111 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 111 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp Tyr Lys Phe Lys His Cys Leu Ser Leu Thr Phe Asp Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Ser Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 112 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 112 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Thr Tyr Lys Phe Lys His Trp Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Glu Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 113 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 113 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Ala Leu Gln Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 114 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 114 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser His Lys Phe Lys His Ser Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Gln Tyr Asn Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys

145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 115 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 115 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Thr Cys Lys Phe Lys His Gln Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 116 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 116 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp His Lys Phe Lys His Gln Leu Ser Leu Thr Phe Asp Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 117 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 117 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Ala Leu Gln Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Lys Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 118 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 118 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp Tyr Lys Phe Lys His Cys Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Arg Tyr Tyr Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 119 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 119 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Tyr Tyr Arg Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 120 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 120 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Arg Gln 20 25 30 Asp Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp His Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80

Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 121 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 121 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ala Cys Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Arg Tyr Gln Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 122 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 122 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asn Gly Lys Phe Lys His Gln Leu Ser Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Ala Asp Lys Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 123 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 123 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Gln Leu Gln Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 124 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 124 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Arg Gln 20 25 30 Asp Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Asn Asp Asn Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 125 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 125 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Ser Lys Phe Lys His Arg Leu His Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp His Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 126 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 126 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15

Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Arg Pro Asn Gln 20 25 30 Ser Ala Lys Phe Lys His Tyr Leu Gln Leu Thr Phe Thr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp His Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 127 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 127 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Arg Gln 20 25 30 Asp Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Lys Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Gln Tyr Asn Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 128 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 128 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro His Gln 20 25 30 Ser Ser Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Lys Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 129 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 129 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Arg Pro Asn Gln 20 25 30 Ser Ala Lys Phe Lys His Tyr Leu Gln Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Lys Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 130 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 130 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Asp Tyr Lys Phe Lys His Cys Leu Ser Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Asp Tyr Lys Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 131 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 131 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Val Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ala Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165

<210> SEQ ID NO 132 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 132 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Gln Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 133 <211> LENGTH: 163 <212> TYPE: PRT <213> ORGANISM: Chlamydomonas reinhardtii <400> SEQUENCE: 133 Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe 1 5 10 15 Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln Ser 20 25 30 Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Gln Val Thr Gln Lys 35 40 45 Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val 50 55 60 Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Asp Tyr Ile Leu Ser Glu 65 70 75 80 Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys 85 90 95 Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu 100 105 110 Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp 115 120 125 Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr 130 135 140 Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys 145 150 155 160 Ser Ser Pro <210> SEQ ID NO 134 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: NLS peptide <400> SEQUENCE: 134 Lys Lys Lys Arg Lys 1 5 <210> SEQ ID NO 135 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: HA-tag peptide <400> SEQUENCE: 135 Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 1 5 <210> SEQ ID NO 136 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: S-tag peptide <400> SEQUENCE: 136 Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser 1 5 10 15 <210> SEQ ID NO 137 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 137 tagtatacag aaactgttgc atcgc 25 <210> SEQ ID NO 138 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer <400> SEQUENCE: 138 cgtctgctgc tccatacaag 20 <210> SEQ ID NO 139 <211> LENGTH: 585 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: IRES polynucleotide <400> SEQUENCE: 139 gcccctctcc ctcccccccc cctaacgtta ctggccgaag ccgcttggaa taaggccggt 60 gtgcgtttgt ctatatgtta ttttccacca tattgccgtc ttttggcaat gtgagggccc 120 ggaaacctgg ccctgtcttc ttgacgagca ttcctagggg tctttcccct ctcgccaaag 180 gaatgcaagg tctgttgaat gtcgtgaagg aagcagttcc tctggaagct tcttgaagac 240 aaacaacgtc tgtagcgacc ctttgcaggc agcggaaccc cccacctggc gacaggtgcc 300 tctgcggcca aaagccacgt gtataagata cacctgcaaa ggcggcacaa ccccagtgcc 360 acgttgtgag ttggatagtt gtggaaagag tcaaatggct ctcctcaagc gtattcaaca 420 aggggctgaa ggatgcccag aaggtacccc attgtatggg atctgatctg gggcctcggt 480 gcacatgctt tacatgtgtt tagtcgaggt taaaaaaacg tctaggcccc ccgaaccacg 540 gggacgtggt tttcctttga aaaacacgat gataatatgg ccaca 585 <210> SEQ ID NO 140 <400> SEQUENCE: 140 000 <210> SEQ ID NO 141 <211> LENGTH: 172 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_1 NLS polypeptide <400> SEQUENCE: 141 Met Lys Lys Lys Arg Lys Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu 1 5 10 15 Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln 20 25 30 Ile Glu Pro Asn Gln Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr 35 40 45 Phe Ala Val Thr Gln Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu 50 55 60 Val Asp Glu Ile Gly Val Gly Tyr Val His Asp Gln Gly Ser Val Ser 65 70 75 80 Asn Tyr Ile Leu Ser Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln 85 90 95 Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu 100 105 110 Arg Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe 115 120 125 Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser 130 135 140 Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser 145 150 155 160 Leu Ser Glu Lys Lys Lys Ser Ser Pro Ala Ala Asp 165 170 <210> SEQ ID NO 142 <211> LENGTH: 175 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: mO_2 TagHA polypeptide <400> SEQUENCE: 142 Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Asn Thr Lys Tyr Asn Lys 1 5 10 15

Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Ser Asp Gly Ser Ile 20 25 30 Val Ala Gln Ile Lys Pro Asn Gln Ser Tyr Lys Phe Lys His Gln Leu 35 40 45 Ser Leu Thr Phe Tyr Val Thr Gln Lys Thr Gln Arg Arg Trp Phe Leu 50 55 60 Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Arg Asp Ser Gly 65 70 75 80 Ser Val Ser Gln Tyr Ile Leu Ser Glu Ile Lys Pro Leu His Asn Phe 85 90 95 Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala Asn 100 105 110 Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser Pro 115 120 125 Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala Leu 130 135 140 Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala Val 145 150 155 160 Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser Ser Pro Ala Ala Asp 165 170 175 <210> SEQ ID NO 143 <211> LENGTH: 182 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_1 Stag polypeptide <400> SEQUENCE: 143 Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser 1 5 10 15 Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe 20 25 30 Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln Ser 35 40 45 Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln Lys 50 55 60 Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val 65 70 75 80 Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser Glu 85 90 95 Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys 100 105 110 Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln Leu 115 120 125 Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp 130 135 140 Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr 145 150 155 160 Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys 165 170 175 Ser Ser Pro Ala Ala Asp 180 <210> SEQ ID NO 144 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_2 NLS+TagHA polypeptide <400> SEQUENCE: 144 Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Lys Lys Lys Arg Lys Ala 1 5 10 15 Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val 20 25 30 Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln Ser Tyr 35 40 45 Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln Lys Thr 50 55 60 Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly 65 70 75 80 Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser Glu Ile 85 90 95 Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu 100 105 110 Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro 115 120 125 Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val 130 135 140 Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser 145 150 155 160 Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser 165 170 175 Ser Pro Ala Ala Asp 180 <210> SEQ ID NO 145 <211> LENGTH: 187 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_1NLS+STag polypeptide <400> SEQUENCE: 145 Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser 1 5 10 15 Lys Lys Lys Arg Lys Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu 20 25 30 Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile 35 40 45 Glu Pro Asn Gln Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe 50 55 60 Ala Val Thr Gln Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val 65 70 75 80 Asp Glu Ile Gly Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn 85 90 95 Tyr Ile Leu Ser Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu 100 105 110 Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg 115 120 125 Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu 130 135 140 Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys 145 150 155 160 Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu 165 170 175 Ser Glu Lys Lys Lys Ser Ser Pro Ala Ala Asp 180 185 <210> SEQ ID NO 146 <211> LENGTH: 354 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Single-chain MO_1/mO_2 polypeptide <400> SEQUENCE: 146 Met Ala Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Gly Gly Ser Asp Lys Tyr Asn Gln Ala Leu 165 170 175 Ser Lys Tyr Asn Gln Ala Leu Ser Lys Tyr Asn Gln Ala Leu Ser Gly 180 185 190 Gly Gly Gly Ser Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val 195 200 205 Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln Ser Tyr 210 215 220 Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln Lys Thr 225 230 235 240 Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly 245 250 255 Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser Glu Ile 260 265 270 Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu 275 280 285 Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro 290 295 300 Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val 305 310 315 320 Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser 325 330 335 Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser 340 345 350 Ser Pro

<210> SEQ ID NO 147 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_2 E8K+E61R polypeptide <400> SEQUENCE: 147 Met Ala Asn Thr Lys Tyr Asn Lys Lys Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Ser Asp Gly Ser Ile Val Ala Gln Ile Lys Pro Asn Gln 20 25 30 Ser Tyr Lys Phe Lys His Gln Leu Ser Leu Thr Phe Tyr Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Arg Ile Gly 50 55 60 Val Gly Tyr Val Arg Asp Ser Gly Ser Val Ser Gln Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Lys Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 148 <211> LENGTH: 167 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: MO_1 K7E+K96E polypeptide <400> SEQUENCE: 148 Met Ala Asn Thr Lys Tyr Asn Glu Glu Phe Leu Leu Tyr Leu Ala Gly 1 5 10 15 Phe Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Glu Pro Asn Gln 20 25 30 Ser Arg Lys Phe Lys His Arg Leu Arg Leu Thr Phe Ala Val Thr Gln 35 40 45 Lys Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly 50 55 60 Val Gly Tyr Val His Asp Gln Gly Ser Val Ser Asn Tyr Ile Leu Ser 65 70 75 80 Glu Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu 85 90 95 Glu Leu Lys Gln Lys Gln Ala Asn Leu Ala Leu Arg Ile Ile Glu Gln 100 105 110 Leu Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr 115 120 125 Trp Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr 130 135 140 Thr Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys 145 150 155 160 Lys Ser Ser Pro Ala Ala Asp 165 <210> SEQ ID NO 149 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Single-chain meganuclease linker <400> SEQUENCE: 149 Gly Gly Ser Asp Lys Tyr Asn Gln Ala Leu Ser Lys Tyr Asn Gln Ala 1 5 10 15 Leu Ser Lys Tyr Asn Gln Ala Leu Ser Gly Gly Gly Gly Ser 20 25 30 <210> SEQ ID NO 150 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: I-CreI variant <400> SEQUENCE: 150 Leu Ala Gly Leu Ile Asp Ala Asp Gly 1 5

Claims

1-43. (canceled)

44. A method of cleaving a DNA target sequence from a mouse ROSA26 locus comprising contacting said DNA target sequence with an I-CreI variant to thereby cleave said DNA target sequence wherein said I-CreI variant comprises a first monomer and a second monomer which are associated to form an active form, wherein said I-CreI variant comprises at least two substitutions in at least one of the monomers, wherein at least one substitution is of a residue in the range of positions 26 to 40 of I-CreI and at least one substitution is of a residue in the range of positions 44 to 77 of I-CreI and wherein said DNA target sequence is at least one sequence selected from the group consisting of SEQ ID NO: 5 to 14 and 16 to 30.

45. The method of claim 44, wherein said at least one substitution of a residue in the range of 26 to 40 of I-CreI is at least one substitution of a residue selected from the group consisting of positions 26, 28, 30, 32, 33, 38 and 40.

46. The method of claim 44, wherein said at least one substitution of a residue in the range of 44 to 77 of I-CreI is at least one substitution of a residue selected from the group consisting of positions 44, 68, 70, 75 and 77.

47. The method of claim 44, wherein said substitutions comprise replacing the wild-type amino acids with an amino acid selected from the group consisting of A, D, E, G, H, K, N, P, Q, R, S, T, Y, C, W, L and V.

48. The method of claim 44, wherein said I-CreI variant further comprises at least one substitution selected from the group consisting of: G19S, I24V, S79G, V105A, K107R, V151A, D153G and K158E.

49. The method of claim 44, wherein said I-CreI variant further comprises at least one substitution at positions 137 to 143 of I-CreI.

50. The method of claim 44, which comprises substitution of the aspartic acid in position 75 of I-CreI.

51. The method of claim 50, wherein position 75 of I-CreI is substituted with an asparagine residue.

52. The method of claim 44, wherein said variant is a homodimer.

53. The method of claim 44, wherein said variant is a heterodimer, resulting from the association of a first and a second monomer having different mutations in positions 26 to 40 and 44 to 77 of I-CreI.

54. The method of claim 53, wherein the first and the second monomer of said I-CreI variant, respectively, comprise at least one pair of substitutions selected from the group consisting of: N30H, Y33S, Q44E, R68c, R70S, D75N and N30D, Y33R, Q38T, Q44K, R68E, R70S, I77R, S32N, Y33G, Q44K, R70E, D75N and S32T, Q38W, Q44K, R68E, R70S, I77R, Y33R, Q38N, S40Q, Q44N, R70S, D75R, I77D and N30H, Y33S, Q44A, R70S, D75Q, I77E, K28S, Q38R, S40K, Q44D, R68Y, R70S, D75S, I77R and Y33C, Q38A, R68A, R70K, D75N, Y33C, Q44T, R70S, D75Y and S32D, Q38C, Q44D, R68Y, R70S, D75S, I77R, S32T, Y33C, R68T, R70N, D75N and S32T, Q38W, Q44K, R70E, D75N, R70S, D75R, I77Y and Y33R, Q38A, S40Q, Q44A, R70S, D75N, K28S, Q38R, S40K, Q44T, R68N, R70N, D75N and Y33H, Q38S, Q44K, R68Y, R70S, D75Q, I77N, K28A, Y33S, Q38R, S40K, Q44N, R68Y, R70S, D75R, I77V and S32T, Y33C, Q44A, R70S, D75N, S32D, Y33H, Q44K, R68E, R70S, I77R and S32D, Y33H, Q44D, R68N, R70S, D75N, N30R, S32D, R68S, R70K, D75N and D75N, K28R, Y33A, Q38Y, S40Q, R68Y, R70S, D75R, I77Q and Y33R, Q38A, S40Q, R70S, I77K, K28R, N30D, D75E, I77R and S32D, Q38C, Q44A, R70S, D75R, I77Y, Y33R, Q38A, S40Q, R70S, D75N and R70S, D75Y, I77R, Y33R, Q38A, S40Q, Q44N, R68Y, R70S, D75R, I77V and N30R, S32D, Q44T, R68H, R70H, D75N, Y33P, S40Q, Q44K, R68Y, R70S, D75Q, I77N and S32A, Y33C, R68Y, R70S, D75R, I77Q, K28A, Y33S, Q38R, S40K, R68N, R70S, D75N, I77R and S32N, Y33G, Q44A, R68A, R70K, D75N, N30H, Y33S, Q44Y, R70S, I77V and Y33R, S40Q, Q44A, R70S, D75N, S32D, Y33H, R68T, R70N, D75N and N30R, S32D, Q44T, R68N, R70N, D75N, S32R, Y33D, Q44A, R70S, D75N and Y33S, Q38R, S40H, R68H, R70H, D75N, Y33P, S40Q, Q44K, R68Y, R70S, D75Q, I77N and K28R, Y33A, Q38Y, S40Q, Q44T, R68H, R70H, D75N, K28Q, Q38R, S40K, Q44A, R70S, D75E, I77R and N30R, S32D, Q44K, R68Y, R70S, D75Q, I77N, Y33T, Q38A, R68H, R70H, D75N and N30H, Y33S, R70S, I77K, Y33T, S40T, R68A, R70K, D75N and K28R, Y33A, Q38Y, S40Q, R70S, and S32D, Y33H, Q44N, R70S, D75R, I77D and S32D, Q38C, R70S, I77K.

55. The method of claim 53, wherein the first monomer is selected from the group consisting of SEQ ID NO: 82 to 106 and the second monomer is selected from the group consisting of SEQ ID NO: 107 to 116, 4, and 117 to 130.

56. The method of claim 53, wherein the target sequence is SEQ ID NO: 15.

57. The method of claim 56, wherein the first monomer has substitutions selected from the group consisting of: I24V, Q44Y, R70S and D75N; I24V, Q44Y, R68Y, R70S, D75Y and I77R; I24V, Q44Y, R70S, D75N and I77V; I24V, Q44Y, R68N, R70S and D75R; I24V, Q44Y, R68S, R70S and D75R; I24V, Q44Y, R70S and D75Q; I24V, Q44Y, R68Y, R70S, D75R and I77V; I24V, Q44Y, R70S, D75Y and I77T, and the second monomer has substitutions selected from the group consisting of: K28E, Y33R, Q38R, S40R, Q44A, R68H, R70Q and D75N; K28E, Y33R, Q38R, S40R, Q44A, R70N and D75N; K28E, Y33R, Q38R, S40K, Q44A, R68H, R70Q and D75N; K28E, Y33R, Q38R, S40K, Q44V, R70A and D75N; K28E, Y33R, Q38R, S40K, Q44A, R70G and D75N.

58. The method of claim 57, wherein the first monomer is selected from the group consisting of SEQ ID NO: 39, 43, 45, 49, 50, 51, 53 and 54, and the second monomer is selected from the group consisting of SEQ ID NO: 60, 61, 63, 65 and 66.

59. The method of claim 58, wherein at least one of the two I-CreI monomers has at least 95% sequence identity with, for the first monomer, SEQ ID NO: 39, 43, 45, 49, 50, 51, 53 or 54, and, for the second monomer, SEQ ID NO: 60, 61, 63, 65 or 66.

60. The method of claim 56, wherein the first and the second monomer, respectively, comprise at least the following substitutions: I24V, Q44Y, R70S, D75Y, I77T and K28E, Y33R, Q38R, S40R, Q44A, R68S, R70Q, D75N.

61. The method of claim 60, wherein the first and the second monomers are SEQ ID NO:54 and SEQ ID NO: 62, respectively.

62. The method of claim 61, wherein at least one of the two I-CreI monomers has at least 95% sequence identity with, for the first monomer, SEQ ID NO: 54, and, for the second monomer, SEQ ID NO: 62.

63. The method of claim 56, wherein the first monomer has substitutions selected from the group consisting of: I24V, Q44Y, R68N, R70S and D75R; I24V, Q44Y, R68S, R70S and D75R; I24V, Q44Y, R70S and D75Q; I24V, Q44Y, R68Y, R70S, D75R and I77V; I24V, Q44Y, R70S, D75Y and I77T, and the second monomer has substitutions selected from the group consisting of: K28E, Y33R, Q38R, S40K, Q44A, R70S, D75N and K28E, Y33R, Q38R, S40K, Q44A, R68T, R70N, D75N.

64. The method of claim 63, wherein the first monomer is selected from the group consisting of the sequences SEQ ID NO: 49, 50, 51, 53 and 54, and the second monomer is selected from the group consisting of the sequences SEQ ID NO: 64 and 67.

65. The method of claim 64, wherein at least one of the two I-CreI monomers has at least 95% sequence identity with, for the first monomer, SEQ ID NO: 49, 50, 51, 53 or 54, and, for the second monomer, SEQ ID NO: 64 or 67.

66. The method of claim 56, wherein the first monomer is selected from the group consisting of the sequences SEQ ID NO: 72 and 73 and the second monomer is selected from the group consisting of the sequences SEQ ID NO: 74 to 77.

67. The method of claim 66, wherein at least one of the two I-CreI monomers has at least 95% sequence identity with, for the first monomer, SEQ ID NO: 72 or 73, and, for the second monomer, SEQ ID NO: 74, 75, 76, or 77.

68. The method of claim 53, wherein the first monomer further comprises the D137R mutation and the second monomer further comprises the R51D mutation.

69. The method of claim 53, wherein the first monomer further comprises the E8R or E8K and E61R mutations and the second monomer further comprises the K7E and K96E mutations.

70. The method of claim 44, wherein said variant is a single-chain chimeric meganuclease comprising two I-CreI monomers.

71. The method of claim 70, wherein said chimeric meganuclease comprises a first monomer and a second monomer wherein each monomer has the same substitutions.

72. The method of claim 70, wherein said chimeric meganuclease comprises a first monomer and a second monomer wherein each monomer has at least one different substitution in positions 26 to 40 and 44 to 77 of I-CreI.

73. The method of claim 44, wherein said I-CreI variant is made from the starting scaffold of SEQ ID NO: 1.

74. The method of claim 44, wherein said I-CreI variant is made from the starting scaffold of SEQ ID NO: 133.

75. The method of claim 44, wherein said I-CreI variant is made from the starting scaffold of SEQ ID NO: 4.

76. The method of claim 44 wherein said contacting is in a cell.

77. The method of claim 44 wherein said I-CreI variant is expressed in a cell from a polynucleotide encoding said I-CreI variant.